AMIDE COMPOUNDS AND USE THEREOF

Abstract

Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof: (I), in which each of variables R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Y is defined herein. Also disclosed are methods for reducing the glycemic level and treating glucagon-associated disorders with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.

Description

FIELD OF THE DISCLOSURE

The present disclosure relates to compounds that act as antagonists or inverse agonists of the glucagon receptor, pharmaceutical compositions comprising the compounds, and the uses of the compounds or compositions.

BACKGROUND

Diabetes is a major public health issue and affects millions of people in the world. The two major hormones, insulin and glucagon, which regulate blood sugar homeostasis, play important roles in diabetes. The glucagon is secreted by pancreatic alpha cells and can stimulate glycogenolysis and gluconeogenesis. Moreover, the glucagon signaling might also affect lipid metabolism, food intake, cardiovascular system and adipose tissue mass. The antagonism of glucagon signaling has been pursued as a potential therapy for diabetes for a long time. Many of them were done through interfering the receptor-ligand binding. The glucagon receptor is a class B G-protein coupled receptor and is mainly expressed in liver and less in other tissues.

Antagonism of glucagon receptor by small molecules reduces the downstream secondary messengers including cAMP and calcium ion which lead to gluconeogenic genes expression and subsequent blood sugar elevation. Glucagon receptor −/− mice exhibit resistance to diet-induced obesity and streptozotocin-induced diabetes. Currently several small molecules glucagon receptor antagonists have entered clinical trials and showed significant blood sugar reduction versus placebo. Glucagon receptor antagonism also may have benefit in cardiovascular disease through cardiomyocytes protection. In glucagon receptor inactivated mouse model, animals showed higher survival rate and lower heart failure after myocardial infarction.

There is a need to develop new glucagon receptor modulators that have fewer and less deterious side effects for therapeutic use.

SUMMARY

The present disclosure relates to certain amide compounds as glucagon receptor modulators for treating glucagon-associated disorders. Unexpectedly, these compounds, acting as antagonists or inverse agonists of the glucagon receptor, produce higher efficacy in modulating the glucagon receptor for reducing the glycemic level, as compared to known therapeutic agents.

An aspect of this disclosure is drawn to the compounds of formula (I) below and pharmaceutically acceptable salts thereof:

In this formula, each of A₁, A₂, A₃ and A₄ independently is CR₆ or N, with the proviso that no more than two of A₁, A₂, A₃, and A₄ are N. X is —CH₂—, —NH—, —O—, —S— or a direct bond. Y is —(C═O)—, —CH₂— or a direct bond. R₁ is C_1-6 alkyl, C_1-6 alkoxy, aryl, heteroaryl, C_3-12 cycloalkyl, C_1-12 heterocycloalkyl, or —(C_1-6 alkyl)-(C_3-12 Cycloalkyl); the C_1-6 alkyl being optionally substituted with one to three moieties selected from the group consisting of halo, hydroxyl, C_1-6 alkoxy, aryl and heteroaryl; each of the C_1-6 alkoxy, aryl, heteroaryl, C_3-12 cycloalkyl, and C_1-12 hetarocycloalkyl being optionally substituted with one to three moieties selected from the group consisting of halo, aryl, C_1-6 alkyl optionally substituted with one to three halo and C_1-6 alkoxy optionally substituted with one to three halo; the heteroaryl being optionally fused with one aryl moiety; and the aryl being optionally substituted with heteroaryl or heteroaryl fused with one aryl moiety. R₂ is C_1-6 alkyl,

R₃ is H, methyl or ethyl. R₄ is H, C_1-6 alkyl, or C_1-6 alkoxy, each of the C_1-6 alkyl and C_1-6 alkoxy being optionally substituted with one to three halo. R₅ is tetrazolyl, —CH₂-tetrazolyl, —CH₂CH₂CO₂R₁₀, —CH₂CH(OH)CO₂H, or —(CH₂)₂SO₃H. R₆ is H, halo, C_1-6 alkyl, or C_1-6 alkoxy, each of the C_1-6 alkyl and C_1-6 alkoxy being optionally substituted with one to three halo. R₇ is H, halo, C_1-6 alkyl or C_1-6 alkoxy. R₈ is H, halo, C_1-6 alkyl or C_1-6 alkoxy. R₉ is H, halo, C_1-6 alkyl, C_1-6 alkoxy, C_3-12 cycloalkyl, aryl or heteroaryl; the C_1-6 alkyl being optionally substituted with one to three halo; each of the C_1-6 alkoxy, C_3-12 cycloalkyl, aryl and heteroaryl being optionally substituted with one to three moiety selected from the group consisting of halo, aryl, C_1-6 alkyl optionally substituted with one to three halo, C_1-6 alkoxy optionally substituted with one to three halo, amino, and CN; and the heteroaryl being optionally fused with one aryl moiety or one heteroaryl moiety. R₁₀ is H or C_1-6 alkyl. And, each of J₁, J₂, J₃, J₄ independently is C or N, with the proviso that no more than two of J₁, J₂, J₃ and J₄ are N.

The term “alkyl” herein refers to a straight or branched hydrocarbon group, containing 1-6 carbon atoms. Examples include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl.

The term “cycloalkyl” refers to a saturated and partially unsaturated monocyclic, bicyclic, tricyclic, or tetracyclic hydrocarbon group having 3-12 (e.g., 3-10 and 3-7) carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

The term “heterocycloalkyl” refers to a nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having one or more heteroatoms (e.g., O, N, P, and S). Examples include piperazinyl, imidazolidinyl, azepanyl, pyrrolidinyl, dihydrothiadiazolyl, dioxanyl, morpholinyl, tetrahydropuranyl, and tetrahydrofuranyl.

The term “alkoxy” refers to an —O-alkyl group. Examples include methoxy, ethoxy, propoxy, and isopropoxy.

The term “halo” refers to a fluoro, chloro, bromo, or iodo radical.

The term “amino” refers to a radical derived from amine, which is unsubstituted or mono-/di-substituted with alkyl, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl.

The term “aryl” refers to a 6-carbon monocyclic, 10-carbon bicyclic, 14-carbon tricyclic aromatic ring system. Examples of aryl groups include phenyl, naphthyl, and anthracenyl.

The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having one or more heteroatoms (e.g., O, N, P, and S). Examples include triazolyl, oxazolyl, thiadiazolyl, tetrazolyl, pyrazolyl, pyridyl, furyl, imidazolyl, benzimidazolyl, pyrimidinyl, thienyl, quinolinyl, indolyl, thiazolyl, and benzothiazolyl.

Alkyl, cycloalkyl, heterocycloalkyl, alkoxy, aryl, and heteroaryl mentioned herein include both substituted and unsubstituted moieties. Possible substituents on cycloalkyl, heterocycloalkyl, alkoxy, aryl, and heteroaryl include, but are not limited to, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-12 cycloalkyl, C_3-12 cycloalkenyl, C_1-12 heterocycloalkyl, C_1-12 heterocycloalkenyl, C_1-6 alkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, amino, C_1-6 alkylamino, C_1-20 dialkylamino, arylamino, diarylamino, C_1-6 alkylsulfonamino, arylsulfonamino, C_1-6 alkylimino, arylimino, C_1-6 alkylslfonimino, arylsulfonimino, hydroxyl, halo, thio, C_1-6 alkylthio, arylthio, C_1-6 alkylsulfonyl, arylsulfonyl, acylamino, aminoacyl, aminothioacyl, amido, amidino, guanidine, ureido, thioureido, cyano, nitro, nitroso, azido, acyl, thioacyl, acyloxy, carboxyl, and carboxylic ester. On the other hand, possible substituents on alkyl include all of the above-recited substituents except C_1-6 alkyl. Cycloalkyl, heterocycloalkyl, aryl, and heteroaryl can also be fused with each other.

In addition to the compounds of formula (I) described above, their pharmaceutically acceptable salts and solvates, where applicable, are also covered by this disclosure. A salt can be formed between an anion and a positively charged group (e.g., amino) on a compound. Examples of a suitable anion include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, acetate, malate, tosylate, tartrate, fumurate, glutamate, glucuronate, lactate, glutarate, and maleate. A salt can also be formed between a cation and a negatively charged group. Examples of a suitable cation include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion. A salt further includes those containing quaternary nitrogen atoms. A solvate refers to a complex formed between an active compound and a pharmaceutically acceptable solvent. Examples of a pharmaceutically acceptable solvent include water, ethanol, isopropanol, ethyl acetate, acetic acid, and ethanolamine.

Another aspect of this disclosure is a pharmaceutical composition for treating disorders associated with glucagon, such as a metabolic disorder associated with glucagon (e.g., type I diabetes and type II diabetes).

The pharmaceutical composition contains one of the compounds of formula (I) described above or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, excipient or diluent.

This disclosure also covers use of such a composition for the manufacture of a medicament for treating disorders (for example, a metabolic disorder) associated with glucagon.

A composition for oral administration can be any orally acceptable dosage form including capsules, tablets, emulsions and aqueous suspensions, dispersions, and solutions. In the case of tablets, commonly used carriers include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient can be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added. Oral solid dosage forms can be prepared by spray dried techniques; hot melt extrusion strategy, micronization, and nano milling technologies.

A nasal aerosol or inhalation composition can be prepared according to techniques well known in the art of pharmaceutical formulation. For example, such a composition can be prepared as a solution in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. A composition having an active compound can also be administered in the form of suppositories for rectal administration.

The carrier, the excipient and the diluent in the pharmaceutical composition must be “acceptable” in the sense that it is compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and not deleterious to the subject to be treated. One or more solubilizing agents can be utilized as pharmaceutical excipients for delivery of an active compound. Examples of other carriers include colloidal silicon oxide, magnesium stearate, cellulose, sodium lauryl sulfate, and D&C Yellow #10.

Still within the scope of the present disclosure is a method of treating disorders (for example, a metabolic disorder) associated with glucagon.

The method includes administering to a subject in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

The above-described compounds or a pharmaceutical composition containing one or more of them can be administered to a subject orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.

The term “treating”, “treat” or “treatment” refers to application or administration of the compound to a subject with the purpose to cure, alleviate, relieve, alter, remedy, improve, or affect the disease, the symptom, or the predisposition. “An effective amount” refers to the amount of the compound which is required to confer the desired effect on the subject. Effective amounts vary, as recognized by those skilled in the art, depending on route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments such as use of other active agents.

The details of one or more embodiments of the disclosure are set forth in the description below. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims.

DETAILED DESCRIPTION

A first embodiment of the present disclosure is the compounds of formula (I) or pharmaceutically acceptable salts thereof:

in which each of variables each of variables R₁, R₂, R₃, R₄, R₅, A₁, A₂, A₃, A₄, X and Y is defined as in the SUMMARY section.

A second embodiment of the present disclosure is the compound of the first embodiment or a pharmaceutically acceptable salt thereof wherein R₃ is H, and R₄ is H.

A third embodiment of the present disclosure is the compound of the first or second embodiments or a pharmaceutically acceptable salt thereof, wherein

is

A fourth embodiment of the present disclosure is the compound of any one of the first to third embodiments or a pharmaceutically acceptable salt thereof wherein X is —O— or —S—, Y is —CH₂—, R₂ is

R₃ is H, and R₄ is H.

A fifth embodiment of the present disclosure is the compound of the fourth embodiment or a pharmaceutically acceptable salt thereof, wherein R₂ is

R₇ is H, halo, C_1-6 alkyl or C_1-6 alkoxy, and R₈ is H, halo or C_1-6 alkyl.

A sixth embodiment of the present disclosure is the compound of the fourth or fifth embodiments or a pharmaceutically acceptable salt thereof, wherein R₇ and R₈ are the same, and R₇ and R₈ are H, methyl, ethyl, propyl, isopropyl, butyl t-butyl, F or Cl.

A seventh embodiment of the present disclosure is the compound of the fourth or fifth embodiments or a pharmaceutically acceptable salt thereof; wherein R₇ is F, Cl, methoxy, ethoxy, propoxy or isobutoxy, and R₈ is H.

An eighth embodiment of the present disclosure is the compound of the fourth embodiment or a pharmaceutically acceptable salt thereof; wherein R₂ is

R₇ is F or Cl, R₈ is H, F or Cl.

A ninth embodiment of the present disclosure is the compound of any one of the first to third embodiments or a pharmaceutically acceptable salt thereof; wherein R₂ is

and R₇ is C_1-6 alkyl.

A tenth embodiment of the present disclosure is the compound of the third or ninth embodiments or a pharmaceutically acceptable salt thereof, wherein R₇ is methyl or ethyl.

An eleventh embodiment of the present disclosure is the compound of any one of the first to third embodiments or a pharmaceutically acceptable salt thereof; wherein X is —CH₂—, Y is a direct bond, R₂ is

R₃ is H, and R₄ is H.

A twelfth embodiment of the present disclosure is the compound of any one of the first to third and eleventh embodiments or a pharmaceutically acceptable salt thereof, wherein R₇ and R₈ are H.

A thirteenth embodiment of the present disclosure is the compound of any one of the first to third embodiments or a pharmaceutically acceptable salt thereof; wherein X is —CH₂—, Y is a direct bond, R₂ is

R₃ is H, and R₄ is H.

A fourteenth embodiment of the present disclosure is the compound of any one of the first to third embodiments or a pharmaceutically acceptable salt thereof; wherein X and Y are direct bonds, R₂ is

R₃ is H, and R₄ is H.

A fifteenth embodiment of the present disclosure is the compound of any one of the first to third embodiments or a pharmaceutically acceptable salt thereof; wherein X is —O—, Y is —CH₂—, R₂ is

R₃ is H, and R₄ is H.

A sixteenth embodiment of the present disclosure is the compound of any one of the first to third embodiments or a pharmaceutically acceptable salt thereof, wherein X is —NH—, Y is —(C═O)—, R₂ is

R₃ is H, and R₄ is H.

A seventeenth embodiment of the present disclosure is the compound of any one of the first to sixteenth embodiments or a pharmaceutically acceptable salt thereof, wherein R₁ is methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, n-pentyl, isopentyl, methoxy, ethoxymethyl, 1-methoxypropyl, 1-methoxy-2methylpropyl, ethoxy, n-propoxy, i-propoxy, 3-isobutoxypropan-2-yl, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, phenyl, benzyl, biphenyl, naphthyl, benzofuranyl or indolyl; each of the methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, n-pentyl and isopentyl, is optionally substituted with one to three moieties selected from the group consisting of F, Cl, methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, phenyl, biphenyl and naphthyl; each of the methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy and t-butoxy is optionally substituted with one to three F or Cl; each of the phenyl, biphenyl, naphthyl and indolyl is optionally substituted with one to three moieties selected from the group consisting of F, Cl, methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, trifluoromethyl, benzofuranyl and methoxy substituted pyrimidyl.

An eighteenth embodiment of the present disclosure is the compound of any one of the first to seventeenth embodiments or a pharmaceutically acceptable salt thereof, wherein R₅ is tetrazolyl, —CH₂-tetrazolyl, —CH₂CH₂CO₂H, —CH₂CH₂CO₂Et, —CH₂CH₂CO₂Me, —CH₂CH(OH)CO₂H, or —(CH₂)₂SO₃H.

A nineteenth embodiment of the present disclosure is the compound of any one of the first to eighteenth embodiments or a pharmaceutically acceptable salt thereof, wherein R₉ is methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, phenyl, benzyl, biphenyl, naphthyl, pyridinyl, pyridazinyl, benzofuranyl, benzothiazolyl, imidazopyridinyl, oxadiazol, benzooxazol, pyrazol or indolyl; each of the methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl and t-butyl is optionally substituted with one to three moieties selected from the group consisting of F, Cl, methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, phenyl, biphenyl and naphthyl; each of the methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy and t-butoxy is optionally substituted with one to three F, Cl or amino; each of the phenyl, benzyl, biphenyl, naphthyl, pyridinyl, pyridazinyl, benzofuranyl, benzothiazolyl, imidazopyridinyl, oxadiazol, benzooxazol, pyrazol and indolyl is optionally substituted with one to three moieties selected from the group consisting of F, Cl, methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, —CF₃, —OCF₃ and phenyl.

A twentieth embodiment of the present disclosure is the compound of any one of the first to nineteenth embodiments or a pharmaceutically acceptable salt thereof, wherein R₆ is H, or C_1-6 alkyl.

A twenty first embodiment of the present disclosure is the compound of any one of the first to nineteenth embodiments or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) can be the compound of the following formula (II):

A twenty first embodiment of the present disclosure is a compound selected from the group consisting of Compounds 1-1 to 1-54, Compounds 2-1 to 2-13, Compounds 3-1 to 3-24, Compounds 4-1 to 4-5, Compounds 5-1 to 5-3, Compounds 6-1 to 6-3, Compounds 7-1 to 7-11, Compounds 8-1 to 8-25, Compounds 9-1 to 9-6, Compounds 10-1 to 10-19, Compounds 11-1 to 11-2, Compounds 12-1 to 12-11, Compounds 13-1 to 13-14, Compounds 14-1 and 14-2, Compounds 15-1 to 15-37, Compounds 16-1 and 16-2, Compounds 17-1 to 17-12, Compounds 18-1 to 18-9, Compounds 19-1 to 19-34, Compounds 20-1 to 20-7, Compounds 21-1 to 21-3, Compounds 22-1 to 22-20, Compounds 23-1 to 23-35 and Compounds 24-1 to 24-28, which are listed in the following Tables 1 to 24.

In one aspect of the present disclosure, the compound can be any one selected from the group consisting of Compound 1-2, Compound 1-8, Compound 1-9, Compound 1-12, Compound 1-16, Compound 1-17, Compound 1-18, Compound 1-19, Compound 1-20, Compound 1-22, Compound 1-25, Compound 1-30, Compound 1-32, Compound 1-48, Compound 1-52, Compound 1-54, Compound 2-4, Compound 2-6, Compound 2-9, Compound 2-10, Compound 3-2, Compound 3-3, Compound 3-4, Compound 3-5, Compound 3-8, Compound 3-9, Compound 3-10, Compound 3-12, Compound 3-43, Compound 3-14, Compound 3-15, Compound 3-19, Compound 3-20, Compound 3-22, Compound 3-24, Compound 4-2, Compound 7-1, Compound 7-5, Compound 7-8, Compound 7-11, Compound 8-3, Compound 8-5, Compound 8-8, Compound 8-11, Compound 8-13, Compound 8-15, Compound 8-16, Compound 8-20, Compound 8-22, Compound 8-23, Compound 8-25, Compound 9-1, Compound 11-1, Compound 11-2, Compound 13-1, Compound 13-2, Compound 13-3, Compound 13-4, Compound 13-6, Compound 13-7, Compound 13-8, Compound 13-9, Compound 13-10, Compound 13-11, Compound 13-14, Compound 14-2, Compound 15-3, Compound 15-7, Compound 15-9, Compound 15-10, Compound 15-13, Compound 15-22, Compound 15-28, Compound 15-29, Compound 18-2, Compound 18-3, Compound 18-7, Compound 18-8, Compound 19-5, Compound 22-1, Compound 22-18, Compound 23-1, Compound 23-5 and Compound 23-10.

The compounds of the present disclosure may contain asymmetric or chiral centers, and exist in different stereoisomeric forms. Unless specified otherwise, all stereoisomeric forms of the compounds of the present disclosure as well as mixtures thereof including racemic mixtures are within the scope of the present disclosure. In addition, the compounds of the present disclosure may also exist in different geometric and positional isomers. For example, both the cis- and trans-forms, as well as mixtures of the compound with a double bond or a fused ring, are also within the scope of the present disclosure.

Diastereomeric mixtures can be separated into their individual diastereoisomers by any methods, such as by chromatography and/or fractional crystallization. Enantiomers can be separated by use of a chiral HPLC column or by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound to separate the diastereoisomers and convert the individual diastereoisomers into pure enantiomers. The specific stereoisomers may be synthesized by converting one stereoisomer into the other by asymmetric transformation, by using an optically active starting material or by asymmetric synthesis using optically active reagents, catalysts, substrates or solvents.

In the compounds of the present disclosure, the carbon attached to both NR₃ and Y can have a stereoisomeric configuration of R or S, and such compounds can have an enantiomeric excess of 90% or higher (e.g., ≥95% and ≥99%).

Also within the present disclosure is a pharmaceutical composition comprising: (1) the compound of the present disclosure or the pharmaceutically acceptable salt thereof, and (2) a pharmaceutically acceptable carrier, excipient or diluent. The composition may also comprise at least one additional pharmaceutical agent such as anti-obesity agents and/or anti-diabetic agent. The compound or the pharmaceutically acceptable salt thereof or the composition of the present disclosure may be used in the manufacture of a medicament of treating diseases, conditions or disorders associated with glucagon.

Also within the present disclosure is a method for reducing the glycemic level in a subject, which includes the step of administering to the subject in need thereof an effective amount of the compound of the present disclosure or the pharmaceutically acceptable salt thereof.

Further covered by the present disclosure a method of treating diseases, conditions or disorders associated with glucagon, which includes the step of administering to a subject in need thereof an effective amount of the compound of the present disclosure or the pharmaceutically acceptable salt thereof.

In the present disclosure, the aforesaid subject can be mammal, for example, human.

In the present disclosure, the diseases, conditions or disorders associated with glucagon can be, for example, hyperglycemia, Type II diabetes, metabolic syndrome, impaired glucose tolerance, glucosuria, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, hyperinsulinemia, insulin resistance syndrome, cataracts, obesity, dyslididemia, hypertension and myocardial infarction. However, the present disclosure is not limited thereto, and the compounds or the pharmaceutically acceptable salt thereof of the present disclosure can be applied to any other diseases, conditions or disorders associated with the glucagon signaling pathway. In one aspect of the present disclosure, the diseases, conditions or disorders associated with glucagon is hyperglycemia, Type II diabetes, impaired glucose tolerance, insulin resistance syndrome and obesity. In another aspect of the present disclosure, the diseases, conditions or disorders associated with glucagon is Type II diabetes.

The compounds or the pharmaceutically acceptable salt thereof of the present disclosure may be administered in combination with at least one additional pharmaceutical agent such as anti-obesity agents and/or anti-diabetic agent. The administration formulation can be, for example, (a) a single formulation comprising the compound of the present disclosure or the pharmaceutically acceptable salt thereof a pharmaceutically acceptable carrier, excipient or diluent and at least one additional pharmaceutical agent; or (b) two formulations administered simultaneously or sequentially and in any order, wherein one comprises the compound of the present disclosure or the pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, excipient or diluent and the other one comprises at least one additional pharmaceutical agent.

Suitable anti-diabetic agents may include an acetyl-CoA carboxylase-2 (ACC-2) inhibitor, an A2 antagonist, a biguanide (e.g., metformin), a diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitor, a dipeptidyl peptidase IV (DPP-IV) inhibitor (e.g., alogliptin, sitagliptin, saxagliptin and vildagliptin), a fatty acid oxidation inhibitor, a glucagon-like peptide 1 (GLP-1) agonist (e.g., exendin-3 and exendin-4), a glycogen phosphorylase inhibitor, insulin, an insulin mimetic, an insulin secreatagogue, a meglitinide, a phosphodiesterase (PDE)-10 inhibitor, a protein tyrosine phosphatase-1B (PTP-1B) inhibitor (e.g., hyrtiosal extract and trodusquemine), a sulfonylurea (e.g., acetohexamide, chlorpropamide, diabinese, glibenclamide, gliclazide, glimepiride, glipentide, glipizide, gliquidone, glisolamide, glyburide, tolazamide, and tolbutamide), an α-amylase inhibitor (e.g., tendamistat, trestatin and AL-3688), an α-glucoside hydrolase inhibitor (e.g., acarbose), an α-glucosidase inhibitor (e.g., adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-Q, and salbostatin), a PPARy agonist (e.g., balaglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone, rosiglitazone and troglitazone), a PPAR α/γ agonist (e.g., CLX-0940, GW-1536, GW-1929, GW-2433, KRP-297, L-796449, LR-90, MK-0767 and SB-219994), SIRT-1 inhibitor (e.g., resveratrol), an SGLT1 inhibitor, an SGLT2 inhibitor (e.g. dapagliflozin, remogliflozin, sergliflozin and AVE2268), a c-jun amino-terminal kinase (JNK) inhibitor, and a VPAC2 receptor agonist. In one embodiment of the present disclosure, suitable anti-diabetic agents may include metformin, SGLT2 inhibitors and/or DPP-IV inhibitors.

Suitable anti-obesity agents may include a 11β-hydroxy steroid dehydrogenase-1 (11β-HSD type 1) inhibitor, a 5HT2c agonist (e.g., lorcaserin), an anorectic agent (such as a bombesin agonist), a ciliary neurotrophic factor (such as Axokine™), a cholecystokinin-A (CCK-A) agonist (e.g., N-benzyl-2-[4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-2,3,6,10b-tetraaza-benzo[e]azulen-6-yl]-N-isopropyl-acetamide), a dehydroepiandrosterone or an analog thereof, a dopamine agonist (such as bromocriptine), a galanin antagonist, a ghrelin antagonist, a glucagon-like peptide-1 agonist, a glucocorticoid agonist or antagonist, a histamine 3 antagonist or inverse agonist, a human agouti-related protein (AGRP) inhibitor, a leptin analogs, a leptin agonists, a lipase inhibitors (such as tetrahydrolipstatin, i.e. orlistat and cetilistat), a MCR-4 agonist, a melanin concentrating hormone antagonist, a leptin (the OB protein), a melanocyte-stimulating hormone analog, a monoamine reuptake inhibitor (such as sibutramine), a MTP/ApoB inhibitor (e.g., a gut-selective MTP inhibitor, such as dirlotapide, mitratapide and implitapide, R56918 (CAS No. 403987) and CAS No. 913541-47-6), a neuropeptide-Y antagonist (e.g., a NPY Y5 antagonist), a neuromedin U agonist, an opioid antagonist (e.g., naltrexone), an orexin antagonist, an orexin antagonist, a PYY_3-36 or an analog thereof, a stearoyl-CoA desaturase-1 (SCD-1) inhibitor, a sympathomimetic agents, a thyromimetic agent, and a β₃ adrenergic agonist. In one embodiment of the present disclosure, suitable anti-obesity agents may include a 5HT2c agonist, a CCK-A agonists, a gut-selective MTP inhibitor, a lipase inhibitor, a MCR-4 agonist, PYY_3-36, an opioid antagonist, bromocriptine, exenatid, leptin, liraglutide, obinepitide, odistat, oleoyl-estrone, pramlintide, tesofensine, sibutramine and AOD-9604.

Methods for synthesizing the compounds of formula (I) are well known in the art. See, for example, R. Larock, Comprehensive Organic Transformations (2^nd Ed., VCH Publishers 1999); P. G. M. Wuts and T. W. Greene, Greene's Protective Groups in Organic Synthesis (4^th Ed., John Wiley and Sons 2007); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis (John Wiley and Sons 1994); L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis (2^nd ed., John Wiley and Sons 2009); P. Roszkowski, J. K. Maurin, Z. Czarnocki “Enantioselective synthesis of (R)-(−)-praziquantel (PZQ)” Tetrahedron: Asymmetry 17 (2006) 1415-1419; and L. Hu, S. Magesh, L. Chen, T. Lewis, B. Munoz, L. Wang “Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators,” WO2013/067036.

The compounds of formula (I) thus prepared can be initially screened using in vitro assays, e.g., the glucagon cAMP inhibition assay and I¹²⁵-glucagon binding assay both described below, for their potency in binding to glucagon receptor and inhibiting downstream cAMP. They can be subsequently evaluated using in vivo assays known in the field. The selected compounds can be further tested to verify their efficacy in disease related efficacy and adverse effects models. Based on the results, an appropriate dosage range and administration route can be determined.

The following embodiments are made to clearly exhibit the above-mentioned and other technical contents, features and/or effects of the present disclosure. Through the exposition by means of the specific embodiments, people would further understand the technical means and effects the present disclosure adopts to achieve the above-indicated objectives. Moreover, as the contents disclosed herein should be readily understood and can be implemented by a person skilled in the art, all equivalent changes or modifications which do not depart from the concept of the present disclosure should be encompassed by the appended claims.

EXAMPLE

Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present disclosure to its fullest extent. The following specific examples, i.e., EXAMPLES 1-26, are therefore to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference in their entirety.

Among the specific examples, EXAMPLES 1-24 set forth the procedures for preparing certain intermediates and 390 exemplary compounds of formula (I), as well as the analytical data for the compounds thus prepared; and EXAMPLES 25 and 26 set forth the protocols for testing these compounds.

Described below are the procedures used to synthesize the exemplary compounds of the present disclosure.

Unless otherwise stated, all starting materials used were commercially available and used as supplied. Reactions requiring anhydrous conditions were performed in flame-dried glassware and cooled under an argon or nitrogen atmosphere. Unless otherwise stated, reactions were carried out under argon or nitrogen and monitored by analytical thin-layer chromatography performed on glass-backed plates (5 cm_10 cm) precoated with silica gel 60 F254 as supplied by Merck. Visualization of the resulting chromatograms was done by looking under an ultraviolet lamp (λ=254 nm), followed by dipping in an nBuOH solution of Ninhydrin (0.3% w/v) containing acetic acid (3% v/v) or ethanol solution of phosphomolybdic acid (2.5% w/v) and carring by heat gun. Solvents for reactions were dried under an argon or nitrogen atmosphere prior to use as follows. THF, Toluene, and DCM were dried by the column of Dried molecular Sieve 5A (LC technology solution Inc). DMF dried by calcium hydride or anhydrous is commercial available. Flash chromatography was used routinely for purification and separation of product mixtures using RediSep Rf Silica Gel Disposable Flash Columns, Gold® 20-40/40-60 microns silica gel and Reusable RediSep Rf Gold® C18 Reversed Phase columns, 20-40 microns supplied by RediSep. Eluent systems are given in volume/volume concentrations. ¹³C and ¹H NMR spectra were recorded on Bruker AVIII (400 MHz). Chloroform-d or dimethyl sulfoxido-d6 and CDsOD was used as the solvent and TMS (δ 0.00 ppm) as an internal standard. Chemical shift values are reported in ppm relative to the TMS in delta (δ) units. Multiplicities are recorded as s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublet), dt (doublet of triplet), m (multiplet). Coupling constants (J) are expressed in Hz. Electrospray mass spectra (ESMS) were recorded using a Thermo LTQ XL mass spectrometer. Spectral data were recorded as m/z values.

In the preparation of compounds of the present invention, protection of remote functionality (e.g., primary or secondary amine) of intermediates may be necessary. The need for such protection may vary depending on the nature of the remote functionality and the conditions of the preparation methods. Suitable amino protecting groups (NHPg) include, for example, acetyl, trifluoroacetyl, tbutoxycarbonyl (BOC), 9-fluorenylmethyleneoxycarbonyl (Fmoc) and benzyloxycarbonyl (CBz). Similarly, a “hydroxyl protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable hydroxyl protecting groups (OPg) include, for example, allyl, acetyl, silyl, benzyl, paramethoxy benzyl, trityl, and the like. The need for such protection is readily determined by one skilled in the art.

Reaction Schemes I and II illustrate the general procedures that can be used to synthesize the following compounds of the formula (I) of the present disclosure.

Preparation of Intermediate 1: (S)-tert-butyl 1-(4-bromophenoxy)-3-methylbutan-2-ylcarbamate

Step I: Mesiylation

(S)-tert-butyl 1-hydroxy-3-methylbutan-2-ylcarbamate (4.26 g, 21.1 mmol) was dissolved in anhydrous DCM (80 mL) and Et₃N (3.52 mL, 25.29 mmol) was added to the solution. A solution of methanesulfonyl chloride (1.96 mL, 25.3 mmol) in anhydrous DCM (10 mL) was added dropwise to the mixture. The reaction mixture was stirred for 3 h. The mixture was poured to the cold water and white solid was precipitated to give crude (S)-2-(tert-butoxycarbonylamino)-3-methylbutyl methanesulfonate (5.91 g, in qualitatively yield), which was of suitable purity to use directly in next reaction.

Step II: SN₂

To a 500 mL round-bottomed flask, cesium carbonate (15.6 g, 48 mmol) was dried with nitrogen at 100° C. then added DMF into the flask. 4-bromophenol (2.77 g, 16 mmol) in 90 mL DMF was added at 60° C. and the mixture was stirred at 60-70° C. under nitrogen condition for 18 h. (S)-2-(tert-butoxycarbonylamino)-3-methylbutyl methanesulfonate (5.91 g, 21 mmol) were added. After another 40 h it was partitioned between EtOAc and H₂O, the aqueous phase extracted twice with EtOAc and the combined organic phase washed with NaHCO₃ solution. Drying (MgSO₄) and concentration afforded an oily residue that was purified by column chromatography on silica gel to give (S)-tert-butyl 1-(4-bromophenoxy)-3-methylbutan-2-ylcarbamate (2.86 g, 50%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ7.30-7.38 (m, 2H), 6.71-6.79 (m, 2H), 4.74 (d, J=8.8 Hz, 1H), 3.85-4.02 (m, 2H), 3.67 (t, J=8.3 Hz, 1H), 1.97 (dq, J=13.7, 6.8 Hz, 1H), 1.43 (s, 9H), 0.93-0.99 (m, 6H).

Preparation of Intermediate 2: (S)-tert-butyl 1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-ylcarbamate

Step II: Suzuki Coupling

A solution of (S)-tert-butyl 1-(4-bromophenoxy)-3-methylbutan-2-ylcarbamate (2.86 g, 8 mmol), 2-benzofuranylboronic acid (1.61 g, 10 mmol), palladium acetate(II) (66 mg, 0.8 mmol), triphenylphosphine (420 mg, 1.6 mmol) and 2M K₂CO₃ (14 mL, 28 mmol) in EtOH/PhMe (2 mL/12 mL) was heated at 90° C. for 18 h. The reaction mixture was cooled, poured into half-saturated NaHCO_3(aq) and extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was purified by silica gel chromatography to afford(S)-tert-butyl 1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-ylcarbamate. (2.21 g, 70%). ¹H NMR (400 MHz, CDCl₃): δ 7.74-7.80 (m, 2H), 7.50-7.56 (m, 1H), 7.47 (d, J=8.3 Hz, 1H), 7.16-7.24 (m, 2H), 6.91-7.00 (m, 2H), 6.87 (d, J=1.0 Hz, 1H), 4.79 (d, J=8.8 Hz, 1H), 4.08 (dd, J=9.3, 2.9 Hz, 1H), 4.00 (dd, J=9.3, 3.9 Hz, 1H), 3.71 (br. s., 1H), 1.94-2.07 (m, 1H), 1.44 (s, 9H), 0.94-1.02 (m, 6H).

Preparation of Intermediate 3: 4-(benzofuran-2-yl)phenol

To a 1 L round-bottomed flask, potassium carbonate (28 g, 203 mol) was added and dissolved in 102 mL water and benzofuran-2-ylboronic acid (11.3 g, 70 mmol) 4-bromophenol (10 g, 58 mmol) was added followed by toluene (232 ml), EtOH (58 ml) and PPh₃ (3.04 g, 11.6 mmol). The mixture was bubbled with nitrogen for 30 min then added Pd(OAc)₂ (1.3 g, 5.8 mmol) and raised temperature to reflux. The reaction was stirred for overnight quenched with Japanese acid spray and purified through celite. The mixture was extracted with EA and dried with MgSO₄ purified through column chromatography and got 4-(benzofuran-2-yl)phenol (8.8 g, 72%) as white solid. ¹H NMR (400 MHz, CDCl₃): δ7.71-7.77 (m, 2H), 7.51-7.56 (m, 1H), 7.45-7.50 (m, 1H), 7.16-7.26 (m, 2H), 6.87-6.92 (m, 2H), 6.85-6.87 (m, 1H), 4.90 (s, 1H).

Preparation of Intermediate 4: (S)-tert-butyl 1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-ylcarbamate

Deprotonation flask: To a 500 mL round-bottomed flask, cesium carbonate (37 g, 113 mmol) was dried with nitrogen at 100° C. then added DMF into the flask. 4-(benzofuran-2-yl)phenol (8.74 g, 42 mmol) was added at 60° C. and the mixture was stirred at 60-70° C. under nitrogen condition for 18 h.

To a 250 mL round-bottomed flask, (S)-tert-butyl 1-hydroxy-3-methylbutan-2-ylcarbamate (11.4 g, 56 mmol) was dissolved in 110 mL anhydrous DCM and cooled to 5° C. by ice bath was added TEA (11.33 g, 112 mmol) and MsCl (7.7 g, 67.2 mmol) was added dropwise over 10 min, the reaction was stirred at room temperature for 2 h. The reaction was quenched with water and extracted with DCM, dried with MgSO₄. The organic layer was combined and removed solvent by vacuo and ready for the next reaction. The (S)-2-(tert-butoxycarbonylamino)-3-methylbutyl methanesulfonate was dissolved in 40 mL DMF and poured into the deprotonation flask, the reaction was stirred at 60-70° C. for 24 h. The mixture was removed salt by filter and removed solvent by rotavapor, extracted with EA and water. The organic layer was washed with water and dried with MgSO₄. Crude compound was purified through column chromatography and got (S)-tert-butyl 1-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-ylcarbamate (8.31 g, 50%). ¹H NMR (400 MHz, CDCl₃): δ7.74-7.80 (m, 2H), 7.50-7.56 (m, 1H), 7.47 (d, J=8.3 Hz, 1H), 7.16-7.24 (m, 2H), 6.91-7.00 (m, 2H), 6.87 (d, J=1.0 Hz, 1H), 4.79 (d, J=8.8 Hz, 1H), 4.08 (dd, J=9.3, 2.9 Hz, 1H), 4.00 (dd, J=9.3, 3.9 Hz, 1H), 3.71 (br. s., 1H), 1.94-2.07 (m, 1H), 1.44 (s, 9H), 0.94-1.02 (m, 6H).

Preparation of Intermediate 5: (S)-1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-amine

The compound (S)-tert-butyl 1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-ylcarbamate (574 mg, 13.4 mmol) was suspended in trifluoroacetic acid (15 mL, 200 mmol) in anhydrous dichloromethane (150 mL) at room temperature for overnight. After reaction, excess trifluoroacetic acid was neutralized by dropwised addition of Na₂CO_3(aq) until pH=10. Then it was extracted with CH₂Cl₂. The combined organic layer was dried with anhydrous MgSO₄ and concentrated in vacuo to give crude product. It was further purified by silica gel flash column chromatography using dichloromethane and methanol as eluent to give compound white solid. ¹H NMR (400 MHz, CDCl₃): δ 7.74-7.80 (m, 2H), 7.51-7.56 (m, 1H), 7.46-7.50 (m, 1H), 7.21 (m, 2H), 6.94-6.99 (m, 2H), 6.87 (d, J=1.0 Hz, 1H), 4.03 (dd, J=8.8, 3.9 Hz, 1H), 3.83 (dd, J=9.3, 7.8 Hz, 1H), 2.97 (ddd, J=7.8, 5.9, 3.9 Hz, 1H), 1.80 (dq, J=13.1, 6.7 Hz, 1H), 1.34 (s, 2H), 0.99 (m, 6H).

Example 1: Synthesis of Compounds 1-1 to 1-54

Compound 1-1: Ethyl(S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido) propanoate

A solution of (S)-1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-amine (7.40 g, 25 mmol) and ethyl 3-(4-iodobenzamido)propanoate (10 g, 29 mmol) and 2-isobutyrylcyclohexan-1-one (0.84 g, 5 mmol), Cesium carbonate (16.3 g, 50 mmol) in 25 ml DMF (dried), and bubbled the solution with N_2(g) for 10 min then added copper iodide (0.48 g, 2.5 mmol). The reaction was stirred at room temperature for 5 days. The reaction was then diluted with ethyl acetate (100 mL), filtered through Celite and extracted with ethyl acetate (2×100 mL). The combined organics were washed with brine, dried over sodium sulfate, filtered and concentrated to give crude product, and purification via column chromatography (0-70% ethyl acetatein hexanes) gave ethyl (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido) propanote (5.20 g 40%) as white solid. ¹H NMR (400 MHz, CDCl₃): δ 7.72-7.79 (m, 2H), 7.56-7.63 (m, 2H), 7.51-7.55 (m, 1H), 7.43-7.49 (m, 1H), 7.16-7.24 (m, 2H), 6.89-6.96 (m, 2H), 6.87 (s, 1H), 6.57-6.65 (m, 3H), 4.10-4.21 (m, 3H), 4.07 (dd, J=4.4, 2.0 Hz, 2H), 3.67 (q, J=6.2 Hz, 2H), 3.55-3.63 (m, 1H), 2.56-2.64 (m, 2H), 2.09-2.21 (m, 1H), 1.24 (t, J=7.1 Hz, 3H), 1.04 (d, J=6.4 Hz, 3H), 1.05 (d, J=6.8 Hz, 3H). MS(M+1): 515.

Compound 1-2: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

To a solution of ethyl (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoate (5.15 g, 10 mmol) in THF (50 mL) was added 2 N aqueous lithium hydroxide (20 mL, 40 mmol). The reaction was stirred at room Temperature for 3 hours. The THF was then removed in vacuo and the residue was extracted with dichloromethane. The aqueous phase was acidified to pH=4 with 3 N aqueous hydrochloric acid and extracted with ethyl acetate (2×100 mL). The combined organics were washed with brine, dried over sodium sulfate, filtered and concentrated to give (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl) amino)benzamido)propanoic acid as a white solid (4.47 g, 92%). ¹H NMR (400 MHz, DMSO-d₆): δ 12.14 (s, 1H), 8.05-8.02 (m, 1H), 7.81-7.85 (m, 2H), 7.57-7.62 (m, 4H), 7.21-7.30 (m, 3H), 7.04-7.07 (m, 2H), 6.66 (d, J=8.8 Hz, 1H), 6.11 (d, J=8.9 Hz, 1H), 4.02-4.14 (m, 2H), 3.64-3.70 (m, 1H), 3.38-3.43 (m, 2H), 2.45-2.47 (m, 2H), 2.01-2.09 (m, 1H), 1.01 (d, J=6.8 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H). MS(M+1): 487.

Compound 1-3: 3-(4-(((2S,3S)-1-((4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J=7.8 Hz, 2H), 7.36-7.52 (m, 6H), 6.90 (d, J=8.8 Hz, 2H), 6.63-6.72 (m, 1H), 6.57 (d, J=8.3 Hz, 2H), 4.05 (br. s., 2H), 3.58-3.72 (m, 3H), 2.57-2.70 (m, 2H), 1.79-1.92 (m, 1H), 1.56-1.71 (m, 1H), 1.16-1.29 (m, 1H), 0.99 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 517.

Compound 1-4: 3-(4-(((2S,3S)-1-(4-(benzofuran-2-yl)phenoxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, J=8.8 Hz, 2H), 7.58 (d, J=8.8 Hz, 2H), 7.50-7.54 (m, 1H), 7.46 (d, J=8.3 Hz, 1H), 7.16-7.23 (m, 2H), 6.90 (d, J=8.8 Hz, 2H), 6.85 (s, 1H), 6.74 (t, J=5.6 Hz, 1H), 6.57 (d, J=8.3 Hz, 2H), 4.00-4.09 (m, 2H), 3.59-3.70 (m, 3H), 2.65 (t, J=5.6 Hz, 2H), 1.79-1.90 (m, 1H), 1.63 (ddd, J=13.2, 7.3, 3.9 Hz, 1H), 1.18-1.28 (m, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 501.

Compound 1-5: 3-(4-(((2S)-3-methyl-1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.55-7.64 (m, 6H), 7.48 (d, J=8.8 Hz, 2H), 6.90-6.93 (d, J=8.8 Hz, 2H), 6.58 (d, J=8.3 Hz, 2H), 4.02-4.10 (m, 2H), 3.60-3.70 (m, 3H), 2.61-2.67 (m, 2H), 1.80-1.92 (m, 1H), 1.64 (ddd, J=13.1, 7.5, 3.9 Hz, 1H), 1.18-1.28 (m, 1H), 0.99 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 529.

Compound 1-6: 3-(4-(((2S,3S)-3-methyl-1-((4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.26 (t, J=5.2 Hz, 1H), 7.71 (d, J=8.8 Hz, 2H), 7.57 (t, J=8.8 Hz, 4H), 7.39 (d, J=8.3 Hz, 2H), 7.01 (d, J=8.8 Hz, 2H), 6.64 (d, J=8.8 Hz, 2H), 6.14 (d, J=8.8 Hz, 1H), 4.06-4.15 (m, 1H), 3.96-4.05 (m, 1H), 3.61-3.72 (m, 1H), 2.13 (t, J=6.8 Hz, 2H), 1.72-1.83 (m, 1H), 1.54-1.66 (m, 1H), 1.18-1.34 (m, 1H), 0.94 (d, J=6.8 Hz, 3H), 0.89 (t, J=7.4 Hz, 3H). MS(M+1): 545.

Compound 1-7: 3-(4-(((2S,3S)-1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.57 (d, J=8.3 Hz, 2H), 7.44 (d, J=2.0 Hz, 1H), 7.18-7.32 (m, 4H), 6.90 (d, J=8.3 Hz, 2H), 6.79-6.86 (m, 1H), 6.57 (d, J=8.3 Hz, 2H), 4.02-4.09 (m, 2H), 3.60-3.70 (m, 3H), 2.64 (t, J=5.6 Hz, 2H), 1.81-1.92 (m, 1H), 1.57-1.70 (m, 1H), 1.18-1.30 (m, 1H), 0.99 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 529.

Compound 1-8: N-((1H-tetrazol-5-yl)methyl)-4-((2S,3S)-1-(4-(benzofuran-2-yl)phenoxy)-3-methylpentan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (t, J=5.4 Hz, 1H), 7.83 (d, J=8.8 Hz, 2H), 7.67 (d, J=8.3 Hz, 2H), 7.52-7.64 (m, 2H), 7.18-7.32 (m, 3H), 7.05 (d, J=8.8 Hz, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.26 (d, J=8.8 Hz, 1H), 4.68 (d, J=5.9 Hz, 2H), 4.15 (dd, J=10.0, 3.7 Hz, 1H), 3.99-4.08 (m, 1H), 3.66-3.75 (m, 1H), 1.72-1.87 (m, 1H), 1.61 (ddd, J=13.1, 7.5, 3.9 Hz, 1H), 1.19-1.32 (m, 1H), 0.96 (d, J=6.8 Hz, 3H), 0.90 (t, J=7.3 Hz, 31). MS(M+1): 511.

Compound 1-9: (R)-3-(4-(((2S,3S)-1-(4-(benzofuran-2-yl)phenoxy)-3-methylpentan-2-yl)amino)benzamido)-2-hydroxypropanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.02 (t, J=5.4 Hz, 1H), 7.83 (d, J=8.3 Hz, 2H), 7.54-7.69 (m, 4H), 7.18-7.31 (m, 3H), 7.05 (d, J=8.8 Hz, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.19 (d, J=8.8 Hz, 1H), 4.09-4.17 (m, 2H), 4.04 (dd, J=10.0, 6.1 Hz, 1H), 3.70 (br. s., 1H), 3.48-3.60 (m, 1H), 3.34-3.45 (m, 1H), 1.69-1.85 (m, 1H), 1.51-1.69 (m, 1H), 1.26 (dt, J=13.8, 8.0 Hz, 1H), 0.95 (d, J=6.8 Hz, 3H), 0.90 (t, J=7.3 Hz, 3H). MS(M+1): 517.

Compound 1-10: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)hexan-2-yl)amino)benzamido) propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.49-7.65 (m, 4H), 7.32-7.46 (m, 3H), 7.13 (q, J=7.4, 1.2 Hz, 2H), 6.64-6.82 (m, 3H), 6.29-6.45 (m, 2H), 3.61-3.80 (m, 2H), 3.41-3.55 (m, 3H), 2.39-2.51 (m, 2H), 1.49-1.61 (m, 1H), 1.32-1.42 (m, 1H), 1.03-1.20 (m, 4H), 0.71 (t, J=6.9 Hz, 3H). MS(M+1): 501.

Compound 1-11: (S)-3-(4-((1-((4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹HNMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.8 Hz, 2H), 7.39-7.52 (m, 6H), 6.91 (d, J=8.3 Hz, 2H), 6.69-6.77 (m, 1H), 6.58 (d, J=8.8 Hz, 2H), 3.93-4.06 (m, 2H), 3.71-3.79 (m, 1H), 3.62-3.72 (m, 2H), 2.63-2.69 (m, 2H), 1.76-1.87 (m, 1H), 1.54-1.69 (m, 1H), 1.26-1.44 (m, 4H), 0.89 (t, J=7.1 Hz, 3H). MS(M+1): 517.

Compound 1-12: (S)-3-(4-((1-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (t, J=5.4 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.48-7.42 (m, 4H), 6.94 (d, J=8.8, 2H), 6.76 (d, J=8.8, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.11 (d, J=8.8, 1H), 4.07-3.96 (m, 2H), 3.66-3.63 (m, 1H), 3.43-3.38 (m, 2H), 2.47 (t, J=7.3 Hz, 2H), 2.08-2.02 (m, 1H), 1.01-0.96 (m, 6H). MS(M+1): 490.

Compound 1-13: Preparation of N-((1H-tetrazol-5-yl)methyl)-4-(((2S,3S)-1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.74 (t, J=5.6 Hz, 1H), 7.61-7.73 (m, 3H), 7.44-7.50 (m, 1H), 7.36-7.42 (m, 1H), 7.34 (d, J=8.3 Hz, 2H), 7.01 (d, J=8.3 Hz, 2H), 6.68 (d, J=8.8 Hz, 2H), 6.26 (d, J=8.8 Hz, 1H), 4.69 (d, J=5.4 Hz, 2H), 4.09-4.17 (m, 1H), 4.03 (dd, J=9.8, 5.9 Hz, 1H), 3.65-3.78 (m, 1H), 1.74-1.86 (m, 1H), 1.53-1.68 (m, 1H), 1.27 (dt, J=13.8, 8.0 Hz, 1H), 0.96 (d, J=6.8 Hz, 3H), 0.90 (t, J=7.3 Hz, 3H). MS(M+1): 539.

Compound 1-14: (R)-3-(4-(((2S,3S)-1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)-2-hydroxypropanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.05 (br. s., 1H), 7.57-7.68 (m, 3H), 7.42-7.49 (m, 1H), 7.37 (d, J=8.3 Hz, 1H), 7.32 (d, J=8.8 Hz, 2H), 7.00 (d, J=8.8 Hz, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.17 (d, J=8.8 Hz, 1H), 4.06-4.16 (m, 1H), 3.97-4.06 (m, 1H), 3.89 (br. s., 1H), 3.68 (br. s., 1H), 3.42 (br. s., 2H), 1.72-1.85 (m, 1H), 1.60 (ddd, J=13.1, 7.5, 3.9 Hz, 1H), 1.19-1.34 (m, 1H), 0.94 (d, J=6.8 Hz, 3H), 0.89 (t, J=7.3 Hz, 3H). MS(M+1): 545.

Compound 1-15: (S)-3-(4-((1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.06 (t, J=5.4 Hz, 1H), 7.82 (d, J=8 Hz, 2H), 7.75 (d, J=8 Hz, 2H), 7.66 (d, J=8.8 Hz, 2H), 7.60 (d, J=8.8 Hz, 2H), 7.04 (d, J=8.8 Hz, 2H), 6.64 (d, J=8.8 Hz, 2H), 6.13 (d, J=8.8 Hz, 1H), 3.95-4.06 (m, 2H), 3.73-3.86 (m, 1H), 3.38-3.42 (m, 2H), 2.45-2.49 (m, 2H), 1.65-1.79 (m, 1H), 1.57 (td, J=8.9, 5.1 Hz, 1H), 1.25-1.48 (m, 4H), 0.87 (t, J=7.3 Hz, 3H). MS(M+1): 529.

Compound 1-16: Preparation of(S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.73-8.80 (m, 1H), 7.81-7.85 (m, 2H), 7.74-7.79 (m, 2H), 7.63-7.69 (m, 4H), 7.05 (d, J=8.8 Hz, 2H), 6.67 (d, J=9.3 Hz, 2H), 6.20-6.27 (m, 1H), 4.69 (d, J=5.4 Hz, 2H), 4.01 (d, J=4.9 Hz, 2H), 3.76-3.88 (m, 1H), 1.68-1.78 (m, 1H), 1.49-1.64 (m, 1H), 1.32 (br. s., 4H), 0.84-0.90 (m, 3H); MS(M+1): 539.

Compound 1-17: (S)-3-(4-((1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.61 (d, J=8.8 Hz, 2H), 7.46 (d, J=2.0 Hz, 1H), 7.32 (d, J=8.8 Hz, 2H), 7.21-7.28 (m, 3H), 6.93 (d, J=8.8 Hz, 2H), 6.69 (t, J=5.9 Hz, 1H), 6.60 (d, J=8.8 Hz, 2H), 3.97-4.09 (m, 2H), 3.74-3.82 (m, 1H), 3.69 (q, J=5.9 Hz, 2H), 2.68 (t, J=5.9 Hz, 2H), 1.77-1.91 (m, 1H), 1.57-1.72 (m, 1H), 1.30-1.54 (m, 4H), 0.91 (t, J=7.1 Hz, 3H); MS(M+1): 529.

Compound 1-18: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.75 (t, J=5.4 Hz, 1H), 7.68 (d, J=2.4 Hz, 1H), 7.65 (d, J=8.8 Hz, 2H), 7.47 (dd, J=8.3, 2.0 Hz, 1H), 7.39 (d, J=83 Hz, 1H), 7.34 (d, J=8.8 Hz, 2H), 7.00 (d, J=8.8 Hz, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.21 (d, J=8.3 Hz, 1H), 4.68 (d, J=5.4 Hz, 2H), 4.00 (d, J=5.4 Hz, 2H), 3.75-3.86 (m, 1H), 1.66-1.80 (m, 1H), 1.51-1.64 (m, 1H), 1.27-1.48 (m, 4H), 0.87 (t, J=7.1 Hz, 3H); MS(M+1): 539.

Compound 1-19: (S)-3-(4-((1-((2′-chloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.70 (d, J=1.0 Hz, 3H), 7.59 (d, J=8.8 Hz, 2H), 7.52 (dd, J=8.1, 1.2 Hz, 1H), 7.40 (d, J=7.8 Hz, 1H), 7.32-7.35 (m, 2H), 6.90-6.98 (m, 2H), 6.77 (t, J=5.9 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 3.97-4.06 (m, 2H), 3.73-3.81 (m, 1H), 3.67 (q, J=5.9 Hz, 2H), 2.65 (t, J=5.9 Hz, 2H), 1.76-1.88 (m, 1H), 1.58-1.69 (m, 1H), 1.29-1.50 (m, 4H), 0.89 (t, J=7.1 Hz, 3H). MS(M+1): 563.

Compound 1-20: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-((2′-chloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.76 (t, J=5.6 Hz, 1H), 7.94 (d, J=1.0 Hz, 1H), 7.76 (dd, J=8.1, 1.2 Hz, 1H), 7.66 (d, J=8.8 Hz, 2H), 7.60 (d, J=7.8 Hz, 1H), 7.41 (d, J=8.8 Hz, 2H), 7.04 (d, J=8.8 Hz, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.23 (d, J=8.3 Hz, 1H), 4.69 (d, J=5.4 Hz, 2H), 4.02 (d, J=5.4 Hz, 2H), 3.77-3.88 (m, 1H), 1.69-1.81 (m, 1H), 1.53-1.64 (m, 1H), 1.26-1.50 (m, 4H), 0.88 (t, J=7.1 Hz, 3H). MS(M+1): 573.

Compound 1-21: (R)-3-(4-(((S)-1-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)-2-hydroxypropanoic acid

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.10 (dd, J=8.8, 3 Hz, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.69 (d, J=8, 1H), 7.62-7.56 (m, 3H), 7.43 (d, J=1.5 Hz, 1H), 7.34 (dt, J=8, 1.5 Hz, 1H), 7.27 (dt, J=8.8, 1.5 Hz, 1H), 7.22 (d, J=3 Hz, 1H), 7.09 (dd, J=8.8, 3 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.13 (d, J=8.8 Hz, 1H), 4.17-4.05 (m, 2H), 3.69-3.60 (m, 2H), 3.44-3.38 (m, 1H), 3.21-3.17 (m, 1H), 2.06-2.01 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 506.

Compound 1-22: (S)-3-(4-((1-((2′-chloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.08 (br. s., 1H), 7.94 (s, 1H), 7.76 (d, J=7.8 Hz, 1H), 7.53-7.63 (m, 3H), 7.35-7.45 (m, 2H), 6.99-7.08 (m, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.00-4.14 (m, 2H), 3.61-3.72 (m, 2H), 3.39 (d, J=5.4 Hz, 3H), 2.40 (t, J=7.1 Hz, 2H), 1.98-2.11 (m, 1H), 0.94-1.06 (m, 6H). MS(M+1): 549.

Compound 1-23: 3-(4-((2-(4-(benzofuran-2-yl)phenoxy)-1-phenylethyl)amino)benzamido) propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, J=8.8 Hz, 3H), 7.28-7.54 (m, 13H), 7.17-7.26 (m, 9H), 6.96 (d, J=9.3 Hz, 3H), 6.88 (s, 1H), 6.54 (d, J=8.8 Hz, 4H), 4.72-4.89 (m, 1H), 4.22-4.37 (m, 1H), 3.63-3.77 (m, 6H), 2.66 (t, J=5.9 Hz, 2H). MS(M+1): 521.

Compound 1-24: (S)-3-(4-((3-methyl-1-(4-(5-(trifluoromethyl)pyridin-2-yl)phenoxy)butan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.96 (s, 1H), 8.16-8.22 (m, 1H), 8.11 (d, J=8.8 Hz, 3H), 7.49-7.63 (m, 2H), 7.03-7.11 (m, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.01-4.17 (m, 3H), 3.62-3.72 (m, 2H), 3.36 (br. s., 2H), 2.20-2.32 (m, 2H), 2.05 (dq, J=13.0, 6.6 Hz, 1H), 0.99 (d, J=5.9 Hz, 3H), 0.99 (d, J=19.1 Hz, 3H). MS(M+1): 516.

Compound 1-25: (S)-3-(4-((1-((2′-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)aminobenzamido)propanoic acid

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.03 (t, J=5.4 Hz, 1H), 7.74-7.71 (m, 2H), 7.64-7.59 (m, 3H), 7.54-7.52 (m, 2H), 7.06 (d, J=8.8 Hz, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.13-4.02 (m, 2H), 3.70-3.63 (m, 1H), 3.44-3.39 (m, 2H), 2.47 (t, J=6.8 Hz, 2H), 2.09-2.01 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 533.

Compound 1-26: 3-(4-(((2S,3S)-1-((2,4′-difluoro-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J=8.8 Hz, 2H), 7.35-7.39 (m, 2H), 7.31 (td, J=8.8, 6.4 Hz, 1H), 6.81-6.93 (m, 4H), 6.77 (t, J=5.9 Hz, 1H), 6.57 (d, J=8.8 Hz, 2H), 4.00-4.08 (m, 2H), 3.60-3.70 (m, 3H), 2.64 (t, J=5.9 Hz, 2H), 1.79-1.92 (m, 1H), 1.58-1.69 (m, 1H), 1.17-1.27 (m, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 497.

Compound 1-27: (S)-3-(4-((1-((2′-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.8 Hz, 2H), 7.34-7.52 (m, 5H), 6.94 (d, J=8.8 Hz, 2H), 6.79 (t, J=5.9 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 4.01 (tt, J=9.5, 4.6 Hz, 2H), 3.72-3.80 (m, 1H), 3.66 (q, J=5.9 Hz, 2H), 2.64 (t, J=5.6 Hz, 2H), 1.76-1.86 (m, 1H), 1.57-1.68 (m, 1H), 1.29-1.49 (m, 4H), 0.89 (t, J=7.1 Hz, 3H). MS(M+1): 547.

Compound 1-28: 3-(4-((1-phenyl-2-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)ethyl)amino) benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58-7.65 (m, 4H), 7.48-7.53 (m, 4H), 7.24-7.43 (m, 5H), 6.86-7.08 (m, 2H), 6.69 (t, J=5.9 Hz, 1H), 6.52 (d, J=8.8 Hz, 2H), 4.79 (dd, J=7.8, 3.9 Hz, 1H), 4.27 (dd, J=9.8, 3.9 Hz, 1H), 4.04-4.15 (m, 1H), 3.62 (q, J=5.9 Hz, 2H), 2.61 (t, J=5.9 Hz, 2H).

Compound 1-29: (S)-3-(4-((3-methyl-1-(4-(6-(trifluoromethyl)pyridazin-3-yl)phenoxy)butan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.46 (d, J=8.8 Hz, 1H), 8.26-8.20 (m, 3H), 8.03 (t, J=5.4 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.14 (d, J=8.8, 3 Hz, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.18-4.06 (m, 2H), 3.72-3.65 (m, 1H), 3.43-3.39 (m, 2H), 2.46 (t, J=6.8 Hz, 2H), 2.09-1.98 (m, 1H), 1.02-0.98 (m, 6H). MS(M+1): 517.

Compound 1-30: Ethyl (S)-3-(4-((1-(4-(benzo[d]thiazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propenoate

¹H NMR (400 MHz, CDCl₃): δ 7.97-8.03 (m, 3H), 7.86 (d, J=7.3 Hz, 1H), 7.57-7.64 (m, 2H), 7.41-7.48 (m, 1H), 7.30-7.37 (m, 1H), 6.91-6.98 (m, 2H), 6.56-6.65 (m, 3H), 4.07-4.20 (m, 5H), 3.68 (q, J=5.9 Hz, 2H), 3.56-3.64 (m, 1H), 2.56-2.63 (m, 2H), 2.09-2.21 (m, 1H), 1.21-1.28 (m, 3H), 1.04 (d, J=6.8 Hz, 3H), 1.05 (d, J=6.8 Hz, 3H). MS(M+1): 532.

Compound 1-31: Methyl (S)-3-(4-((1-(4-(benzo[d]thiazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino) benzamido)propanoate

¹H NMR (DMSO-d₆): δ 8.04-8.13 (m, 2H), 7.96-8.04 (m, 3H), 7.55-7.65 (m, 2H), 7.52 (td, J=7.6, 1.5 Hz, 1H), 7.39-7.45 (m, 1H), 7.07-7.14 (m, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.14 (d, J=8.8 Hz, 1H), 4.04-4.20 (m, 2H), 3.64-3.74 (m, 1H), 3.57-3.63 (m, 3H), 3.39-3.48 (m, 2H), 2.55 (t, J=7.1 Hz, 2H), 2.05 (dq, J=13.2, 6.5 Hz, 1H), 0.98 (d, J=6.8 Hz, 3H), 1.01 (d, J=6.8 Hz, 3H). MS(M+1): 518.

Compound 1-32: (S)-3-(4-((1-(4-(benzo[d]thiazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.06-8.15 (m, 2H), 7.97-8.05 (m, 3H), 7.55-7.63 (m, J=8.3 Hz, 2H), 7.47-7.54 (m, 1H), 7.38-7.46 (m, 1H), 7.11 (d, J=9.3 Hz, 2H), 6.61-6.71 (m, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.15 (dd, J=10.0, 4.2 Hz, 1H), 4.07 (dd, J=10.0, 6.1 Hz, 1H), 3.64-3.72 (m, 2H), 3.34-3.42 (m, 2H), 2.35-2.44 (m, 2H), 2.05 (dq, J=12.8, 6.6 Hz, 1H), 1.00 (d, J=5.4 Hz, 3H), 1.00 (d, J=19.1 Hz, 3H). MS(M+1): 504.

Compound 1-33: (S)-2-(4-((1-((2′-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)ethane-1-sulfonic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.09 (t, J=5.4 Hz, 1H), 7.75-7.71 (m, 2H), 7.64-7.62 (m, 1H), 7.54-7.52 (m, 4H), 7.07 (d, J=8.8 Hz, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.13-4.02 (m, 2H), 3.70-3.63 (m, 1H), 3.50-3.45 (m, 2H), 2.64 (t, J=6.8 Hz, 2H), 2.10-1.99 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 569.

Compound 1-34: (R)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido) propanoic acid

¹HNMR (400 MHz, DMSO-d₆): δ 12.14 (s, 1H), 8.05-8.02 (m, 1H), 7.81-7.85 (m, 2H), 7.57-7.62 (m, 4H), 7.21-7.30 (m, 3H), 7.04-7.07 (m, 2H), 6.66 (d, J=8.8 Hz, 1H), 6.11 (d, J=8.9 Hz, 1H), 4.02-4.14 (m, 2H), 3.64-3.70 (m, 1H), 3.38-3.43 (m, 2H), 2.45-2.47 (m, 2H), 2.01-2.09 (m, 1H), 1.01 (d, J=6.8 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H). MS(M+1): 487.

Compound 1-35: (R)-3-(4-((1-((2′-chloro-4′-(trifluoroethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.08 (br. s., 1H), 7.94 (s, 1H), 7.76 (d, J=7.8 Hz, 1H), 7.53-7.63 (m, 3H), 7.35-7.45 (m, 2H), 6.99-7.08 (m, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.00-4.14 (m, 2H), 3.61-3.72 (m, 2H), 3.39 (d, J=5.4 Hz, 3H), 2.40 (t, J=7.1 Hz, 2H), 1.98-2.11 (m, 1H), 0.94-1.06 (m, 6H). MS(M+1): 549.

Compound 1-36: (S)-3-(4-((1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)oxy)-3,3-dimethylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.02 (t, 1H), 7.68 (d, J=2.4 Hz, 1H), 7.56 (d, J=8.8 Hz, 2H), 7.43-7.50 (dd, 1H), 7.27-7.42 (d, 3H), 6.91-6.99 (dt, 2H), 6.70 (d, J=8.8 Hz, 2H), 5.99 (d, J=9.8 Hz, 1H), 4.22-4.35 (dd, 1H), 3.88-4.09 (m, 2H), 3.62-3.71 (m, 1H), 2.46 (t, J=7.1 Hz, 2H), 1.02 (s, 9H). MS(M+1): 529.

Compound 1-37: (S)-3-(4-((1-((2′-chloro-4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.04 (t, J=5.6 Hz, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.26 (d, J=8.8 Hz, 2H), 7.15 (d, J=8.8 Hz, 1H), 6.94 (d, J=8.8 Hz, 2H), 6.76-6.71 (m, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.06-3.97 (m, 2H), 3.67-3.62 (m, 1H), 2.46 (t, J=6.8 Hz, 2H), 2.08-2.02 (m, 1H), 1.01-0.96 (m, 6H). MS(M+1): 524.

Compound 1-38: 3-(4-(((2S,3S)-1-((2′-chloro-4′-methoxy-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.68 (d, J=8.3 Hz, 2H), 7.45-7.50 (m, 1H), 7.25-7.33 (m, 3H), 7.05 (d, J=2.4 Hz, 1H), 6.92-7.01 (m, 3H), 6.73 (d, J=8.8 Hz, 2H), 5.48-5.56 (m, 1H), 4.18 (dd, J=16.9, 4.6 Hz, 2H), 3.85 (s, 3H), 3.59 (d, J=5.9 Hz, 2H), 2.61 (t, J=6.6 Hz, 2H), 1.88-1.95 (m, 1H), 1.68-1.80 (m, 1H), 1.28-1.41 (m, 1H), 1.05 (d, J=6.8 Hz, 3H), 0.96 (t, J=7.6 Hz, 3H). MS(M+1): 525.

Compound 1-39: (S)-3-(4-((1-(4-(imidazo[1,2-a]pyridin-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.48 (d, J=7.8 Hz, 1H), 8.26 (s, 1H), 8.03 (t, J=5.6 Hz, 1H), 7.86 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 2H), 7.53 (d, J=7.8 Hz, 1H), 7.23-7.19 (m, 1H), 6.98 (d, J=8.8 Hz, 2H), 6.86 (t, J=7.8 Hz, 1H), 6.66 (d, J=8.8 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.11-3.99 (m, 2H), 3.67-3.63 (m, 1H), 2.47 (t, J=6.8 Hz, 2H), 2.08-2.03 (m, 1H), 1.01-0.97 (m, 6H). MS(M+1): 487.

Compound 1-40: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3,3-dimethylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.00-8.07 (m, 1H), 7.81 (d, J=8.8 Hz, 1H), 7.54-7.63 (m, 3H), 7.20-7.31 (m, 2H), 7.00 (d, J=8.8 Hz, 1H), 6.70 (d, J=8.8 Hz, 1H), 5.97-6.03 (m, 1H), 4.27-4.34 (m, 1H), 3.94-4.01 (m, 1H), 3.64-3.72 (m, 1H), 3.40 (d, J=5.4 Hz, 2H), 2.42-2.48 (m, 2H), 1.03 (s, 9H). MS(M+1): 501.

Compound 1-41: (S)-3-(4-((1-(4-(furo[3,2-b]pyridin-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.46 (dd, 1H), 8.02-8.09 (m, 1H), 7.98 (d, 1H), 7.91 (dt, 2H), 7.58 (d, 2H), 7.47 (s, 1H), 7.28 m (q, 1H), 7.09 (dt, 2H), 6.66 (d, 2H), 6.12 (d, 1H), 4.01-4.17 (m, 2H), 3.62-3.73 (m, 2H), 2.45 (t, 2H), 2.00-2.11 (m, 1H), 1.24 (s, 1H), 0.99 (m, 6H). MS(M+1): 488.

Compound 1-42: (S)-3-(4-((1-((2′-chloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3,3-dimethylbutan-2-yl)amino)benzamido)propanoic aid

¹H NMR (400 MHz, CDCl₃): δ 7.69 (s, 1H), 7.58 (d, J=8.3 Hz, 2H), 7.52 (d, J=8.3 Hz, 1H), 7.39 (d, J=7.8 Hz, 1H), 7.32 (d, J=8.8 Hz, 2H), 6.89 (d, J=8.3 Hz, 2H), 6.63 (d, J=8.3 Hz, 3H), 4.20 (dd, J=9.5, 4.2 Hz, 1H), 4.03 (dd, J=9.3, 4.9 Hz, 1H), 3.68 (d, J=4.4 Hz, 2H), 3.57 (t, J=4.6 Hz, 1H), 2.68 (br. s., 2H), 1.07 (s, 9H). MS(M+1): 563.

Compound 1-43: 3-(4-((3-methyl-1-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)phenoxy)butan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.98 (d, J=8.0 Hz, 2H), 7.58 (d, J=8.8 Hz, 2H), 6.96 (d, J=8.0 Hz, 2H), 6.80 (t, J=5.9 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 4.09 (d, J=4.0 Hz, 2H), 3.60-3.72 (m, 2H), 2.64 (t, J=5.6 Hz, 2H), 2.11 (dq, J=13.4, 6.8 Hz, 1H), 0.95-1.09 (m, 6H). MS(M+1): 507.

Compound 1-44: 3-(4-((3-methyl-1-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)phenoxy) pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.97 (d, J=8.0 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 6.96 (d, J=8.8 Hz, 2H), 6.85 (t, J=5.4 Hz, 1H), 6.57 (d, J=8.8 Hz, 2H), 4.03-4.15 (m, 2H), 3.59-3.70 (m, 3H), 2.62 (t, J=5.6 Hz, 2H), 1.79-1.89 (m, 1H), 1.51-1.70 (m, 1H), 1.10-1.31 (m, 2H), 0.98 (d, J=6.8 Hz, 3H), 0.88-0.95 (t, J=8.0 Hz, 3H). MS(M+1): 521.

Compound 1-45: 3-(4-(((2S,3S)-1-(4-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)phenoxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.90 (d, J=8.8 Hz, 2H), 7.58 (d, J=8.8 Hz, 2H), 6.91 (d, J=8.8 Hz, 2H), 6.88-6.81 (m, 1H), 6.56 (d, J=8.3 Hz, 2H), 4.14-4.01 (m, 2H), 3.69-3.58 (m, 3H), 2.67-2.58 (m, 2H), 1.89-1.78 (m, 1H), 1.68-1.57 (m, 1H), 1.44 (s, 9H), 1.30-1.18 (m, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.92 (t, J=7.3 Hz, 3H). MS(M+1): 509.

Compound 1-46: 3-(4-(((2S,3S)-3-methyl-1-(4-(5-phenyl-1,3,4-oxadiazol-2-yl)phenoxy)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.16-8.05 (m, 2H), 8.04-7.96 (m, 2H), 7.59 (d, J=8.3 Hz, 2H), 7.53-7.42 (m, 3H), 6.95 (d, J=8.8 Hz, 2H), 6.83-6.69 (m, 1H), 6.58 (d, J=8.3 Hz, 2H), 4.16-4.03 (m, 2H), 3.72-3.59 (m, 3H), 2.72-2.60 (m, 2H), 1.91-1.78 (m, 1H), 1.72-1.57 (m, 1H), 1.30-1.19 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 529. HPLC 99%.

Compound 1-47: Ethyl (S)-3-(4-((1-(4-(benzo[d]oxazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoate

¹H NMR (400 MHz, DMSO-d₆): δ 8.09-8.16 (m, 2H), 8.05 (t, J=5.4 Hz, 1H), 7.71-7.79 (m, 2H), 7.54-7.62 (m, 2H), 7.34-7.42 (m, 2H), 7.11-7.18 (m, 2H), 6.61-6.71 (m, J=8.8 Hz, 2H), 6.13 (d, J=9.3 Hz, 1H), 4.14-4.22 (m, 1H), 4.01-4.12 (m, 3H), 3.65-3.75 (m, 1H), 3.38-3.47 (m, 2H), 2.52-2.55 (m, 2H), 2.05 (dq, J=13.2, 6.7 Hz, 1H), 1.17 (t, J=7.1 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H), 1.01 (d, J=6.8 Hz, 3H), MS(M+1): 516. HPLC 95%.

Compound 1-48: (S)-3-(4-((1-(4-(benzo[d]oxazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 12.16 (br. s., 1H), 8.09-8.15 (m, 2H), 8.04 (t, J=5.6 Hz, 1H), 7.71-7.78 (m, 2H), 7.56-7.63 (m, J=8.8 Hz, 2H), 7.35-7.42 (m, 2H), 7.11-7.18 (m, 2H), 6.67 (d, J=9.3 Hz, 2H), 6.13 (d, J=9.3 Hz, 1H), 4.17 (dd, J=10.0, 4.2 Hz, 1H), 4.08 (dd, J=10.0, 6.1 Hz, 1H), 3.63-3.74 (m, 1H), 3.37-3.45 (m, 2H), 2.42-2.48 (m, 2H), 2.05 (dq, J=12.9, 6.8 Hz, 1H), 1.01 (d, J=6.8 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H). MS(M+1): 488.

Compound 1-49: (S)-3-(4-((1-(4-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)phenoxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.91 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.3 Hz, 2H), 6.92 (d, J=9.3 Hz, 2H), 6.83-6.71 (m, 1H), 6.57 (d, J=8.8 Hz, 2H), 4.04-4.00 (m, 2H), 3.81-3.73 (m, 1H), 3.71-3.61 (m, 2H), 2.71-2.59 (m, 2H), 1.87-1.72 (m, 1H), 1.70-1.56 (m, 1H), 1.45 (s, 9H), 1.41-1.28 (m, 4H), 0.89 (t, J=6.6 Hz, 3H). MS(M+1): 509.

Compound 1-50: (S)-3-(4-((1-(4-(5-phenyl-1,3,4-oxadiazol-2-yl)phenoxy)hexan-2-yl)amino) benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.07 (td, J=2.3, 5.1 Hz, 2H), 8.02-7.95 (m, 2H), 7.59 (d, J=8.3 Hz, 2H), 7.53-7.44 (m, 3H), 6.97-6.81 (m, 3H), 6.60-6.53 (m, 2H), 4.04-3.96 (m, 2H), 3.80-3.72 (m, 1H), 3.69-3.61 (m, 2H), 2.67-2.60 (m, 2H), 1.85-1.73 (m, 1H), 1.60 (d, J=4.9 Hz, 1H), 1.47-1.28 (m, 4H), 0.87 (t, J=7.1, 3H). MS(M+1): 529.

Compound 1-51: Ethyl (R)-3-(4-((1-(4-(benzo[d]thiazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino) benzamido)propanoate

¹H NMR (400 MHz, DMSO-d₆): δ 7.96-8.13 (m, 5H), 7.56-7.64 (m, J=8.8 Hz, 2H), 7.51 (d, J=1.0 Hz, 1H), 7.43 (d, J=8.3 Hz, 1H), 7.06-7.16 (m, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.12 (s, 1H), 4.06 (q, J=6.8 Hz, 4H), 3.64-3.75 (m, 1H), 3.44 (d, J=5.4 Hz, 2H), 2.52-2.56 (m, 2H), 2.05 (dq, J=13.3, 6.7 Hz, 1H), 1.17 (t, J=7.1 Hz, 3H), 1.00 (d, J=4.9 Hz, 3H), 1.00 (d, J=18.6 Hz, 3H). MS(M+1): 532.

Compound 1-52: (R)-3-(4-((1-(4-(benzo[d]thiazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.97-8.12 (m, 5H), 7.56-7.63 (m, J=8.8 Hz, 2H), 7.51 (td, J=7.7, 1.2 Hz, 1H), 7.38-7.46 (m, 1H), 7.04-7.14 (m, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.01-4.18 (m, 2H), 3.63-3.73 (m, 1H), 3.35-3.44 (m, 2H), 2.44 (t, J=7.1 Hz, 2H), 2.05 (dq, J=13.1, 6.7 Hz, 1H), 0.99 (d, J=5.4 Hz, 3H), 0.99 (d, J=19.1 Hz, 3H). MS(M+1): 504.

Compound 1-53: Ethyl (R)-3-(4-((1-(4-benzo[d]oxazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoate

¹H NMR (400 MHz, DMSO-d₆): δ 8.08-8.16 (m, J=8.8 Hz, 2H), 8.00-8.08 (m, 1H), 7.68-7.77 (m, 2H), 7.59 (d, J=8.3 Hz, 2H), 7.33-7.42 (m, 2H), 7.14 (d, J=7.3 Hz, 2H), 6.63-6.72 (m, J=8.8 Hz, 2H), 6.13 (d, J=8.8 Hz, 1H), 4.13-4.22 (m, 1H), 3.98-4.13 (m, 3H), 3.64-3.74 (m, 1H), 3.38-3.48 (m, 2H), 2.52-2.57 (m, 2H), 2.05 (dq, J=13.3, 6.7 Hz, 1H), 1.17 (t, J=7.1 Hz, 3H), 1.00 (dd, J=12.2, 6.8 Hz, 6H). MS(M+1): 516.

Compound 1-54: (R)-3-(4-((1-(4-(benzo[d]oxazol-2-yl)phenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.12 (d, J=8.3 Hz, 2H), 8.01-8.08 (m, 1H), 7.70-7.79 (m, 2H), 7.60 (dd, J=8.8, 1.5 Hz, 2H), 7.34-7.42 (m, 2H), 7.14 (dd, J=8.8, 1.5 Hz, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.13 (d, J=8.8 Hz, 1H), 4.16 (d, J=6.8 Hz, 1H), 4.08 (dd, J=9.8, 6.4 Hz, 1H), 3.63-3.73 (m, 1H), 3.36-3.44 (m, 2H), 2.40-2.48 (m, 2H), 2.05 (dq, J=13.3, 6.7 Hz, 1H), 1.01 (d, J=6.4 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H). MS(M+1): 488.

Example 2: Synthesis of Compounds 2-1 to 2-13

Compound 2-1: (R)-3-(4-((1-((2,6-dimethyl-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-phenylpropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.03-8.12 (m, 1H), 7.78 (d, J=7.8 Hz, 2H), 7.60 (dd, J=8.8, 2.0 Hz, 2H), 7.23-7.42 (m, 6H), 7.14-7.23 (m, 1H), 6.68-6.76 (m, 2H), 6.65 (d, J=8.8 Hz, 2H), 6.27 (d, J=7.8 Hz, 1H), 3.91-4.09 (m, 3H), 3.40 (d, J=6.4 Hz, 3H), 3.02 (dd, J=13.7, 5.9 Hz, 1H), 2.91 (dd, J=13.7, 7.3 Hz, 1H), 2.40-2.48 (m, 2H), 1.85-1.94 (m, 6H). MS(M+1): 591.

Compound 2-2: (R)-3-(4-((1-((2,6-dimethyl-4′-trifluoromethoxy)-[1,1′-biphenyl]-4-yl)oxy)-3-phenylpropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.56-7.64 (m, J=8.8 Hz, 2H), 7.15-7.31 (m, 8H), 7.06-7.13 (m, 2H), 6.80-6.91 (m, 1H), 6.59-6.65 (m, 2H), 6.52-6.59 (m, 2H), 3.86-4.01 (m, 4H), 3.63 (d, J=5.4 Hz, 2H), 3.02 (d, J=6.4 Hz, 2H), 2.59 (br. s., 2H), 1.95 (s, 6H). MS(M+1): 591.

Compound 2-3: (S)-3-(4-((1-((2,6-dimethyl-4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=7.8 Hz, 2H), 7.36 (br. s., 1H), 7.15-7.21 (m, 2H), 7.01-7.09 (m, 2H), 6.56-6.65 (m, 2H), 6.40-6.48 (m, 2H), 3.93-4.04 (m, 1H), 3.76-3.93 (m, 2H), 3.71 (br. s., 1H), 3.48 (br. s., 2H), 3.28-3.43 (m, 1H), 2.40 (br. s., 2H), 1.88-1.93 (m, 6H), 1.62-1.75 (m, 1H), 0.82-0.92 (m, 6H). MS(M+1): 573.

Compound 2-4: (S)-3-(4-((1-((2,6-dimethyl-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.60 (d, J=8.3 Hz, 2H), 7.63 (d, J=7.8 Hz, 2H), 7.21 (d, J=7.3 Hz, 2H), 6.87 (br. s., 1H), 6.47-6.74 (m, 4H), 5.47 (br. s., 1H), 3.89-4.18 (m, 2H), 3.65 (br. s., 2H), 3.56 (br. s., 1H), 2.64 (br. s., 2H), 2.15 (m, 1H), 1.94 (br. s., 6H), 0.91-1.14 (m, 6H). MS(M+1): 543.

Compound 2-5: (S)-3-(4-((1-((4′-(tert-butyl)-2,6-dimethyl-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.8 Hz, 2H), 7.30-7.43 (m, J=7.8 Hz, 2H), 6.93-7.06 (m, J=7.8 Hz, 2H), 6.74-6.84 (m, 1H), 6.49-6.68 (m, 4H), 3.95-4.09 (m, 2H), 3.67 (q, J=5.7 Hz, 2H), 3.48-3.60 (m, 1H), 2.66 (t, J=5.6 Hz, 2H), 2.14 (dq, J=13.4, 6.8 Hz, 1H), 1.98 (s, 6H), 1.34 (s, 9H), 1.03 (dd, J=6.8, 2.0 Hz, 6H). MS(M+1): 531.

Compound 2-6: 3-(4-(((2S,3S)-1-((4′-(tert-butyl)-2,6-dimethyl-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.66-7.72 (m, 2H), 7.45-7.48 (m, 2H), 7.01-7.06 (m, 2H), 6.73 (d, J=8.8 Hz, 2H), 6.67 (s, 2H), 4.13 (dd, J=12.0, 4.6 Hz, 2H), 3.71-3.82 (m, 1H), 3.59 (t, J=6.8 Hz, 2H), 2.61 (t, J=6.8 Hz, 2H), 1.95 (s, 6H), 1.36 (s, 9H), 1.05 (d, J=6.8 Hz, 3H), 0.93-0.99 (m, 3H).

Compound 2-7: 3-(4-(((2S,3S)-1-(4-(benzofuran-2-yl)-3,5-dimethylphenoxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.56-7.62 (m, 3H), 7.47 (d, J=7.8 Hz, 1H), 7.20-7.29 (m, 2H), 6.71 (t, J=6.1 Hz, 1H), 6.63 (s, 2H), 6.56-6.60 (m, 3H), 4.01-4.19 (m, 2H), 3.58-3.72 (m, 3H), 2.66 (t, J=5.9 Hz, 2H), 2.19 (s, 6H), 1.81-1.91 (m, 1H), 1.59-1.71 (m, 1H), 1.19-1.31 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.94 (t, J=7.3 Hz, 3H). MS(M+1): 529.

Compound 2-8: 3-(4-(((2S,3S)-1-((2,6-dimethyl-4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.8 Hz, 2H), 7.22 (d, J=8.3 Hz, 2H), 7.1 (d, J=8.8 Hz, 2H), 6.70-6.82 (m, 1H), 6.62 (s, 2H), 6.58 (d, J=8.3 Hz, 2H), 4.04 (d, J=4.4 Hz, 2H), 3.57-3.71 (m, 3H), 2.65 (t, J=5.6 Hz, 2H), 1.6 (s, 6H), 1.80-1.88 (m, 1H), 1.58-1.74 (m, 1H), 1.19-1.31 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.94 (t, J=7.3 Hz, 3H). MS(M+1): 573.

Compound 2-9: 3-(4-(((2S,3S)-1-((2′,4′-dichloro-2,6-dimethyl-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.53-7.60 (m, 2H), 6.76 (br. s., 1H), 6.53-6.64 (m, 4H), 6.48 (s, 2H), 3.98 (d, J=4.4 Hz, 2H), 3.65 (q, J=5.4 Hz, 2H), 3.58 (d, J=6.4 Hz, 1H), 2.63 (t, J=5.6 Hz, 2H), 2.24 (s, 6H), 1.77-1.88 (m, 1H), 1.57-1.68 (m, 1H), 1.15-1.25 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.89-0.94 (m, 3H). MS(M+1): 557.

Compound 2-10: 3-(4-(((2S,3S)-1-((2,6-dimethyl-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.00-8.12 (m, 1H), 7.78 (d, J=7.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 2H), 7.35 (d, J=7.8 Hz, 2H), 6.71 (s, 2H), 6.64 (d, J=8.8 Hz, 2H), 6.04-6.19 (m, 1H), 3.94-4.11 (m, 2H), 3.61-3.72 (m, 1H), 3.39 (q, 2H), 2.45 (t, 2H), 1.91 (s, 6H), 1.73-1.84 (m, 1H), 1.56-1.67 (m, 1H), 1.20-1.34 (m, 1H), 0.96 (d, 3H), 0.91 (t, 3H). MS(M+1): 557.

Compound 2-11: (S)-3-(4-((1-((2′-chloro-2,6-dimethyl-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.02 (t, J=5.4 Hz, 1H), 7.53-7.63 (m, 2H), 6.78 (s, 1H), 6.64 (d, J=8.8 Hz, 2H), 6.47-6.57 (m, 1H), 6.03 (dd, J=8.8, 4.9 Hz, 1H), 3.88-4.07 (m, 2H), 3.54-3.68 (m, 1H), 3.38-3.45 (m, 2H), 2.46 (t, J=7.1 Hz, 2H), 2.30 (s, 3H), 2.20 (s, 3H), 1.97-2.07 (m, 1H), 0.90-1.03 (m, 6H).

Compound 2-12: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3,5-dimethylphenoxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.55-7.65 (m, 3H), 7.47 (d, J=7.8 Hz, 1H), 7.17-7.31 (m, 2H), 6.77-6.88 (m, 1H), 6.53-6.70 (m, 4H), 3.99 (dd, J=8.3, 4.4 Hz, 2H), 3.75 (br. s., 1H), 3.62-3.71 (m, 2H), 2.66 (t, J=5.6 Hz, 2H), 2.20 (s, 6H), 1.72-1.88 (m, 1H), 1.54-1.70 (m, 1H), 1.29-1.51 (m, 4H), 0.90 (t, J=6.8 Hz, 3H); MS(M+1): 529.

Compound 2-13: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-(4-(benzofuran-2-yl)-3,5-dimethylphenoxy)hexan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.77 (t, J=5.6 Hz, 1H), 7.62-7.70 (m, 3H), 7.56 (d, J=8.3 Hz, 1H), 7.22-7.32 (m, 2H), 6.86 (s, 1H), 6.76 (s, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.22 (d, J=8.3 Hz, 1H), 4.70 (d, J=5.9 Hz, 2H), 3.95-4.03 (m, 2H), 3.74-3.86 (m, 1H), 2.15 (s, 6H), 1.68-1.80 (m, 1H), 1.50-1.64 (m, 1H), 1.27-1.50 (m, 4H), 0.88 (t, J=7.1 Hz, 3H); MS(M+1): 539.

Example 3: Synthesis of Compounds 3-1 to 3-24

Compound 3-1: N-((1H-tetrazol-5-yl)methyl)-4-(((2S,3S)-1-(4-(benzofuran-2-yl)-3-chlorophenoxy)-3-methylpentan-2-yl)amino)benzamide

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.68 (t, J=5.9 Hz, 1H), 7.91 (d, J=8.8 Hz, 1H), 7.70-7.60 (m, 4H), 7.43 (s, 1H), 7.34 (t, J=8.3 Hz, 1H), 7.27 (t, J=8.3 Hz, 1H), 7.22 (d, J=2.5 Hz, 1H), 7.09 (dd, J=8.8, 2.5 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.26 (d, J=8.8 Hz, 1H), 4.67 (d, J=5.9 Hz, 2H), 4.21-4.07 (m, 2H), 3.75-3.68 (m, 1H), 1.78-1.70 (m, 1H), 1.64-1.59 (m, 1H), 1.30-1.26 (m, 1H), 0.96 (d, J=6.9 Hz, 3H), 0.90 (t, J=7.3 Hz, 3H). MS(M+1): 545.

Compound 3-2: (R)-3-(4-(((S)-1-((2,2′-dichloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)-2-hydroxypropanoic acid

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.10-8.07 (m, 1H), 7.98 (s, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.59-7.53 (m, 3H), 7.27 (d, J=8.8 Hz, 1H), 7.23-7.19 (m, 1H), 7.04-7.01 (m, 1H), 6.68-6.63 (m, 2H), 6.15-6.07 (m, 1H), 4.15-3.98 (m, 3H), 3.67-3.60 (m, 3H), 2.06-2.01 (m, 1H), 1.02-0.94 (m, 6H). MS(M+1): 599.

Compound 3-3: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-((2,2′-dichloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamide

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.72-8.69 (m, 1H), 7.99 (s, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.67-7.55 (m, 3H), 7.29-7.18 (m, 2H), 7.05-7.00 (m, 1H), 6.69 (d, J=8.8 Hz, 2H), 6.20 (d, J=8.8 Hz, 1H), 4.67 (d, J=4.9 Hz, 2H), 4.17-4.06 (m, 2H), 3.71-3.65 (m, 1H), 2.06-2.03 (m, 1H), 1.02-0.98 (m, 6H). MS(M+1): 593.

Compound 3-4: (S)-3-(4-((1-((2,2′-dichloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.17 (pseudo-brs, 1H), 7.99 (d, J=1.5 Hz, 1H), 7.79 (dd, J=8, 1.5 Hz, 1H), 7.61-7.55 (m, 3H), 7.28-7.18 (m, 2H), 7.01 (dt, J=8, 3 Hz, 1H), 6.66 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.12-4.05 (m, 2H), 3.38-3.35 (m, 3H), 3.42-3.37 (m, 2H), 2.29 (t, J=8.8 Hz, 2H), 2.09-2.00 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 583.

Compound 3-5: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-(4-(benzofuran-2-yl)-3-chlorophenoxy)-3-methylbutan-2-yl)amino)benzamide

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.64 (t, J=5.9 Hz, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.70-7.60 (m, 4H), 7.43 (s, 1H), 7.34 (t, J=8.3 Hz, 1H), 7.27 (t, J=8.3 Hz, 1H), 7.22 (d, J=2.5 Hz, 1H), 7.09 (dd, J=8.8, 2.5 Hz, 1H), 6.69 (d, J=8.8 Hz, 2H), 6.19 (d, J=8.8 Hz, 1H), 4.67 (d, J=5.9 Hz, 2H), 4.19-4.06 (m, 2H), 3.72-3.65 (m, 1H), 2.08-2.01 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 531.

Compound 3-6: (R)-3-(4-(((S)-1-(4-(benzofuran-2-yl)-3-chlorophenoxy)-3-methylbutan-2-yl)amino)benzamido)-2-hydroxypropanoic acid

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.10 (dd, J=8.8, 3 Hz, 1H), 7.90 (d, J=8.8 Hz, 1H), 7.69 (d, J=8, 1H), 7.62-7.56 (m, 3H), 7.43 (d, J=1.5 Hz, 1H), 7.34 (dt, J=8, 1.5 Hz, 1H), 7.27 (dt, J=8.8, 1.5 Hz, 1H), 7.22 (d, J=3 Hz, 1H), 7.09 (dd, J=8.8, 3 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.13 (d, J=8.8 Hz, 1H), 4.17-4.05 (m, 2H), 3.69-3.60 (m, 2H), 3.44-3.38 (m, 1H), 3.21-3.17 (m, 1H), 2.06-2.01 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 537.

Compound 3-7: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3-chlorophenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.12 (t, J=5.9 Hz, 1H), 7.89 (d, J=8.8 Hz, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.62-7.58 (m, 3H), 7.42 (s, 1H), 7.33 (dt, J=8.3 Hz, 1H), 7.27 (t, J=8 Hz, 1H), 7.21 (d, J=3 Hz, 1H), 7.08 (dd, J=8.8, 2.5 Hz, 1H), 6.66 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.17-4.05 (m, 2H), 3.68-3.64 (m, 1H), 3.40-3.35 (m, 2H), 2.31 (t, J=8.8 Hz, 2H), 2.05-2.00 (m, 1H), 1.02-0.96 (m, 6H). MS(M+1): 521.

Compound 3-8: (S)-3-(4-((1-((2,2′-dichloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, J=1.0 Hz, 1H), 7.60 (d, J=8.3 Hz, 2H), 7.54 (d, J=8.1, 1.2 Hz, 1H), 7.35 (d, J=7.8 Hz, 1H), 7.12 (d, J=8.8 Hz, 1H), 7.01 (d, J=2.4 Hz, 1H), 6.84 (dd, J=8.6, 2.7 Hz, 1H), 6.70 (t, J=6.1 Hz, 1H), 6.59 (d, J=8.8 Hz, 2H), 3.96-4.04 (m, 2H), 3.74-3.81 (m, 1H), 3.68 (q, J=5.9 Hz, 2H), 2.67 (t, J=5.9 Hz, 2H), 1.76-1.86 (m, 1H), 1.57-1.68 (m, 1H), 1.31-1.49 (m, 4H), 0.90 (t, J=7.1 Hz, 3H). MS(M+1): 597.

Compound 3-9: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-((2,2′-dichloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.77 (t, J=5.6 Hz, 1H), 7.99 (d, J=1.0 Hz, 1H), 7.79 (dd, J=8.1, 1.2 Hz, 1H), 7.67 (d, J=8.8 Hz, 2H), 7.56 (d, J=7.8 Hz, 1H), 7.28 (d, J=8.8 Hz, 1H), 7.16-7.20 (m, 1H), 6.99-7.05 (m, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.24 (d, J=8.3 Hz, 1H), 4.69 (d, J=5.9 Hz, 2H), 4.05 (d, J=5.4 Hz, 2H), 3.77-3.87 (m, 1H), 1.67-1.79 (m, 1H), 1.53-1.64 (m, 1H), 1.27-1.50 (m, 4H), 0.88 (t, J=7.1 Hz, 3H). MS(M+1): 606.

Compound 3-10: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3-chlorophenoxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.90 (d, J=8.8 Hz, 1H), 7.55-7.62 (m, 2H), 7.47 (d, J=8.3 Hz, 1H), 7.34 (s, 1H), 7.17-7.29 (m, 2H), 6.98 (d, J=2.4 Hz, 1H), 6.86 (dd, J=8.8, 2.4 Hz, 1H), 6.78 (t, J=5.9 Hz, 1H), 6.57 (d, J=8.8 Hz, 2H), 3.90-4.01 (m, 2H), 3.70-3.77 (m, 1H), 3.66 (q, J=5.9 Hz, 2H), 2.65 (t, J=5.6 Hz, 2H), 1.72-1.83 (m, 1H), 1.53-1.65 (m, 1H), 1.30-1.45 (m, 4H), 0.88 (t, J=7.1 Hz, 3H). MS(M+1): 535.

Compound 3-11: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-(4-(benzofuran-2-yl)-3-chlorophenoxy) hexan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.69 (t, J=5.4 Hz, 1H), 7.91 (d, J=8.8 Hz, 1H), 7.64-7.71 (m, 3H), 7.61 (d, J=8.3 Hz, 1H), 7.43 (s, 1H), 7.24-7.37 (m, 2H), 7.21 (d, J=2.4 Hz, 1H), 7.09 (dd, J=8.8, 2.4 Hz, 1H), 6.66 (d, J=8.8 Hz, 2H), 6.22 (d, J=8.3 Hz, 1H), 4.67 (d, J=5.4 Hz, 2H), 4.06 (d, J=4.9 Hz, 2H), 3.77-3.86 (m, 1H), 1.66-1.79 (m, 1H), 1.58 (td, J=8.7, 4.6 Hz, 1H), 1.28-1.49 (m, 4H), 0.87 (t, J=7.1 Hz, 3H); MS(M+1): 545.

Compound 3-12: (S)-3-(4-((1-((2,2′,4′-trichloro-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino) benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.8 Hz, 2H), 7.46 (d, J=2.0 Hz, 1H), 7.26 (dd, J=8.3, 2.0 Hz, 1H), 7.09-7.17 (m, 2H), 6.98 (d, J=2.4 Hz, 1H), 6.82 (dd, J=8.3, 2.4 Hz, 1H), 6.72 (t, J=5.9 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 3.95-4.03 (m, 2H), 3.73-3.80 (m, 1H), 3.67 (q, J=5.9 Hz, 2H), 2.66 (t, J=5.9 Hz, 2H), 1.75-1.87 (m, 1H), 1.57-1.68 (m, 1H), 1.31-1.48 (m, 4H), 0.89 (t, J=7.1 Hz, 3H); MS(M+1): 563.

Compound 3-13: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-((2,2′,4′-trichloro-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.76 (t, J=5.4 Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.67 (d, J=8.3 Hz, 2H), 7.49 (dd, J=8.3, 2.4 Hz, 1H), 7.33 (d, J=8.4 Hz, 1H), 7.21-7.27 (m, 1H), 7.15 (d, J=2.0 Hz, 1H), 6.97-7.01 (m, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.22 (d, J=8.3 Hz, 1H), 4.69 (d, J=5.4 Hz, 2H), 4.04 (d, J=4.9 Hz, 2H), 3.76-3.86 (m, 1H), 1.72 (td, J=9.2, 5.1 Hz, 1H), 1.51-1.63 (m, 1H), 1.26-1.49 (m, 4H), 0.88 (t, J=7.1 Hz, 3H); MS(M+1): 573.

Compound 3-14: (S)-3-(4-((1-(4-(benzofuran-2-yl)-2,5-dichlorophenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.98 (s, 1H), 7.57-7.76 (m, 4H), 7.50 (d, J=6.8 Hz, 2H), 7.24-7.39 (m, 2H), 6.69 (d, J=8.8 Hz, 2H), 6.03 (d, J=8.8 Hz, 1H), 4.10-4.31 (m, 2H), 3.66-3.74 (m, 1H), 3.36-3.47 (m, 2H), 2.44-2.48 (m, 1H), 2.02-2.16 (m, 1H), 1.01 (dd, J=8.8, 6.8 Hz, 6H). MS(M+1): 521.

Compound 3-15: 3-(4-((2-((2′-chloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-1-phenylethyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.69-7.72 (m, 1H), 7.48-7.54 (m, 3H), 7.24-7.44 (m, 8H), 6.94-6.98 (m, 2H), 6.64 (t, J=6.1 Hz, 1H), 6.49-6.56 (m, 2H), 4.80 (dd, J=7.8, 3.9 Hz, 1H), 4.29 (dd, J=9.8, 3.9 Hz, 1H), 4.01-4.19 (m, 1H), 3.63 (q, J=5.9 Hz, 2H), 2.62 (t, J=5.9 Hz, 2H). MS(M+1): 583.

Compound 3-16: (S)-3-(4-((1-((2-chloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.60 (d, J=8.8 Hz, 2H), 7.36-7.41 (m, 2H), 7.16-7.25 (m, 3H), 6.96-7.00 (m, 1H), 6.86 (t, J=5.9 Hz, 1H), 6.82 (dd, J=8.8, 2.4 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 3.93-4.03 (m, 2H), 3.71-3.80 (m, 1H), 3.66 (q, J=5.9 Hz, 2H), 2.64 (t, J=5.9 Hz, 2H), 1.73-1.86 (m, 1H), 1.55-1.67 (m, 1H), 1.30-1.48 (m, 4H), 0.89 (t, J=7.1 Hz, 3H). MS(M+1): 563.

Compound 3-17: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((1-((2-chloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.76 (t, J=5.6 Hz, 1H), 7.64-7.71 (m, 2H), 7.47-7.56 (m, 2H), 7.39-7.45 (m, 2H), 7.30-7.38 (m, 1H), 7.09-7.16 (m, 1H), 6.96-7.06 (m, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.21 (d, J=8.8 Hz, 1H), 4.69 (d, J=5.9 Hz, 2H), 4.03 (d, J=4.9 Hz, 2H), 3.73-3.87 (m, 1H), 1.63-1.79 (m, 1H), 1.51-1.63 (m, 1H), 1.20-1.45 (m, 4H), 0.88 (t, J=7.1 Hz, 3H). MS(M+1): 573.

Compound 3-18: (S)-2-(4-((1-(4-(benzofuran-2-yl)-3-chlorophenoxy)-3-methylbutan-2-yl)amino)benzamido)ethane-1-sulfonic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.13 (t, J=5.4 Hz, 1H), 7.89 (d, J=8.8 Hz, 1H), 7.68 (d, J=8.3 Hz, 1H), 7.61-7.55 (m, 3H), 7.41 (s, 1H), 7.32 (dt, J=8, 1.5 Hz, 1H), 7.27-7.24 (m, 1H), 7.19 (d, J=2.4 Hz, 1H), 7.07 (dd, J=8.8, 3 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.16 (d, J=8 Hz, 1H), 4.15-4.06 (m, 2H), 3.64 (brs, 1H), 3.53-3.48 (m, 2H), 2.69 (t, J=6.8 Hz, 2H), 2.05-2.00 (m, 1H), 1.00-0.95 (m, 6H). MS(M+1): 558.

Compound 3-19: 3-(4-(((2S,3S)-1-(4-(benzofuran-2-yl)-2,5-dichlorophenoxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.85-8.12 (m, 2H), 7.55-7.67 (m, 2H), 7.28-7.52 (m, 2H), 6.91-7.04 (m, 1H), 6.54-6.68 (m, 3H), 3.99-4.21 (m, 3H), 3.63-3.78 (m, 2H), 2.69 (t, J=5.6 Hz, 1H), 1.93 (dd, J=7.3, 3.4 Hz, 1H), 1.64-1.72 (m, 1H), 1.20-1.28 (m, 2H), 0.87-1.10 (m, 6H). MS(M+1): 569.

Compound 3-20: 3-(4-(((2S,3S)-3-methyl-1-((2,2′,5-trichloro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.72-7.77 (m, 1H), 7.55-7.65 (m, 3H), 7.33-7.40 (m, 1H), 7.01 (s, 1H), 6.61-6.68 (m, 3H), 4.10-4.22 (m, 2H), 3.71 (q, J=6.0 Hz, 3H), 2.71 (t, J=6.0 Hz, 2H), 1.95 (ddd, J=12.4, 7.2, 3.6 Hz, 1H), 1.72 (ddd, J=12.4, 7.2, 3.6 Hz, 1H), 1.07 (d, J=7.2 Hz, 3H), 0.99 (t, J=7.2 Hz, 3H). MS(M+1): 631.

Compound 3-21: 3-(4-(((2S,3S)-1-((2,5-dichloro-2′-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.55-7.65 (m, 3H), 7.36-7.51 (m, 2H), 6.94-7.03 (m, 1H), 6.57-6.72 (m, 3H), 4.02-4.22 (m, 3H), 3.63-3.76 (m, 3H), 2.70 (t, J=5.6 Hz, 2H), 1.84-2.01 (m, 1H), 1.61-1.78 (m, 1H), 1.05 (dd, J=13.2, 7.2 Hz, 3H), 0.97 (q, J=7.2 Hz, 3H). MS(M+1): 615.

Compound 3-22: (S)-3-(4-((1-((2-chloro-2′-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ7.60 (d, J=8.8 Hz, 2H), 7.34-7.47 (m, 3H), 7.14-7.21 (m, 1H), 6.97-7.03 (m, 1H), 6.76-6.88 (m, 2H), 6.58 (d, J=8.8 Hz, 2H), 3.99 (tt, J=9.0, 4.6 Hz, 2H), 3.70-3.81 (m, 1H), 3.59-3.70 (m, 2H), 2.65 (t, J=5.9 Hz, 2H), 1.71-1.86 (m, 1H), 1.56-1.66 (m, 1H), 1.29-1.47 (m, 4H), 0.89 (t, J=6.8 Hz, 3H). MS(M+1): 581.

Compound 3-23: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3-chlorophenoxy)-3,3-dimethylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.93 (d, J=8.8 Hz, 1H), 7.67 (d, J=8.8 Hz, 3H), 7.54 (d, J=1.0 Hz, 1H), 7.41 (s, 1H), 7.33 (td, 1H), 7.26 (td, 1H), 7.12 (d, J=2.4 Hz, 1H), 7.03 (dd, 1H), 6.78 (d, J=8.8 Hz, 2H), 4.45 (q, 1H), 4.18 (q, 1H), 3.76-3.84 (m, 1H), 3.58 (t, 2H), 2.62 (t, J=6.6 Hz, 2H), 1.12 (s, 9H). MS(M+1): 535.

Compound 3-24: (S)-3-(4-((1-((2-chloro-2′-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3,3-dimethylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.84 (s, 1H), 7.70-7.75 (m, 1H), 7.67 (d, J=8.3 Hz, 2H), 7.60 (d, J=7.8 Hz, 1H), 7.41 (d, 2H), 7.01 (d, 2H), 6.78 (d, J=8.3 Hz, 2H), 4.39 (dd, J=10.0, 3.7 Hz, 1H), 4.12 (dd, J=9.8, 6.8 Hz, 1H), 3.75-3.83 (m, 1H), 3.59 (q, 2H), 2.62 (t, J=6.8 Hz, 2H), 1.13 (s, 9H). MS(M+1): 581.

Example 4: Synthesis of Compounds 4-1 to 4-5

Compound 4-1: (S)-3-(6-((3-methyl-1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)butan-2-yl)amino)nicotinamido)propanoic acid

White solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.48 (d, J=4 Hz, 1H), 8.20 (t, J=4 Hz, 1H), 7.83-7.74 (m, 5H), 7.66 (d, J=8 Hz, 2H), 7.08-7.04 (m, 3H), 6.59 (d, J=8 Hz, 1H), 4.30-4.28 (m, 1H), 4.13-4.06 (m, 2H), 3.74-3.71 (m, 1H), 3.42 (quartet, J=8 Hz, 2H), 2.48 (t, J=8 Hz, 2H), 2.10-1.98 (m, 1H), 0.99-0.96 (m, 6H). MS(M+1): 516.

Compound 4-2: (S)-3-(6-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)amino)nicotinamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.48 (d, J=2.4 Hz, 1H), 8.23 (t, J=5.4 Hz, 1H), 7.80-7.86 (m, 2H), 7.78 (dd, J=8.8, 2.4 Hz, 1H), 7.55-7.64 (m, 2H), 7.20-7.31 (m, 3H), 7.00-7.14 (m, 3H), 6.59 (d, J=8.8 Hz, 1H), 4.29 (br. s., 1H), 4.05-4.15 (m, 2H), 3.33-3.46 (m, 2H), 2.39-2.47 (m, 3H), 2.07 (dq, J=13.4, 6.8 Hz, 1H), 0.98 (t, J=6.8 Hz, 6H); MS(M+1): 488.

Compound 4-3: 3-(6-(((2S,3S)-1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)nicotinamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.46 (d, J=1.9 Hz, 1H), 8.18 (t, J=5.4 Hz, 1H), 7.76 (dd, J=8.4, 1.9 Hz, 1H), 7.68 (d, J=1.9 Hz, 1H), 7.47 (dd, J=8.4, 1.9 Hz, 1H), 7.39 (d, J=8.8 Hz, 1H), 7.33 (d, J=8.8 Hz, 2H), 7.10 (d, J=8.8 Hz, 1H), 7.02 (d, J=8.8 Hz, 2H), 6.56 (d, J=8.8 Hz, 1H), 4.31 (brs, 1H), 4.10 (d, J=4.9 Hz, 1H), 3.35-3.32 (m, 2H), 2.47 (t, J=7 Hz, 2H), 1.85-1.82 (m, 1H), 1.59-1.56 (m, 1H), 1.27-1.22 (m, 1H), 0.95 (d, J=6.8 Hz, 3H), 0.88 (t, J=6.8 Hz, 3H). MS(M+1): 530.

Compound 4-4: 3-(6-(((2S,3S)-1-(4-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)phenoxy)-3-methylpentan-2-yl)amino)nicotinamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.25-8.18 (d, J=9.3 Hz, 1H), 8.16-8.09 (m, 1H), 7.90 (d, J=8.8 Hz, 2H), 7.77-7.69 (m, 1H), 6.90 (d, J=9.3 Hz, 2H), 6.79-6.69 (d, J=9.3 Hz, 1H), 4.24-4.14 (m, 1H), 4.13-4.07 (m, 1H), 3.89-3.78 (m, 1H), 3.75-3.60 (m, 2H), 2.58-2.48 (m, 2H), 1.94-1.82 (m, 1H), 1.66-1.56 (m, 1H), 1.43 (s, 9H), 1.37-1.30 (m, 1H), 1.03 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 510.

Compound 4-5: 3-(6-(((2S,3S)-3-methyl-1-(4-(5-phenyl-1,3,4-oxadiazol-2-yl)phenoxy)pentan-2-yl)amino)nicotinamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.19 (s, 1H), 8.15 (d, J=8.8 Hz, 1H), 8.04 (dd, J=2.0, 7.3 Hz, 2H), 7.96 (d, J=8.8 Hz, 2H), 7.73-7.65 (m, 1H), 7.50-7.42 (m, 3H), 6.91 (d, J=8.8 Hz, 2H), 6.70 (d, J=9.3 Hz, 1H), 4.21-4.14 (m, 1H), 4.14-4.08 (m, 1H), 3.85 (br. s., 1H), 3.70-3.60 (m, 2H), 2.53 (dd, J=4.2, 6.6 Hz, 2H), 1.92-1.81 (m, 1H), 1.61 (ddd, J=3.9, 7.6, 13.4 Hz, 1H), 1.35-1.25 (m, 1H), 1.02 (d, J=6.8 Hz, 3H), 0.95-0.87 (m, 3H). MS(M+1): 530.

Example 5: Synthesis of Compounds 5-1 to 5-3

Compound 5-1: (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)thio)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.03 (t, J=5.4 Hz, 1H), 7.78-7.88 (m, 2H), 7.55-7.71 (m, 4H), 7.36-7.44 (m, 3H), 7.23-7.36 (m, 2H), 6.50-6.65 (m, 2H), 6.12 (d, J=9.3 Hz, 1H), 3.46-3.70 (m, 1H), 3.36-3.46 (m, 2H), 3.30 (dd, J=12.7, 4.4 Hz, 1H), 3.08 (dd, J=12.7, 8.3 Hz, 1H), 2.43-2.49 (m, 2H), 1.91-2.03 (m, 1H), 0.84-1.02 (m, 6H). MS(M+1): 503.

Compound 5-2: 3-(4-(((2S,3S)-3-methyl-1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)thio)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.51-7.68 (m, 6H), 7.45 (d, J=8.8 Hz, 2H), 7.32-7.41 (m, 2H), 7.24 (s, 1H), 6.73 (br. s., 1H), 6.38-6.50 (m, 2H), 5.06 (br. s., 1H), 3.65 (q, J=5.9 Hz, 2H), 3.56 (q, J=5.9 Hz, 1H), 3.21 (dd, J=13.2, 4.4 Hz, 1H), 3.04 (dd, J=13.2, 6.8 Hz, 1H), 2.64 (t, J=5.9 Hz, 2H), 1.69-1.84 (m, 1H), 1.37-1.61 (m, 1H), 1.04-1.31 (m, 1H), 0.78-0.98 (m, 6H). MS(M+1): 545.

Compound 5-3: 3-(4-(((2S,3S)-1-((4-(benzofuran-2-yl)phenyl)thio)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.67-7.73 (m, 2H), 7.46-7.57 (m, 4H), 7.18-7.34 (m, 5H), 6.96 (d, J=1.0 Hz, 1H), 6.65 (t, J=5.6 Hz, 1H), 6.44 (d, J=8.8 Hz, 2H), 3.65 (d, J=5.9 Hz, 1H), 3.65 (d, J=16.6 Hz, 1H), 3.49-3.60 (m, 1H), 3.20 (dd, J=13.2, 4.9 Hz, 1H), 3.02 (dd, J=13.2, 6.8 Hz, 1H), 2.65 (br. s., 2H), 1.72-1.82 (m, 1H), 1.47-1.59 (m, 1H), 1.04-1.30 (m, 1H), 0.80-0.96 (m, 6H). MS(M+1): 517.

Example 6: Synthesis of Compounds 6-1 to 6-3

Compound 6-1: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)(methyl) amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.11 (t, J=5.4 Hz, 1H), 7.80 (d, J=8.8 Hz, 2H), 7.67 (d, J=8.8 Hz, 2H), 7.61-7.57 (m, 2H), 7.29-7.21 (m, 3H), 6.98 (d, J=8.8, 2H), 6.80 (d, J=8.8 Hz, 2H), 4.27-4.42 (m, 2H), 4.01-3.96 (m, 1H), 3.45-3.40 (m, 2H), 2.83 (s, 3H), 2.48 (t, J=6.8, 2H), 2.15-2.10 (m, 1H), 1.07 (d, J=6.4 Hz, 3H), 0.84 (d, J=6.4 Hz, 3H); MS(M+1): 501.

Compound 6-2: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)(ethyl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.10 (t, J=5.4 Hz, 1H), 7.82 (d, J=8.8 Hz, 2H), 7.66 (d, J=8.8 Hz, 2H), 7.62-7.57 (m, 2H), 7.29-7.21 (m, 3H), 7.01 (d, J=8.8, 2H), 6.80 (d, J=8.8 Hz, 2H), 4.27-4.25 (m, 2H), 4.04-3.97 (m, 1H), 3.45-3.40 (m, 4H), 2.83 (s, 3H), 2.48 (t, J=6.8, 2H), 2.15-2.12 (m, 1H), 1.08-1.01 (m, 6H), 0.84 (d, J=6.4 Hz, 3H); MS(M+1): 515.

Compound 6-3: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenoxy)-3-ethoxypropan-2-yl)amino) benzamido)propanoic acid

¹H-NMR (400 MHz, DMSO-d₆): δ 12.14 (s, 1H), 8.08-8.06 (t, 1H), 7.87-7.84 (d, 1H), 7.63-7.61 (d, 2H), 7.48-7.47 (d, 1H), 7.43-7.40 (d, 2H), 7.30-7.22 (m, 2H), 7.04-7.01 (d, 2H), 6.70-6.68 (d, 2H), 6.21-6.19 (d, 1H), 4.17-4.08 (m, 2H), 4.04-3.98 (m, 1H), 3.59-3.57 (d, 2H), 3.54-3.46 (m, 2H), 3.43-3.38 (q, 2H), 2.47-2.45 (t, 2H), 1.14-1.10 (t, 3H), MS(M+1): 503.

Example 7: Synthesis of Compounds 7-1 to 7-11

Compound 7-1: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3,5-difluorophenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.04 (t, J=5.4 Hz, 1H), 7.70 (d, J=8.8 Hz, 1H), 7.64-7.58 (m, 3H), 7.35 (dt, J=7, 1.4 Hz, 1H), 7.31-7.27 (m, 1H), 7.18 (d, J=1 Hz, 1H), 6.94 (dd, J=8.8 Hz, 2H), 6.65 (d, J=8.8 Hz, 2H), 6.12 (d, J=8 Hz, 1H), 4.19-4.06 (m, 2H), 3.70-3.64 (m, 1H), 3.43-3.38 (m, 2H), 2.46 (t, J=6.8 Hz, 2H), 2.05-1.98 (m, 1H), 1.01-0.96 (m, 6H). MS(M+1): 523.

Compound 7-2: (S)-3-(4-((1-((2′-chloro-2,6-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.06-8.02 (m, 2H), 7.83 (d, J=8.3 Hz, 1H), 7.70 (d, J=8.3 Hz, 1H), 7.60-7.57 (m, 2H), 7.69-7.70 (m, 2H), 7.12-7.07 (m, 2H), 6.08 (d, J=8.8 Hz, 1H), 4.17-4.01 (m, 2H), 3.69-3.64 (m, 1H), 3.43-3.37 (m, 2H), 2.47 (t, J=7 Hz, 2H), 2.05-1.97 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 585.

Compound 7-3: (S)-3-(4-((1-((2,6-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.04 (t, J=5.4 Hz, 1H), 7.83 (d, J=8.8 Hz, 2H), 7.64 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 2H), 6.89 (d, J=8.8 Hz, 2H), 6.65 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.38-4.34 (m, 1H), 4.16-4.04 (m, 2H), 3.68-3.63 (m, 1H), 3.43-3.37 (m, 2H), 2.46 (t, J=7 Hz, 2H), 2.05-1.96 (m, 1H), 1.01-0.96 (m, 6H). MS(M+1): 551.

Compound 7-4: (S)-3-(4-((3-methyl-1-((2,2′,6-trifluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)butan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.03 (t, J=5.4 Hz, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.71-7.70 (m, 2H), 7.60-7.57 (m, 2H), 6.93 (d, J=8.8 Hz, 2H), 6.65 (d, J=8.8 Hz, 2H), 6.11 (d, J=8.8 Hz, 1H), 4.17-4.05 (m, 2H), 3.68-3.65 (m, 1H), 3.34-3.38 (m, 2H), 2.47 (t, J=7 Hz, 2H), 1.81-1.74 (m, 1H), 2.05-1.91 (m, 1H), 1.01-0.97 (m, 6H). MS(M+1): 569.

Compound 7-5: (S)-3-(4-((1-((2′-chloro-2,6-difluoro-4′-(trifluoromethyl)-[1,1-biphenyl]-4-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.07 (t, J=5.4 Hz, 1H), 8.02 (s, 1H), 7.80 (d, J=7.8 Hz, 1H), 7.69-7.61 (m, 3H), 6.87 (d, J=8.8 Hz, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.04-4.01 (m, 2H), 3.87-3.83 (m, 1H), 3.45-3.41 (m, 2H), 2.48 (t, J=7 Hz, 2H), 1.80-1.75 (m, 1H), 1.56-1.52 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H). MS(M+1): 599.

Compound 7-6: (S)-3-(4-((1-((2,6-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.06 (t, J=5.4 Hz, 1H), 7.81 (d, J=7.8 Hz, 1H), 7.63-7.60 (m, 4H), 6.85 (d, J=8.8 Hz, 2H), 6.64 (d, J=8.8 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.02-4.01 (m, 2H), 3.87-3.82 (m, 1H), 3.44-3.39 (m, 2H), 2.47 (t, J=7 Hz, 2H), 1.80-1.74 (m, 1H), 1.56-1.47 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H). MS(M+1): 565.

Compound 7-7: (S)-3-(4-((4-methyl-1-((2,2′,6-trifluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 12.2 (s, 1H), 8.07-8.06 (m, 1H), 7.82-7.61 (m, 4H), 6.88 (d, J=8.8 Hz, 2H), 6.67-6.61 (m, 2H), 6.10-6.04 (m, 1H), 4.04-3.95 (m, 2H), 3.86-3.81 (m, 1H), 3.44-3.38 (m, 2H), 2.48 (t, J=7 Hz, 2H), 1.80-1.73 (m, 1H), 1.56-1.46 (m, 2H), 0.93 (t, J=6.8 Hz, 3H), 0.87 (t, J=6.8 Hz, 3H). MS(M+1): 583.

Compound 7-8: (S)-3-(4-((1-((2′,4′-dichloro-2,6-difluoro-[1,1′-biphenyl]-4-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.05 (t, J=5.4 Hz, 1H), 7.78 (d, J=1.9 Hz, 1H), 7.61 (d, J=8.8 Hz, 2H), 7.54-7.44 (m, 2H), 6.85 (d, J=8.8 Hz, 2H), 6.55-6.59 (m, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.05-4.00 (m, 1H), 3.87-3.82 (m, 1H), 3.44-3.39 (m, 2H), 2.47 (t, J=7 Hz, 2H), 1.79-1.74 (m, 1H), 1.57-1.48 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.87 (d, J=6.8 Hz, 3H). MS(M+1): 565.

Compound 7-9: (S)-3-(4-((1-((3′,5′-dichloro-2,6-difluoro-[1,1′-biphenyl]-4-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.05 (t, J=5.4 Hz, 1H), 7.65-7.59 (m, 3H), 7.47-7.415 (m, 2H), 6.84 (d, J=8.8 Hz, 2H), 6.64 (d, J=8.8 Hz, 2H), 6.08 (d, J=8.8 Hz, 1H), 4.03-4.00 (m, 2H), 3.87-3.82 (m, 1H), 3.44-3.39 (m, 2H), 2.47 (t, J=7 Hz, 2H), 1.79-1.74 (m, 1H), 1.56-1.47 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H). MS(M+1): 565.

Compound 7-10: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3,5-difluorophenoxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.06 (t, J=5.4 Hz, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.62-7.58 (m, 3H), 7.36-7.26 (m, 2H), 7.17 (s, 1H), 6.90 (d, J=8.8 Hz, 2H), 6.64 (d, J=8.8 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.04-3.95 (m, 2H), 3.88-3.79 (m, 1H), 3.42-3.39 (m, 2H), 2.47 (t, J=7 Hz, 2H), 1.79-1.74 (m, 1H), 1.57-1.46 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H). MS(M+1): 537.

Compound 7-11: (S)-3-(4-((1-((2′,4′-dichloro-2,6-difluoro-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.05 (t, J=5.6 Hz, 1H), 7.78 (d, J=2.4 Hz, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.54-7.51 (m, 1H), 7.45 (d, J=8.8 Hz, 1H), 6.86 (d, J=8.8 Hz, 2H), 6.65 (d, J=8.8 Hz, 2H), 6.11 (d, J=8.8 Hz, 1H), 4.14-4.03 (m, 2H), 3.68-3.62 (m, 1H), 2.47 (t, J=6.8 Hz, 2H), 2.04-2.00 (m, 1H), 1.00-0.95 (m, 6H). MS(M+1): 551.

Example 8: Synthesis of Compounds 8-1 to 8-25

Compound 8-1: (S)-3-(4-((1-((2,2′-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.3 Hz, 2H) (m, 2H), 7.36-7.48 (m, 3H), 7.21-7.27 (m, 1H), 6.65-6.78 (m, 3H), 6.59 (d, J=8.3 Hz, 2H), 4.00-4.05 (m, 2H), 3.66 (q, J=5.9 Hz, 2H), 3.54-3.60 (m, 1H), 2.62-2.67 (m, 2H), 2.06-2.15 (m, 1H), 0.99-1.06 (m, 6H). MS(M+1): 551.

Compound 8-2: (S)-2-(4-((1-((2,2′-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)ethane-1-sulfonic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.11 (t, J=4.9 Hz, 1H), 7.78 (d, J=9.3 Hz, 1H), 7.64-7.71 (m, 2H), 7.54 (d, J=8.8 Hz, 2H), 7.35-7.43 (m, 1H), 7.00 (dd, J=11.5, 2.2 Hz, 1H), 6.92 (dd, J=8.8, 2.4 Hz, 1H), 6.64-6.70 (m, 2H), 6.13 (d, J=8.8 Hz, 1H), 4.10-4.16 (m, 1H), 4.02-4.08 (m, 1H), 3.62-3.71 (m, 1H), 3.46-3.54 (m, 2H), 2.68 (t, J=6.1 Hz, 2H), 1.99-2.09 (m, 1H), 0.99 (m, 6H). MS(M+1): 587.

Compound 8-3: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3-fluorophenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.87 (t, J=8.8 Hz, 1H), 7.53-7.62 (m, 3H), 7.47 (d, J=7.8 Hz, 1H), 7.16-7.28 (m, 2H), 7.05 (d, J=2.9 Hz, 1H), 6.81 (t, J=5.9 Hz, 1H), 6.72 (dd, J=8.8, 2.4 Hz, 1H), 6.66 (dd, J=12.7, 2.4 Hz, 1H), 6.57 (d, J=8.8 Hz, 2H), 3.99 (d, J=4.4 Hz, 2H), 3.66 (q, J=5.5 Hz, 2H), 3.52-3.58 (m, 1H), 2.64 (t, J=5.9 Hz, 2H), 2.02-2.13 (m, 1H), 0.96-1.03 (m, 6H). MS(M+1): 505.

Compound 8-4: (S)-2-(4-((1-(4-(benzofuran-2-yl)-3-fluorophenoxy)-3-methylbutan-2-yl)amino)benzamido)ethane-1-sulfonic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.11 (t, J=5.1 Hz, 1H), 7.87 (t, J=9.0 Hz, 1H), 7.59-7.68 (m, 2H), 7.54 (d, J=8.3 Hz, 2H), 7.23-7.34 (m, 2H), 7.16 (d, J=2.9 Hz, 1H), 7.04 (dd, J=13.7, 2.4 Hz, 1H), 6.94 (dd, J=8.8, 2.4 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.14 (d, J=8.8 Hz, 1H), 4.00-4.20 (m, 2H), 3.67 (dd, J=8.6, 4.6 Hz, 1H), 3.44-3.55 (m, 2H), 2.68 (t, J=6.8 Hz, 2H), 1.94-2.08 (m, 1H), 0.93-1.08 (m, 6H). MS(M+1): 541.

Compound 8-5: (S)-3-(4-((1-((2′-chloro-2-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, J=1.0 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.53 (dd, J-=7.8, 1.0 Hz, 1H), 7.39 (d, J=7.8 Hz, 1H), 7.16 (t, J=8.6 Hz, 1H), 6.76-6.85 (m, 1H), 6.64-6.76 (m, 2H), 6.59 (d, J=8.8 Hz, 2H), 4.00-4.06 (m, 2H), 3.66 (q, J=5.9 Hz, 2H), 3.54-3.61 (m, 1H), 2.65 (t, J=5.6 Hz, 2H), 2.08-2.16 (m, 1H), 1.02 (d, J=6.8 Hz, 3H), 1.03 (d, J=6.8 Hz, 3H). MS(M+1): 567.

Compound 8-6: (S)-3-(4-((i-((2,2′-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.54-7.64 (m, 2H), 7.35-7.49 (m, 3H), 6.49-6.80 (m, 5H), 3.79-4.03 (m, 3H), 3.63-3.73 (m, 2H), 2.67 (t, J=5.6 Hz, 2H), 1.44-1.88 (m, 3H), 0.85-1.05 (m, 6H). MS(M+1): 565.

Compound 8-7: 3-(4-(((2S,3S)-1-(4-(benzofuran-2-yl)-3-fluorophenoxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.87 (t, J=8.6 Hz, 1H), 7.52-7.62 (m, 3H), 7.47 (d, J=7.8 Hz, 1H), 7.34 (t, J=8.3 Hz, 1H), 7.15-7.28 (m, 2H), 7.05 (d, J=3.4 Hz, 1H), 6.72-6.75 (m, 1H), 6.67 (dd, J=13.0, 2.2 Hz, 1H), 6.62 (dd, J=10.3, 2.9 Hz, 1H), 6.55 (d, J=8.8 Hz, 2H), 3.98-4.07 (m, 1H), 3.89-3.97 (m, 11H), 3.54-3.70 (m, 3H), 2.64 (t, J=5.4 Hz, 2H), 1.74-1.90 (m, 11H), 1.53-1.66 (m, 1H), 1.18-1.28 (m, 11H), 0.90-0.99 (m, 6H). MS(M+1): 519.

Compound 8-8: 3-(4-(((2S,3S)-1-((2′-chloro-2-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.71 (s, 1H), 7.59 (d, J=8.3 Hz, 2H), 7.53 (d, J=8.3 Hz, 1H), 7.39 (d, J=−8.3 Hz, 1H), 7.16 (t, J=8.6 Hz, 1H), 6.63-6.82 (m, 3H), 6.58 (d, J=8.8 Hz, 2H), 4.01-4.11 (m, 2H), 3.59-3.72 (m, 3H), 2.65 (t, J=5.9 Hz, 2H), 1.80-1.90 (m, 1H), 1.55-1.69 (m, 1H), 1.16-1.23 (m, 1H), 1.00 (d, J=6.4 Hz, 3H), 0.94 (t, J=7.3 Hz, 3H). MS(M+1): 581.

Compound 8-9: (S)-3-(4-((1-((2′,4′-dichloro-2-fluoro-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J=8.8 Hz, 2H), 7.44-7.46 (m, 1H), 7.23-7.27 (m, 1H), 7.19 (d, J=8.3 Hz, 1H), 7.10-7.16 (m, 1H), 6.77-6.89 (m, 1H), 6.62-6.72 (m, 2H), 6.57 (dd, J=8.6, 1.2 Hz, 2H), 3.97-4.05 (m, 2H), 3.66 (d, J=3.4 Hz, 2H), 3.56 (q, J=4.6 Hz, 1H), 2.61-2.67 (m, 2H), 2.11 (ddd, J=13.2, 6.8, 1.5 Hz, 1H), 0.99-1.05 (m, 6H). MS(M+1): 533.

Compound 8-10: 3-(4-(((2S,3S)-1-((2,2′-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.8 Hz, 2H), 7.42-7.46 (m, 2H), 7.38 (d, J=9.8 Hz, 1H), 7.21-7.28 (m, 1H), 6.77-6.87 (m, 1H), 6.65-6.76 (m, 2H), 6.57 (d, J=8.8 Hz, 2H), 4.01-4.07 (m, 2H), 3.60-3.69 (m, 3H), 2.64 (t, J=4.9 Hz, 2H), 1.79-1.89 (m, 1H), 1.63 (ddd, J=13.1, 7.5, 3.9 Hz, 1H), 1.18-1.29 (m, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 2H). MS(M+1): 565.

Compound 8-11: 3-(4-(((2S,3S)-1-((2′,4′-dichloro-2-fluoro-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J=8.8 Hz, 2H), 7.45 (d, J=2.0 Hz, 1H), 7.23-7.27 (m, 1H), 7.16-7.20 (m, 1H), 7.13 (t, J=8.3 Hz, 1H), 6.79 (t, J=5.4 Hz, 1H), 6.62-6.72 (m, 2H), 6.57 (d, J=8.3 Hz, 2H), 3.98-4.07 (m, 2H), 3.59-3.70 (m, 3H), 2.64 (t, J=5.4 Hz, 2H), 1.79-1.90 (m, 1H), 1.64 (ddd, J=13.3, 7.5, 3.7 Hz, 1H), 1.17-1.28 (m, 1H), 0.99 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.6 Hz, 3H). MS(M+1): 547.

Compound 8-12: (S)-3-(4-((1-((3′,5′-dichloro-2-fluoro-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J=8.8 Hz, 2H), 7.34 (t, J=1.5 Hz, 2H), 7.27-7.30 (m, 1H), 7.21-7.27 (m, 1H), 6.77 (d, J=5.4 Hz, 1H), 6.62-6.71 (m, 2H), 6.58 (d, J=8.8 Hz, 2H), 3.98-4.03 (m, 2H), 3.66 (q, J=5.4 Hz, 2H), 3.53-3.59 (m, 1H), 2.64 (t, J=5.6 Hz, 2H), 2.05-2.14 (m, 1H), 1.01 (dd, J=6.6, 4.6 Hz, 6H). MS(M+1): 533.

Compound 8-13: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3-fluorophenoxy)hexan-2-yl)amino)benzamido) propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.87 (t, J=8.6 Hz, 1H), 7.57 (dd, J=15.9, 7.6 Hz, 3H), 7.47 (d, J=8.3 Hz, 1H), 7.17-7.27 (m, 2H), 7.05 (d, J=3.4 Hz, 1H), 6.58-6.76 (m, 3H), 6.55 (d, J=8.3 Hz, 2H), 3.84-3.99 (m, 2H), 3.60-3.74 (m, 3H), 2.62 (t, J=5.6 Hz, 2H), 1.66-1.82 (m, 1H), 1.49-1.64 (m, 1H), 1.23-1.42 (m, 4H), 0.88 (t, J=6.9 Hz, 3H). MS(M+1): 519.

Compound 8-14: 3-(4-(((2S,3S)-1-((2-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.51-7.68 (m, 6H), 7.30 (t, J=8.8 Hz, 1H), 6.82 (t, J=5.9 Hz, 1H), 6.64-6.76 (m, 2H), 6.52-6.61 (m, 2H), 4.00-4.08 (m, 2H), 3.60-3.68 (m, 3H), 2.63 (t, J=5.6 Hz, 2H), 1.78-1.90 (m, 1H), 1.57-1.69 (m, 1H), 1.21-1.27 (m, 1H), 0.90-1.00 (m, 6H). MS(M+1): 547. HPLC: 97%.

Compound 8-15: (S)-3-(4-((1-((2′-chloro-2-fluor-4′-(trifluromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.71 (d, J=1.0 Hz, 1H), 7.60 (d, J=8.3 Hz, 2H), 7.52 (dd, J=8.1, 1.2 Hz, 1H), 7.39 (d, J=8.3 Hz, 1H), 7.14-7.20 (m, 1-), 6.89 (t, J=5.6 Hz, 1H), 6.66-6.76 (m, 2H), 6.58 (d, J=8.8 Hz, 2H), 3.95-4.03 (m, 2H), 3.73-3.80 (m, 1H), 3.65 (q, J=5.9 Hz, 2H), 2.63 (t, J=5.6 Hz, 2H), 1.75-1.84 (m, 1H), 1.56-1.67 (m, 1H), 1.31-1.49 (m, 4H), 0.89 (t, J=7.1 Hz, 3H). MS(M+1): 581.

Compound 8-16: (S)-3-(4-((1-((2′,4′-dichloro-2-fluoro-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.3 Hz, 2H), 7.43-7.46 (m, 1H), 7.23-7.27 (m, 1H), 7.17-7.21 (m, 1H), 7.13 (t, J=8.3 Hz, 1H), 6.80-6.91 (m, 1H), 6.63-6.73 (m, 2H), 6.56 (d, J=8.3 Hz, 2H), 3.91-4.02 (m, 2H), 3.71-3.80 (m, 1H), 3.61-3.69 (m, 2H), 2.59-2.66 (m, 2H), 1.73-1.85 (m, 1H), 1.55-1.66 (m, 1H), 1.29-1.47 (m, 4H), 0.88 (t, J=7.1 Hz, 3H). MS(M+1): 547.

Compound 8-17: (S)-3-(4-((1-((2,2′-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.3 Hz, 2H), 7.41-7.48 (m, 2H), 7.38 (d, 3=9.8 Hz, 1H), 7.21-7.27 (m, 1H), 6.81-6.96 (m, 1H), 6.66-6.77 (m, 2H), 6.57 (d, J=8.8 Hz, 2H), 3.93-4.02 (m, 2H), 3.72-3.80 (m, 1H), 3.65 (q, J=5.4 Hz, 2H), 2.63 (t, J=5.4 Hz, 2H), 1.74-1.85 (m, 1H), 1.56-1.67 (m, 1H), 1.29-1.49 (m, 4H), 0.88 (t, J=6.8 Hz, 3H). MS(M+1): 565.

Compound 8-18: (S)-3-(4-((1-((2-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.54-7.65 (m, 6H), 7.30 (t, J=8.8 Hz, 1H), 6.86 (d, J=4.9 Hz, 1H), 6.64-6.76 (m, 2H), 6.51-6.62 (m, 2H), 3.88-4.02 (m, 2H), 3.57-3.80 (m, 3H), 2.61 (br. s., 2H), 1.71-1.86 (m, 1H), 1.51-1.66 (m, 1H), 1.27-1.46 (m, 4H), 0.88 (t, J=6.8 Hz, 3H). MS(M+1): 547.

Compound 8-19: (S)-3-(4-((1-((2′,4′-dichloro-2-fluoro-[1,1′-biphenyl]-4-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.06 (t, J=5.4 Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.56-7.62 (m, J=8.8 Hz, 2H), 7.48-7.52 (m, 1H), 7.39 (d, J=8.8 Hz, 1H), 7.21-7.29 (m, 1H), 6.92 (dd, J=11.7, 2.4 Hz, 1H), 6.86 (dd, J=8.8, 2.4 Hz, 1H), 6.61-6.67 (m, J=8.8 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 3.99 (d, J=4.9 Hz, 2H), 3.79-3.90 (m, 1H), 3.36-3.43 (m, 2H), 2.45 (t, J=7.2 Hz, 2H), 1.72-1.84 (m, 1H), 1.50-1.57 (m, 2H), 0.95 (d, J=6.8 Hz, 3H), 0.88 (d, J=6.8 Hz, 3H). MS(M+1): 547.

Compound 8-20: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3-fluorophenoxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.08 (br. s., 1H), 7.88 (t, J=9.0 Hz, 1H), 7.67 (dd, J=7.2, 1.2 Hz, 1H), 7.56-7.63 (m, 3H), 7.32 (td, J=7.6, 1.6 Hz, 1H), 7.23-7.29 (m, 1H), 7.14-7.18 (m, 1H), 7.02 (dd, J=13.6, 2.4 Hz, 1H), 6.94 (dd, J=8.8, 2.4 Hz, 1H), 6.64 (d, J=8.8 Hz, 2H), 6.09 (d, J=8.4 Hz, 1H), 4.02 (d, J=5.4 Hz, 2H), 3.80-3.91 (m, 1H), 3.36-3.43 (m, 3H), 2.43 (t, J=7.2 Hz, 2H), 1.72-1.83 (m, 1H), 1.48-1.58 (m, 2H), 0.95 (d, J=6.8 Hz, 4H), 0.88 (d, J=6.8 Hz, 4H). MS(M+1): 518.

Compound 8-21: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3-fluorophenoxy)-3,3-dimethylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.99-8.10 (m, 1H), 7.85 (s, 1H), 7.57 (d, J=8.8 Hz, 4H), 7.22-7.38 (m, 2H), 7.12-7.18 (m, 1H), 6.97-7.05 (m, 1H), 6.82-6.91 (m, 1H), 6.70 (d, J=8.8 Hz, 2H), 5.97-6.05 (m, 1H), 4.27-4.39 (m, 1H), 3.96-4.06 (m, 1H), 3.60-3.78 (m, 1H), 2.39-2.48 (m, 2H), 1.02 (s, 9H). MS(M+1): 519.

Compound 8-22: (S)-3-(4-((1-((2′,4′-dichloro-2-fluoro-[1,1′-biphenyl]-4-yl)oxy)-3,3-dimethylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.67 (d, J=8.8 Hz, 2H), 7.60 (d, J=2.0 Hz, 1H), 7.41-7.47 (m, 2H), 7.38 (d, 1H), 7.22 (t, 1H), 6.74-6.84 (m, 4H), 5.38 (d, 1H), 4.41 (dd, J=9.8, 3.9 Hz, 1H), 4.13 (dd, J=10.0, 7.1 Hz, 1H), 3.75-3.83 (m, 1H), 3.54-3.63 (q, 2H), 2.61 (t, J=6.8 Hz, 3H), 1.12 (s, 9H). MS(M+1): 547.

Compound 8-23: (S)-3-(4-((1-((2,2′-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3,3-dimethylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.84-7.91 (m, 1H), 7.56-7.80 (m, 4H), 7.42-7.52 (m, 1H), 7.23-7.33 (m, 1H), 6.74-6.90 (m, 4H), 5.31-5.44 (m, 1H), 4.38-4.45 (m, 1H), 4.09-4.20 (m, 1H), 3.75-3.87 (m, 1H), 3.53-3.65 (m, 2H), 2.56-2.62 (m, 3H), 1.12 (s, 9H). MS(M+1): 565.

Compound 8-24: (S)-3-(4-((1-(3-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)phenoxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (t, J=6.0 Hz, 1H), 8.00 (t, J=8.8 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.16 (dd, J=13.2, 2.4 Hz, 1H), 7.02 (dd, J=9.0, 2.2 Hz, 1H), 6.63 (d, J=8.8 Hz, 2H), 6.01-6.24 (m, 1H), 4.10 (d, J=5.4 Hz, 2H), 3.74-3.89 (m, 1H), 3.37-3.42 (m, 2H), 2.44-2.48 (m, 2H), 1.51-1.78 (m, 2H), 1.23-1.47 (m, 5H), 0.85-0.87 (t, J=8.0 Hz, 3H). MS(M+1): 539.

Compound 8-25: (S)-3-(4-((1-(4-(benzo[d]thiazol-2-yl)-3-fluorophenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 12.16 (br. s., 1H), 8.48 (d, J=2.4 Hz, 1H), 8.23-8.31 (m, 1H), 8.20 (t, J=5.4 Hz, 1H), 8.14 (d, J=7.8 Hz, 1H), 8.06 (d, J=7.8 Hz, 1H), 7.78 (dd, J=8.8, 2.4 Hz, 1H), 7.51-7.61 (m, 1H), 7.41-7.51 (m, 1H), 7.17 (d, J=13.7 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 7.07 (d, J=8.3 Hz, 1H), 6.59 (d, J=8.8 Hz, 1H), 4.31 (br. s., 1H), 4.09-4.23 (m, 2H), 3.38-3.46 (m, 2H), 2.43-2.48 (m, 2H), 1.99-2.13 (m, 1H), 0.98 (t, J=6.6 Hz, 6H). MS(M+1): 522.

Example 9: Synthesis of Compounds 9-1 to 9-6

Compound 9-1: (S)-3-(5-((1-(4-(benzofuran-2-yl)phenoxy)-3-methylbutan-2-yl)amino)pyrazino-2-carboxamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.51 (d, J=1.0 Hz, 1H), 8.27 (t, J=5.8 Hz, 1H), 8.00 (d, J=1.0 Hz, 1H), 7.83 (d, J=8.8 Hz, 2H), 7.74 (d, J=8.8 Hz, 1H), 7.62-7.57 (m, 2H), 7.30-7.21 (m, 3H), 7.07 (d, J=8.8 Hz, 2H), 4.32-4.27 (m, 1H), 4.16-4.12 (m, 2H), 3.48-3.43 (m, 2H), 2.48 (t, J=8.8 Hz, 2H), 2.13-2.06 (m, 1H), 1.00-0.97 (m, 6H). MS(M+1): 489.

Compound 9-2: 3-(5-(((2S,3 S)-1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)pyrazine-2-carboxamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.50 (d, J=1.9 Hz, 1H), 8.25 (t, J=5.4 Hz, 1H), 7.98 (d, J=1.9 Hz, 1H), 7.78 (d, J=8.4 Hz, 1H), 7.68 (d, J=1.9 Hz, 1H), 7.47 (d, J=8.8, 1.9 Hz, 1H), 7.39 (d, J=8.8 Hz, 1H), 7.33 (d, J=8.8 Hz, 2H), 7.02 (d, J=8.8 Hz, 2H), 4.32 (brs, 1H), 4.17-4.12 (m, 1H), 3.48-3.43 (m, 2H), 2.48 (t, J=7 Hz, 2H), 1.87-1.84 (m, 1H), 1.59-1.55 (m, 1H), 1.28-1.22 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.89 (t, J=6.8 Hz, 3H). MS(M+1): 531.

Compound 9-3: (S)-3-(5-((3-methyl-1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)butan-2-yl)amino)picolinamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.31 (t, J=6 Hz, 1H), 8.06 (d, J=1.5 Hz, 1H), 7.82 (d, J=8 Hz, 2H), 7.76-7.73 (m, 3H), 7.66 (d, J=8 Hz, 2H), 7.11 (dd, J=8, 4 Hz, 1H), 7.04 (d, J=8 Hz, 1H), 6.50 (d, J=10 Hz, 1H), 4.15 (dd, J=10, 6 Hz, 1H), 4.04 (dd, J=10.6 Hz, 1H), 3.74-3.71 (m, 1H), 3.46 (quartet, J=6.8 Hz, 2H), 2.48 (t, J=6.8 Hz, 2H), 2.09-2.01 (m, 1H), 1.02-0.99 (m, 6H). MS(M+1): 516.

Compound 9-4: (S)-3-(6-((1-((2,6-difluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-4-methylpentan-2-yl)amino)nicotinamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.50 (d, J=2.4 Hz, 1H), 8.22 (t, J=5.6 Hz, 1H), 7.83-7.77 (m, 3H), 7.64 (d, J=8.3 Hz, 2H), 7.06 (d, J=7.8 Hz, 1H), 6.94 (d, J=8.8 Hz, 2H), 6.53 (d, J=8.8 Hz, 1H), 4.44 (brs, 1H), 4.12-3.95 (m, 2H), 3.44-3.39 (m, 2H), 2.47 (t, J=6.8 Hz, 2H), 1.73-1.71 (m, 1H), 1.58-1.50 (m, 2H), 0.92 (d, J=6.4 Hz, 3H), 0.85 (d, J=6.4 Hz, 3H). MS(M+1): 566.

Compound 9-5: (S)-3-(6-((1-(4-(benzo[d]thiazol-2-yl)-3-fluorophenoxy)-3-methylbutan-2-yl)amino)nicotinamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ12.16 (br. s., 1H), 8.48 (d, J=2.4 Hz, 1H), 8.23-8.31 (m, 1H), 8.20 (t, J=5.4 Hz, 1H), 8.14 (d, J=7.8 Hz, 1H), 8.06 (d, J=7.8 Hz, 1H), 7.78 (dd, J=8.8, 2.4 Hz, 1H), 7.51-7.61 (m, 1H), 7.41-7.51 (m, 1H), 7.17 (d, J=13.7 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 7.07 (d, J=8.3 Hz, 1H), 6.59 (d, J=8.8 Hz, 1H), 4.31 (br. s., 1H), 4.09-4.23 (m, 2H), 3.38-3.46 (m, 2H), 2.43-2.48 (m, 2H), 1.99-2.13 (m, 1H), 0.98 (t, J=6.6 Hz, 6H). MS(M+1): 523.

Compound 9-6: (S)-3-(4-((1-((1-(2,4-difluorophenyl)-1H-pyrazol-4-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.04 (t, J=5.4 Hz, 1H), 7.89 (d, J=1.9 Hz, 1H), 7.76-7.70 (m, 1H), 7.59-7.57 (m, 3H), 7.52-7.47 (m, 1H), 7.24-7.20 (m, 1H), 6.61 (d, J=8.8 Hz, 2H), 6.07 (d, J=8.8 Hz, 1H), 3.92-3.85 (m, 2H), 3.84-3.76 (m, 1H), 2.46 (t, J=6.8 Hz, 2H), 1.77-1.73 (m, 1H), 1.52-1.48 (m, 2H), 0.93 (d, J=6.8 Hz, 3H), 0.85 (d, J=6.8 Hz, 3H). MS(M+1): 487.

Example 10: Synthesis of Compounds 10-1 to 10-19

Compound 10-1: (S)-3-(4-((3-methyl-1-((6-(4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)butan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.38 (d, J=3 Hz, 1H), 8.21 (d, J=8.8 Hz, 2H), 8.05 (t, J=5.4 Hz, 1H), 7.99 (d, J=8.8 Hz, 1H), 7.78 (d, J=8.8 Hz, 2H), 7.61 (d, J=8.8 Hz, 2H), 7.50 (dd, J=8.8, 2.5 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.13 (d, J=8.8 Hz, 1H), 4.42-4.10 (m, 2H), 3.71-3.65 (m, 1H), 3.44-3.39 (m, 2H), 2.48 (t, J=7 Hz, 2H), 2.07-2.02 (m, 1H), 1.01-0.97 (m, 6H). MS(M+1): 516.

Compound 10-2: (S)-3-(4-((1-((6-(2-chloro-4-(trifluoromethyl)phenyl)pyridin-3-yl)ox)-3-methylbutan-2-yl)aminobenzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.40 (d, J=3 Hz, 1H), 8.06-8.05 (m, 1H), 7.94-7.92 (m, 1H), 7.88 (s, 1H), 7.68-7.60 (m, 3H), 7.53-7.49 (m, 1H), 6.69-6.66 (m, 2H), 6.10-6.04 (m, 1H), 6.13 (d, J=8.8 Hz, 1H), 4.22-4.12 (m, 2H), 3.70-3.67 (m, 1H), 3.44-3.39 (m, 2H), 2.48 (t, J=7 Hz, 2H), 2.09-2.03 (m, 1H), 1.02-0.98 (m, 6H). MS(M+1): 550.

Compound 10-3: (S)-3-(4-((1-((6-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 12.18 (brs, 1H), 8.43 (d, J=3 Hz, 1H), 8.14-8.04 (m, 2H), 7.81-7.73 (m, 2H), 7.66-7.60 (m, 3H), 7.52 (dd, J=8.8, 2.5 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.13 (d, J=8.8 Hz, 1H), 6.55-6.59 (m, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.22-4.12 (m, 2H), 3.72-3.65 (m, 1H), 3.45-3.40 (m, 2H), 2.48 (t, J=7 Hz, 2H), 2.09-2.01 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 534.

Compound 10-4: (S)-3-(4-((1-((6-(2,4-dichlorophenyl)pyridin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.36 (d, J=3 Hz, 1H), 8.04 (t, J=5.4 Hz, 1H), 7.69 (d, J=3 Hz, 1H), 7.61-7.56 (m, 4H), 7.51-7.47 (m, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.21-4.02 (m, 2H), 3.69-3.66 (m, 1H), 3.44-3.39 (m, 2H), 2.47 (t, J=7 Hz, 2H), 2.07-2.02 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 516.

Compound 10-5: (S)-3-(4-((1-((6-(3,5-dichlorophenyl)pyridin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propenoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.35 (d, J=3 Hz, 1H), 8.04-8.02 (m, 4H), 7.60-7.57 (m, 3H), 7.51-7.48 (m, 1H), 6.66 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.21-4.09 (m, 2H), 3.69-3.66 (m, 1H), 3.43-3.38 (m, 2H), 2.47 (t, J=7 Hz, 2H), 2.07-2.03 (m, 1H), 1.01-0.97 (m, 6H). MS(M+1): 516.

Compound 10-6: (S)-3-(4-((1-((6-(benzofuran-2-yl)pyridin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.36 (d, J=3 Hz, 1H), 8.05 (t, J=5.4 Hz, 1H), 7.88 (d, J=8.8 Hz, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.63-7.60 (m, 3H), 7.52 (dd, J=7.8, 3 Hz, 1H), 7.38 (s, 1H), 7.33 (dt, J=7.8, 1.9 Hz, 1H), 7.26 (dt, J=7.8, 1.9 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.22-4.01 (m, 2H), 3.70-3.67 (m, 1H), 3.44-3.39 (m, 2H), 2.48 (t, J=7 Hz, 2H), 2.09-2.02 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 488.

Compound 10-7: (S)-3-(4-((1-((6-(2,4-dichlorophenyl)pyridin-3-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.38 (d, J=2.9 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.52 (d, J=8.8 Hz, 1H), 7.43-7.47 (m, 2H), 7.28 (dd, J=8.3, 2.4 Hz, 1H), 7.21-7.26 (m, 1H), 6.79 (br. s., 1H), 6.58 (d, J=8.3 Hz, 2H), 4.00-4.11 (m, 2H), 3.79 (dd, J=7.3, 5.9 Hz, 1H), 3.65 (d, J=5.4 Hz, 2H), 2.55-2.66 (m, 2H), 1.76-1.86 (m, 1H), 1.56-1.69 (m, 1H), 1.30-1.50 (m, 4H), 0.84-0.94 (t, J=7.1 Hz, 3H). MS(M+1): 530.

Compound 10-8: (S)-3-(4-((1-((6-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.40 (d, J=2.9 Hz, 3H), 7.99 (t, J=8.1 Hz, 3H), 7.70 (d, J=8.8 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.45 (d, J=8.3 Hz, 1H), 7.37 (d, J=10.8 Hz, 1H), 7.20-7.26 (m, 1H), 6.89 (dt, J=11.4, 5.3 Hz, 1H), 6.52-6.62 (m, 2H), 4.00-4.07 (m, 2H), 3.78 (br. s., 1H), 3.64 (d, J=5.9 Hz, 2H), 2.61 (br. s., 2H), 1.74-1.86 (m, 1H), 1.55-1.68 (m, 1H), 1.28-1.46 (m, 4H), 0.87 (t, J=6.8 Hz, 3H). MS(M+1): 548.

Compound 10-9: (S)-3-(4-((1-((6-(4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)hexan-2-yl)amino) benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.33-8.42 (m, 1H), 7.96 (d, J=7.8 Hz, 2H), 7.53-7.71 (m, 5H), 7.24 (dt, J=5.9, 2.9 Hz, 1H), 6.81 (t, J=5.9 Hz, 1H), 6.54-6.62 (m, 2H), 4.01-4.09 (m, 2H), 3.78 (dd, J=7.3, 5.9 Hz, 1H), 3.65 (q, J=5.9 Hz, 2H), 2.63 (t, J=5.9 Hz, 2H), 1.75-1.85 (m, 1H), 1.57-1.69 (m, 1H), 1.30-1.48 (m, 4H), 0.88 (t, J=7.1 Hz, 3H). MS(M+1): 530.

Compound 10-10: (S)-3-(4-((1-((6-(3,5-dichlorophenyl)pyridin-3-yl)oxy)hexan-2-yl)amino)benzamido) propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.33 (d, J=2.9 Hz, 1H), 7.75 (d, J=2.0 Hz, 2H), 7.57 (dd, J=13.2, 8.8 Hz, 3H), 7.30 (t, J=1.7 Hz, 1H), 7.20 (dd, J=8.8, 2.9 Hz, 1H), 6.77 (t, J=5.9 Hz, 1H), 6.57 (d, J=8.8 Hz, 2H), 4.00-4.07 (m, 2H), 3.78 (dd, J=7.3, 5.9 Hz, 1H), 3.62-3.69 (m, 2H), 2.63 (t, J=5.6 Hz, 2H), 1.74-1.87 (m, 1H), 1.57-1.68 (m, 1H), 1.30-1.48 (m, 4H), 0.86-0.91 (t, J=7.1 Hz, 3H). MS(M+1): 530.

Compound 10-11: (S)-3-(4-((1-((6-(2-chloro-4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.39 (d, J=2.4 Hz, 1H), 7.47-7.76 (m, 6H), 7.19-7.28 (m, 1H), 6.77-6.97 (m, 1H), 6.57 (dd, J=8.6, 2.2 Hz, 2H), 3.96-4.12 (m, 2H), 3.78 (m, 1H), 3.62 (m, 2H), 2.58 (m, 2H), 1.72-1.85 (m, 1H), 1.54-1.69 (m, 1H), 1.27-1.51 (m, 4H), 0.88 (t, J=6.8 Hz, 3H). MS(M+1): 564.

Compound 10-12: (S)-3-(4-((1-((6-(benzofuran-2-yl)pyridin-3-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.28-8.39 (m, 1H), 7.76 (td, J=8.2, 4.2 Hz, 1H), 7.44-7.66 (m, 4H), 7.11-7.34 (m, 4H), 6.80-7.00 (m, 1H), 6.47-6.59 (m, 2H), 3.92-4.02 (m, 2H), 3.56-3.78 (m, 3H), 2.63 (br. s., 2H), 1.66-1.84 (m, 1H), 1.48-1.66 (m, 1H), 1.23-1.40 (m, 4H), 0.80-0.89 (m, 3H). MS(M+1): 502.

Compound 10-13: 3-(4-(((2S,3S)-1-((6-(benzofuran-2-yl)pyridin-3-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.32 (d, J=2.9 Hz, 1H), 7.76 (d, J=8.8 Hz, 1H), 7.57 (t, J=7.8 Hz, 3H), 7.48 (d, J=8.3 Hz, 1H), 7.15-7.31 (m, 4H), 6.91 (br. s., 1H), 6.54 (d, J=8.3 Hz, 2H), 4.00-4.12 (m, 2H), 3.52-3.75 (m, 3H), 2.64 (d, J=4.9 Hz, 2H), 1.73-1.87 (m, 1H), 1.48-1.67 (m, 1H), 1.10-1.23 (m, 1H), 0.95 (d, J=5.9 Hz, 3H), 0.90 (t, J=7.3 Hz, 3H). MS(M+1): 502.

Compound 10-14: 3-(4-(((2S,3S)-1-((6-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.39 (d, J=2.9 Hz, 1H), 8.00 (t, J=7.8 Hz, 1H), 7.66-7.74 (m, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.46 (d, J=8.3 Hz, 1H), 7.37 (d, J=10.8 Hz, 1H), 7.17-7.27 (m, 1H), 6.76-6.89 (m, 1H), 6.57 (d, J=8.3 Hz, 2H), 4.04-4.17 (m, 2H), 3.59-3.69 (m, 3H), 2.62 (t, J=5.1 Hz, 2H), 1.78-1.91 (m, 1H), 1.57-1.71 (m, 1H), 1.16-1.29 (m, 1H), 0.98 (d, J=6.4 Hz, 3H), 0.92 (t, J=7.3 Hz, 3H). MS(M+1): 548. HPLC 99%.

Compound 10-15: 3-(4-(((2S,3S)-1-((6-(2,4-dichlorophenyl)pyridin-3-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.36 (d, J=2.9 Hz, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.52 (d, J=8.8 Hz, 1H), 7.43-7.47 (m, 2H), 7.29 (dd, J=8.3, 2.0 Hz, 1H), 7.22 (dd, J=8.8, 2.9 Hz, 1H), 6.76 (t, J=5.4 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 4.07-4.17 (m, 2H), 3.60-3.69 (m, 3H), 2.62 (t, J=5.6 Hz, 2H), 1.80-1.91 (m, 1H), 1.65 (ddd, J=13.6, 7.5, 3.9 Hz, 1H), 1.19-1.29 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 530. HPLC 99%.

Compound 10-16: 3-(4-(((2S,3S)-1-((6-(2-chloro-4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.38 (d, J=2.9 Hz, 1H), 7.70 (d, J=1.0 Hz, 1H), 7.62-7.68 (m, 1H), 7.53-7.62 (m, 4H), 7.24 (dt, J=5.5, 2.9 Hz, 1H), 6.77 (t, J=5.6 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 4.07-4.18 (m, 2H), 3.62-3.69 (m, 3H), 2.62 (t, J=5.6 Hz, 2H), 1.86 (qd, J=6.4, 3.4 Hz, 1H), 1.65 (ddd, J=13.6, 7.5, 3.9 Hz, 1H), 1.18-1.30 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 564. HPLC 99%.

Compound 10-17: (S)-3-(4-((4-methyl-1-((6-(4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.38 (d, J=1.9 Hz, 1H), 8.22 (d, J=7.8 Hz, 2H), 8.05-7.97 (m, 2H), 7.79 (d, J=7.8 Hz, 2H), 7.60 (d, J=8.8 Hz, 2H), 7.51-7.48 (m, 1H), 6.65 (d, J=8.8 Hz, 2H), 6.11 (d, J=8.8 Hz, 1H), 4.13-4.02 (m, 2H), 3.70-3.63 (m, 1H), 3.50-3.45 (m, 2H), 2.64 (t, J=6.8 Hz, 2H), 2.10-1.99 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 530.

Compound 10-18: (S)-3-(4-((1-((6-(2-chloro-4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.39 (d, J=1.9 Hz, 1H), 8.04 (t, J=5.4 Hz, 1H), 7.96 (s, 1H), 7.82-7.76 (m, 2H), 7.68 (d, J=8.8 Hz, 1H), 7.60 (d, J=8.8 Hz, 2H), 7.52-7.49 (m, 1H), 6.65 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.08 (d, J=4.9 Hz, 2H), 3.91-3.85 (m, 1H), 3.42-3.37 (m, 2H), 2.47 (t, J=6.8 Hz, 2H), 1.81-1.76 (m, 1H), 1.58-1.54 (m, 2H), 0.96 (d, J=6.4 Hz, 3H), 0.88 (d, J=6.4 Hz, 3H). MS(M+1): 564.

Compound 10-19: (S)-3-(4-((1-((6-(2,4-dichlorophenyl)pyridin-3-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.36 (d, J=1.9 Hz, 1H), 8.04 (t, J=5.6 Hz, 1H), 7.70 (d, J=1.9 Hz, 1H), 7.61-7.56 (m, 4H), 7.52-7.45 (m, 2H), 6.64 (d, J=8.8 Hz, 2H), 6.11 (d, J=8.8 Hz, 1H), 4.08 (d, J=4.9 Hz, 2H), 3.89-3.85 (m, 2H), 3.42-3.37 (m, 2H), 2.45 (t, J=6.8 Hz, 2H), 1.80-1.75 (m, 1H), 1.58-1.53 (m, 2H), 0.95 (d, J=6.4 Hz, 3H), 0.88 (d, J=6.4 Hz, 3H). MS(M+1): 530.

Example 11: Synthesis of Compounds 11-1 to 11-2

Compound 11-1: (S)-3-(6-((1-((6-(2-chloro-4-(trifluoromethyl)phenyl)pyridin-3-yl)oxy)-3-methylbutan-2-yl)amino)nicotinamido)propanoic acid

White solid. HNMR (400 MHz, DMSO-d₆): δ 8.47 (d, J=1.9 Hz, 1H), 8.42 (d, J=3 Hz, 1H), 8.19 (t, J=5.6 Hz, 1H), 7.96 (s, 1H), 7.82-7.76 (m, 3H), 7.69 (d, J=8.8 Hz, 1H), 7.58-7.55 (m, 1H), 7.08 (d, J=8.8 Hz, 1H), 6.58 (d, J=8.8 Hz, 1H), 4.31 (brs, 1H), 4.20-4.19 (m, 2H), 3.34-3.39 (m, 2H), 2.47 (t, J=6.8 Hz, 2H), 2.11-2.06 (m, 1H), 1.00-0.97 (m, 6H). MS(M+1): 551.

Compound 11-2: (S)-3-(6-((1-((6-(benzofuran-2)pyridin-3-yl)oxy)-3-methylbutan-2-yl)amino)nicotinamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.49-8.48 (m, 1H), 8.37 (m, 1H), 8.21 (t, J=5.6 Hz, 1H), 7.88 (d, J=7.8 Hz, 1H), 7.79-7.76 (m, 1H), 7.68-7.56 (m, 3H), 7.38-7.24 (m, 3H), 7.08 (d, J=8.8 Hz, 1H), 6.58 (d, J=8.8 Hz, 1H), 4.31 (brs, 1H), 4.19-4.18 (m, 2H), 2.48 (t, J=6.8 Hz, 2H), 2.09-2.05 (m, 1H), 0.99-0.96 (m, 6H). MS(M+1): 489.

Example 12: Synthesis of Compounds 12-1 to 12-11

Compound 12-1: (S)-3-(4-((4-methyl-1-((2-(3-methyl-4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-5-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.94 (s, 1H), 8.59 (s, 2H), 8.04 (t, J=5.4 Hz, 1H), 8.04 (t, J=5.6 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 6.63 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.16 (d, J=5.4 Hz, 2H), 3.89-3.86 (m, 1H), 3.42-3.37 (m, 2H), 2.46 (t, J=6.8 Hz, 2H), 1.80-1.75 (m, 1H), 1.57-1.52 (m, 2H), 0.95 (d, J=6.4 Hz, 3H), 0.87 (d, J=6.4 Hz, 3H). MS(M+1): 535.

Compound 12-2: (S)-3-(4-((1-((2-(benzofuran-2-yl)pyrimidin-5-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.64 (s, 2H), 8.04 (t, J=5.4 Hz, 1H), 7.74 (d, J=7.3 Hz, 1H), 7.67 (d, J=8.8 Hz, 1H), 7.55-7.63 (m, 3H), 7.37-7.43 (m, 1H), 7.27-7.34 (m, 1H), 6.66 (d, J=8.8 Hz, 2H), 6.14 (d, J=8.8 Hz, 1H), 4.32 (dd, J=10.0, 4.2 Hz, 1H), 4.23 (dd, J=9.8, 6.4 Hz, 1H), 3.71 (dd, J=8.8, 4.4 Hz, 1H), 2.44-2.48 (m, 2H), 2.04 (dd, J=13.2, 6.4 Hz, 1H), 1.09 (t, J=7.1 Hz, 2H), 0.99 (d, J=9.3 Hz, 3H), 1.01 (d, J=9.3 Hz, 3H); MS(M+1): 489.

Compound 12-3: (S)-3-(4-((1-((2-(benzofuran-2-yl)pyrimidin-5-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.63 (s, 2H), 8.03-8.06 (m, 1H), 7.74 (d, J=7.3 Hz, 1H), 7.64-7.69 (m, 1H), 7.57-7.62 (m, 3H), 7.37-7.43 (m, 1H), 7.28-7.33 (m, 1H), 6.65 (d, J=9.3 Hz, 2H), 6.13 (d, J=8.8 Hz, 1H), 4.19 (d, J=4.9 Hz, 2H), 3.84-3.94 (m, 1H), 3.37-3.44 (m, 2H), 2.44-2.48 (m, 2H), 1.73-1.84 (m, 1H), 1.55 (dt, J=8.3, 5.4 Hz, 2H), 0.96 (d, J=6.8 Hz, 3H), 0.88 (d, J=6.8 Hz, 3H). MS(M+1): 503.

Compound 12-4: 3-(4-(((2S,3S)-1-((6-(2-fluoro-4-(trifluoromethylphenyl)pyridin-3-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (s, 2H), 7.96-8.06 (m, 2H), 7.87-7.92 (m, 1H), 7.81-7.87 (m, 1H), 7.57-7.60 (m, J=8.8 Hz, 2H), 6.63-6.69 (m, J=8.8 Hz, 2H), 6.14 (d, J=8.8 Hz, 1H), 4.33 (dd, J=10.0, 4.2 Hz, 1H), 4.24 (dd, J=10.3, 6.4 Hz, 1H), 3.67-3.75 (m, 1H), 3.37-3.43 (m, 2H), 2.44-2.48 (m, 2H), 2.00-2.10 (m, 1H), 1.00 (d, J=9.8 Hz, 3H), 1.01 (d, J=9.8 Hz, 3H). MS(M+1): 551.

Compound 12-5: (S)-3-(4-((1-((2-(2-chloro-4-(trifluoromethyl)phenyl)pyrimidin-5-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.70 (s, 2H), 8.01-8.07 (m, 1H), 7.98 (s, 1H), 7.90 (d, J=7.8 Hz, 1H), 7.83 (dd, J=8.1, 1.2 Hz, 1H), 7.57-7.62 (m, J=8.8 Hz, 2H), 6.61-6.65 (m, J=8.8 Hz, 2H), 6.16 (d, J=8.3 Hz, 1H), 4.22 (d, J=5.4 Hz, 2H), 3.84 (d, J=4.9 Hz, 1H), 3.38-3.43 (m, 2H), 2.45-2.48 (m, 2H), 1.73 (dd, J=9.0, 4.2 Hz, 1H), 1.53-1.64 (m, 1H), 1.41-1.47 (m, 1H), 1.32 (d, J=6.8 Hz, 3H), 0.88 (t, J=7.1 Hz, 3H). MS(M+1): 565.

Compound 12-6: (S)-3-(4-((1-((2-(2,4-dichlorophenyl)pyrimidin-5-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.66 (s, 2H), 7.99-8.07 (m, 2H), 7.67-7.75 (m, 2H), 7.56-7.62 (m, J=8.3 Hz, 2H), 7.51-7.56 (m, 1H), 6.62-6.69 (m, J=8.8 Hz, 2H), 4.31 (dd, J=9.8, 4.4 Hz, 1H), 4.22 (dd, J=10.3, 6.4 Hz, 1H), 3.39-3.43 (m, 4H), 2.44-2.48 (m, 2H), 2.04 (dq, J=13.2, 6.7 Hz, 1H), 1.01 (d, J=6.8 Hz, 3H), 0.99 (d, J=6.8 Hz, 3H). MS(M+1): 517.

Compound 12-7: (S)-3-(4-((1-((2-(2,4-dichlorophenyl)pyrimidin-5-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.66 (s, 2H), 8.04 (s, 2H), 7.69-7.74 (m, 2H), 7.56-7.62 (m, J=8.8 Hz, 2H), 7.52-7.56 (m, 1H), 6.61-6.65 (m, J=9.3 Hz, 2H), 4.21 (d, J=5.4 Hz, 2H), 3.82-3.85 (m, 1H), 3.37-3.40 (m, 2H), 2.44-2.48 (m, 2H), 1.69-1.77 (m, 1H), 1.59 (td, J=9.2, 5.1 Hz, 1H), 1.1-1.50 (m, 1H), 1.30-1.37 (m, 3H), 0.86-0.89 (m, 3H). MS(M+1): 531.

Compound 12-8: 3-(4-(((2S)-1-((2-(2-chloro-4-(trifluoromethyl)phenyl)pyrimidin-5-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.01-8.05 (m, 2H), 7.90 (d, J=8.3 Hz, 1H), 7.83 (dd, J=8.3, 1.5 Hz, 1H), 7.55-7.63 (m, J=8.8 Hz, 2H), 6.59-6.68 (m, J=8.8 Hz, 2H), 6.19 (d, J=8.8 Hz, 1H), 4.35 (dd, J=10.3, 3.4 Hz, 1H), 4.25 (dd, 5=10.3, 6.4 Hz, 1H), 3.69-3.79 (m, 1H), 3.40-3.44 (m, 2H), 2.44-2.48 (m, 2H), 1.75-1.85 (m, 1H), 1.68-1.57 (m, 1H), 1.25-1.32 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.91 (t, J=7.3 Hz, 3H). MS(M+1): 565. HPLC: 97.2%.

Compound 12-9: (S)-3-(4-((1-((2-(2-chloro-4-(trifluoromethyl)phenyl)pyrimidin-5-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.96-8.05 (m, 2H), 7.86-7.92 (m, 1H), 7.78-7.86 (m, 1H), 7.52-7.65 (m, J=8.8 Hz, 2H), 6.58-6.69 (m, J=8.8 Hz, 2H), 6.12 (d, J=8.3 Hz, 1H), 4.20 (d, J=4.9 Hz, 2H), 3.94-3.82 (m, 1H), 3.39-3.44 (m, 2H), 2.44-2.48 (m, 2H), 1.71-1.86 (m, 1H), 1.46-1.63 (m, 2H), 0.96 (d, J=6.4 Hz, 3H), 0.88 (d, J=6.4 Hz, 3H). MS(M+1): 565. HPLC: 93.5%.

Compound 12-10: 3-(4-(((2S)-1-((2-(2,4-dichlorophenyl)pyrimidin-5-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.02 (s, 1H), 7.69-7.74 (m, 2H), 7.56-7.61 (m, J=8.8 Hz, 2H), 7.53 (dd, J=8.3, 2.0 Hz, 1H), 6.61-6.65 (m, J=8.8 Hz, 2H), 6.19 (d, J=8.8 Hz, 1H), 4.34 (dd, J=10.3, 3.9 Hz, 1H), 4.23 (dd, J=10.3, 6.4 Hz, 1H), 3.69-3.77 (m, 1H), 3.39-3.44 (m, 2H), 2.44-2.48 (m, 2H), 1.75-1.83 (m, 1H), 1.55-1.65 (m, 1H), 1.24-1.32 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.91 (t, J=7.3 Hz, 3H). MS(M+1): 531. HPLC: 92.1%.

Compound 12-11: (S)-3-(4-((1-((2-(2,4-dichlorophenyl)pyrimidin-5-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.01-8.04 (m, 1H), 7.66-7.74 (m, 2H), 7.55-7.63 (m, J=8.8 Hz, 2H), 7.53 (dd, J=8.3, 2.0 Hz, 1H), 6.60-6.68 (m, J=8.3 Hz, 2H), 6.12 (d, J=8.3 Hz, 1H), 4.18 (d, I=4.9 Hz, 2H), 3.82-3.95 (m, 1H), 3.37-3.43 (m, 2H), 2.44-2.48 (m, 2H), 1.72-1.84 (m, 1H), 1.47-1.63 (m, 2H), 0.96 (d, J=6.8 Hz, 3H), 0.88 (d, J=6.8 Hz, 3H). MS(M+1): 531. HPLC: 94.3%.

Example 13: Synthesis of Compounds 13-1 to 13-14

Compound 13-1: 3-(4-(((2S,3S)-1-(4-(benzofuran-2-yl)-3-methoxyphenoxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.92 (d, J=8.3 Hz, 1H), 7.58 (d, J=8.3 Hz, 2H), 7.51-7.55 (m, 1H), 7.45 (d, J=7.8 Hz, 1H), 7.15-7.23 (m, 3H), 6.68 (br. s., 1H), 6.57 (d, J=8.8 Hz, 2H), 6.53 (dd, J=8.6, 2.2 Hz, 1H), 6.49 (d, J=2.0 Hz, 1H), 4.02-4.10 (m, 2H), 3.91 (s, 3H), 3.64 (dd, J=10.3, 5.9 Hz, 3H), 2.65 (br. s., 2H), 1.85 (m, 1H), 1.63 (m, 1H), 1.22-1.29 (m, 1H), 0.99 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 531.

Compound 13-2: 3-(4-(((2S,3S)-1-((2′,4′-dichloro-2-methoxy-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J=8.8 Hz, 2H), 7.42 (d, J=2.4 Hz, 1H), 7.20-7.24 (m, 1H), 7.16 (d, J=7.8 Hz, 1H), 7.02 (d, J=8.8 Hz, 1H), 6.68-6.76 (m, 1H), 6.58 (d, J=8.3 Hz, 2H), 6.48 (dq, J=4.3, 2.3 Hz, 2H), 4.02-4.09 (m, 2H), 3.70 (s, 3H), 3.65 (dd, J=12.2, 5.9 Hz, 3H), 2.65 (br. s., 2H), 1.83-1.92 (m, 1H), 1.65 (br. s., 1H), 1.20-1.30 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.94 (t, J=7.3 Hz, 3H). MS(M+1): 559. HPLC 95%.

Compound 13-3: 3-(4-(((2S,3S)-1-((2′-chloro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, J=1.0 Hz, 1H), 7.59 (d, J=8.3 Hz, 2H), 7.49 (dd, J=8.1, 1.2 Hz, 1H), 7.36 (d, J=8.3 Hz, 1H), 7.04 (d, J=9.3 Hz, 1H), 6.70-6.78 (m, 1H), 6.59 (d, J=8.8 Hz, 2H), 6.48-6.52 (m, 2H), 4.05-4.10 (m, 2H), 3.71 (s, 3H), 3.62-3.69 (m, 3H), 2.66 (br. s., 2H), 1.88 (d, J=5.4 Hz, 1H), 1.66 (br. s., 1H), 1.23-1.29 (m, 1H), 1.01 (d, J=6.8 Hz, 3H), 0.95 (t, J=7.6 Hz, 3H). MS(M+1): 593. HPLC 94%.

Compound 13-4: 3-(4-(((2S,3S)-1-((2′-fluoro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.3 Hz, 2H), 7.37-7.44 (m, 2H), 7.34 (d, J=10.3 Hz, 1H), 7.12 (d, J=8.8 Hz, 1H), 6.80-6.72 (m, 1H), 6.58 (d, J=8.8 Hz, 2H), 6.51 (dq, J=4.5, 2.3 Hz, 2H), 4.04-4.12 (m, 2H), 3.73 (s, 3H), 3.65 (dd, J=10.8, 6.4 Hz, 3H), 2.68-2.62 (m, 2H), 1.82-1.92 (m, 1H), 1.61-1.70 (m, 1H), 1.28-1.22 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.94 (t, J=7.3 Hz, 3H). MS(M+1): 577. HPLC 94%.

Compound 13-5: (S)-3-(4-((1-(4-(benzofuran-2-yl)-3-methoxyphenoxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.92 (d, J=8.3 Hz, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.50-7.55 (m, 1H), 7.45 (d, J=7.8 Hz, 1H), 7.13-7.24 (m, 3H), 6.70 (t, J=6.1 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 6.54 (dd, J=8.8, 2.4 Hz, 1H), 6.49 (d, J=2.4 Hz, 1H), 4.05 (d, J=4.4 Hz, 2H), 3.91 (s, 3H), 3.63-3.70 (m, 2H), 3.57 (d, J=6.4 Hz, 1H), 2.65 (t, J=5.9 Hz, 2H), 2.12 (m, 1H), 1.02 (dd, J=6.8, 2.0 Hz, 6H). MS(M+1): 517.

Compound 13-6: (S)-3-(4-((1-((2′-chloro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.67 (d, J=1.0 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.49 (dd, J=8.1, 1.2 Hz, 1H), 7.35 (d, J=7.8 Hz, 1H), 7.04 (d, J=8.8 Hz, 1H), 6.71 (br. s., 1H), 6.59 (d, J=8.8 Hz, 2H), 6.45-6.53 (m, 2H), 4.06 (dd, J=4.4, 2.4 Hz, 2H), 3.71 (s, 3H), 3.63-3.69 (m, 2H), 3.58 (d, J=6.4 Hz, 1H), 2.65 (t, J=5.6 Hz, 2H), 2.14 (d, J=6.8 Hz, 1H), 1.04 (d, J=6.8 Hz, 6H). MS(M+1): 579. HPLC 99%.

Compound 13-7: (S)-3-(4-((1-((2′,4′-dichloro-2-methoxy-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, J=8.8 Hz, 2H), 7.42 (d, J=2.0 Hz, 1H), 7.19-7.26 (m, 1H), 7.12-7.18 (m, 1H), 6.98-7.06 (m, 1H), 6.75 (br. s., 1H), 6.58 (d, J=8.8 Hz, 2H), 6.48 (dq, J=4.3, 2.3 Hz, 2H), 4.05 (dd, J=4.2, 2.7 Hz, 2H), 3.70 (s, 3H), 3.62-3.68 (m, 2H), 3.60-3.53 (m, 1H), 2.65 (t, J=5.6 Hz, 2H), 2.19-2.09 (m, 1H), 1.03 (d, J=6.8 Hz, 6H). MS(M+1): 545. HPLC 93%.

Compound 13-8: (S)-3-(4-((1-((2′-fluoro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.8 Hz, 2H), 7.37-7.44 (m, 2H), 7.33 (d, J=9.8 Hz, 1H), 7.10-7.14 (m, 1H), 6.72-6.83 (m, 1H), 6.59 (d, J=8.8 Hz, 2H), 6.51 (dq, J=4.5, 2.3 Hz, 2H), 4.05 (dd, J=4.2, 1.7 Hz, 2H), 3.73 (s, 3H), 3.66 (q, J=5.9 Hz, 2H), 3.61-3.55 (m, 1H), 2.65 (t, J=5.4 Hz, 2H), 2.19-2.09 (m, 1H), 1.03 (dd, J=6.8, 1.5 Hz, 61H). MS(M+1): 563. HPLC 97%.

Compound 13-9: (S)-3-(4-((1-((2′,4′-dichloro-2-methoxy-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₁): δ 7.59 (d, J=8.3 Hz, 2H), 7.43 (d, J=2.0 Hz, 1H), 7.21-7.24 (m, 1H), 7.15-7.18 (m, 1H), 7.02 (d, J=8.3 Hz, 1H), 6.69 (t, J=5.9 Hz, 1H), 6.59 (d, J=8.8 Hz, 2H), 6.47-6.52 (m, 2H), 4.01 (t, J=4.9 Hz, 2H), 3.73-3.79 (m, 1H), 3.71 (s, 3H), 3.67 (q, J=5.9 Hz, 2H), 2.66 (t, J=5.9 Hz, 2H), 1.77-1.87 (m, 1H), 1.58-1.68 (m, 1H), 1.32-1.47 (m, 4H), 0.90 (t, J=7.1 Hz, 3H). MS(M+1): 559. HPLC 95%.

Compound 13-10: (S)-3-(4-((1-((2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.53-7.62 (m, 6H), 7.16-7.20 (m, 1H), 6.75 (br. s., 1H), 6.59 (d, J=8.8 Hz, 2H), 6.49-6.53 (m, 2H), 4.02-4.09 (m, 2H), 3.75 (s, 3H), 3.66 (d, J=5.4 Hz, 2H), 3.54-3.60 (m, 1H), 2.65 (br. s., 2H), 2.09-2.19 (m, 1H), 1.03 (dd, J=6.8, 1.5 Hz, 6H). MS(M+1): 545. HPLC 96%.

Compound 13-11: (S)-3-(4-((1-((2-methoxy-4′-(trifluoromethyl)-[, 1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.53-7.64 (m, 6H), 7.14-7.23 (m, 1H), 6.69 (br. s., 1H), 6.59 (d, J=8.8 Hz, 2H), 6.48-6.55 (m, 2H), 4.02 (t, J=4.6 Hz, 2H), 3.76 (s, 3H), 3.68 (q, J=5.9 Hz, 2H), 2.67 (t, J=5.6 Hz, 2H), 1.77-1.88 (m, 1H), 1.56-1.70 (m, 1H), 1.29-1.49 (m, 4H), 0.90 (t, J=7.1 Hz, 3H). MS(M+1): 559.

Compound 13-12: 3-(4-(((2S,3S)-1-(3-methoxy-4-(5-phenyl-1,3,4-oxadiazol-2-yl)phenoxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.07 (dd, J=2.4, 7.3 Hz, 2H), 7.87 (d, J=8.3 Hz, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.54-7.43 (m, 3H), 6.86 (t, J=5.9 Hz, 1H), 6.61-6.49 (m, 3H), 6.46 (d, J=2.0 Hz, 1H), 4.15-4.05 (m, 2H), 3.85 (s, 3H), 3.69-3.61 (m, 3H), 2.64 (t, J=5.6 Hz, 2H), 1.87-1.80 (m, 1H), 1.68-1.59 (m, 1H), 1.30-1.25 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 559. HPLC 98%.

Compound 13-13: 3-(4-(((2S,3S)-1-(4-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)-3-methoxyphenoxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, J=8.8 Hz, 1H), 7.57 (d, J=8.8 Hz, 2H), 6.84-6.75 (m, 1H), 6.54 (d, J=8.3 Hz, 3H), 6.43-6.37 (m, 1H), 4.18-4.13 (m, 1H), 4.07-4.03 (m, 1H), 3.7$ (s, 3H), 3.71-3.59 (m, 3H), 2.68-2.61 (m, 2H), 1.89-1.77 (m, 1H), 1.70-1.57 (m, 1H), 1.43 (s, 9H), 1.31-1.26 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.94 (t, J=7.6 Hz, 3H). MS(M+1): 539.

Compound 13-14: (S)-3-(4-((1-((2′-fluoro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.60 (d, J=8.8 Hz, 2H), 7.45-7.38 (m, 2H), 7.34 (d, J=9.8 Hz, 1H), 7.13 (d, J=8.3 Hz, 1H), 6.72-6.64 (m, 1H), 6.59 (d, J=8.3 Hz, 2H), 6.54-6.49 (m, 2H), 4.02 (t, J=4.9 Hz, 2H), 3.85-3.76 (m 1H), 3.75 (s, 3H), 3.71-3.64 (m, 2H), 2.67 (t, J=5.9 Hz, 2H), 1.88-1.79 (m, 1H), 1.70-1.58 (m, 1H), 1.48-1.33 (m, 4H), 0.90 (t, J=7.1 Hz, 3H). MS(M+1): 577.

Example 14: Synthesis of Compounds 14-1 to 14-2

Compound 14-1: (S)-3-(6-((1-(4-(benzofuran-2-yl)-3-methoxyphenoxy)-3-methylbutan-2-yl)amino)nicotinamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.19 (d, J=8.8 Hz, 1H), 8.11-8.06 (m, 1H), 7.90 (d, J=8.3 Hz, 1H), 7.77-7.70 (m, 1H), 7.51 (d, J=7.3 Hz, 1H), 7.43 (d, J=7.8 Hz, 1H), 7.22-7.10 (m, 3H), 6.74 (d, J=9.3 Hz, 1H), 6.53 (dd, J=2.0, 8.8 Hz, 1H), 6.45 (d, J=2.0 Hz, 1H), 4.23-4.04 (m, 2H), 3.89 (s, 3H), 3.77-3.62 (m, 3H), 2.55 (d, J=4.4 Hz, 2H), 2.22-2.08 (m, 1H), 1.11-1.02 (m, 6H). S(M+1): 518. HPLC 99%.

Compound 14-2: (S)-3-(6-((1-((2′-fluoro-2-methoxy-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)oxy)hexan-2-yl)amino)nicotinamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.26-8.15 (m, 2H), 7.82-7.75 (m, 1H), 7.43-7.36 (m, 2H), 7.32 (d, J=9.8 Hz, 1H), 7.11 (d, J=7.8 Hz, 1H), 6.78 (d, J=9.3 Hz, 1H), 6.52-6.47 (m, 2H), 4.06 (dd, J=2.4, 4.9 Hz, 2H), 3.95 (d, J=3.4 Hz, 1H), 3.73 (s, 3H), 3.68 (d, J=3.9 Hz, 2H), 2.59-2.49 (m, 2H), 1.86-1.78 (m, 1H), 1.76-1.66 (m, 1H), 1.51-1.35 (m, 4H), 0.90 (t, J=6.8 Hz, 3H). MS(M+1): 578. HPLC 98%.

Reaction Scheme III illustrates the general procedures that can be used to synthesize the following compounds of the formula (I) of the present disclosure.

Step I

To a suspension of sodium hydride (2.08 g, 52 mmol) in dry THF (20 mL) was added (S)-tert-butyl 1-hydroxy-3-methylbutan-2-ylcarbamate (9.75 g, 48 mmol) in dry THF (60 mL) at 0° C. The reaction mixture was stirred for 20 mins and then 5-bromo-2-fluoropyridine (7.04 g, 20 mmol) in dry THF (50 mL) was added. After stirring at RT overnight, ice-water (100 mL) was poured into the mixture, then the mixture was extracted with EA. The organic solvent was removed by rotary evaporation. The crude reaction product was purified by column to give(S)-tert-butyl 1-(5-bromopyridin-2-yloxy)-3-methylbutan-2-ylcarbamate as a white solid (7.4 g, 58%).

Step II: Suzuki Coupling

A solution of(S)-tert-butyl 1-(5-bromopyridin-2-yloxy)-3-methylbutan-2-ylcarbamate (3.7 g, 10.3 mmol), (4-(trifluoromethyl)phenyl)boronic acid(2.34 g, 12.36 mmol), Na₂CO₃ (2M, 12 mL) in EtOH/PhMe (12 mL/40 mL) were purged with nitrogen for 30 min. Pd(PPh₃)₄ (0.57 g, 0.5 mmol) was added and heated at 110° C. for 12 h. The reaction mixture was cooled and extracted with EtOAc. The organic layer was dried over MgSO₄ and concentrated in vacuo. The residue was purified by silica gel chromatography to afford (S)-tert-butyl 3-methyl-1-(5-(4-(trifluoromethyl) phenyl)pyridin-2-yloxy)butan-2-ylcarbamate(3.8 g, 87%).

Step II: Deprotection

The compound (S)-tert-butyl 3-methyl-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yloxy)butan-2-ylcarbamate (3.8 g, 8.95 mmol) was suspended in trifluoroacetic acid (10 mL, 134 mmol) in anhydrous dichloromethane (90 mL) at room temperature for 12 h. After reaction, excess trifluoroacetic acid was neutralized by dropwised addition of Na₂CO_3(aq) until pH=10. Then it was extracted with CH₂Cl₂. The combined organic layer was dried with anhydrous MgSO₄ and concentrated in vacuo to give crude product, Compound III-d.

Step IV: Pd-Coupling

Pd(OAc)₂ (0.18 g, 0.8 mmol), BINAP (1 g, 1.6 mmol), cesium carbonate (1.95 g, 6 mmol), (S)-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yloxy)butan-2-amine (1.3 g, 4 mmol), and ethyl 4-(trifluoromethylsulfonyloxy)benzoate (1.43 g, 4.8 mmol) in 40 mL PhMe were purged with nitrogen for 30 min. The mixture was stirred in an oil bath at 100° C. for 18 h. Cool the mixture to ambient temperature, dilute with EtOAc, filter through Celite washing with EtOAc. The mixture was washed with water and brine, dried the organic layer over Na₂SO₄, and concentrate to obtain the crude mixture. The residue was purified by silica gel chromatography to afford (S)-ethyl 4-(3-methyl-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yloxy)butan-2-ylamino)benzoate (1.8 g, 95%).

Step V: Hydrolysis

(S)-ethyl 4-(3-methyl-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yloxy)butan-2-ylamino)benzoate (1.8 g, 4 mmol) was dissolved in 1,4-dioxane (40 mL) followed by addition of LiOH (20 mL). The reaction mixture was stirred in an oil bath at 100° C. for overnight. The reaction was monitored by TLC. With completion of the reaction, the solvent was removed by rotary evaporation and HCl (1.0 M, 15 mL) was added to the mixture. The white solid was collected by suction filtration and afford(S)-4-(3-methyl-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yloxy)butan-2-ylamino)benzoic acid (1.7 g, 100%).

Step VI: Amidation

The compound (S)-4-(3-methyl-1-(5-(4-(trifluoromethyl)phenyl)pyridin-2-yloxy)butan-2-ylamino)benzoic acid (0.66 g, 1.5 mmol), (EtCO₂CH₂CH₂)NH₂HCl, EDCI (0.58 g), and HOBt (0.3 g) were dissolved in DMF (9 mL) followed by addition of TEA (0.4 mL). The mixture was stirred overnight at room temperature. Monitored by TLC, the mixture was added water, aqueous NaHCO₃ and extracted with EA. The organic layer was dried with MgSO₄, and then the solvent was removed by rotary evaporation. The residue was purified by silica gel chromatography to afford Compound III-h (0.8 g, 100%).

Step VII: Hydrolysis (Optional)

Compound III-h (0.8 g, 1.47 mmol) was dissolved in THF/MeOH (7.5/7.5 mL) followed by addition of LiOH (7.5 mL). The reaction mixture was stirred at RT for overnight. The reaction was monitored by TLC. With completion of the reaction, the solvent was removed by rotary evaporation and HCl (1.0 M, 5 mL) was added to the mixture. The white solid was collected by suction filtration and afforded Compound III-i (0.4 g, 53%).

Example 15: Synthesis of Compounds 15-1 to 15-37

Compound 15-1: (S)—N-((2H-tetrazol-5-yl)methyl)-4-((2-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)-1-phenylethyl)amino)benzamide

¹H NMR (400 MHz, DMSO-d₆): δ 8.69-8.76 (m, 2H), 8.22 (dd, J=8.8, 2.4 Hz, 1H), 7.58-7.67 (m, 4H), 7.50 (d, J=7.3 Hz, 2H), 7.24-7.42 (m, 6H), 7.06 (d, J=7.8 Hz, 1H), 6.98 (d, J=8.8 Hz, 1H), 6.62 (d, J=8.3 Hz, 2H), 4.96-5.03 (m, 1H), 4.67 (d, J=5.4 Hz, 2H), 4.50-4.62 (m, 2H). MS(M+1): 532.

Compound 15-2: (S)—N-((1H-tetrazol-5-yl)methyl)-4-((3-methyl-1-((5-(4-(trifluoromethyl) phenyl)pyridin-2-yl)oxy)butan-2-yl)amino)benzamide

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.69 (t, J=5.5 Hz, 1H), 8.56 (d, J=2.5 Hz, 1H), 8.08 (dd, J=8.8, 2.5 Hz, 1H), 7.90 (d, J=8.8 Hz, 2H), 7.81 (d, J=8.8 Hz, 2H), 7.64 (d, J=8.8 Hz, 2H), 6.90 (d, J=8.8 Hz, 1H), 6.70 (d, J=8.8 Hz, 2H), 6.18 (d, J=8.8 Hz, 1H), 4.67 (d, J=6 Hz, 2H), 4.42-4.33 (m, 2H), 3.76-3.70 (m, 1H), 2.05-1.91 (m, 1H), 1.02-0.97 (m, 6H). MS(M+1): 526.

Compound 15-3: (S)-3-(4-((1-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.72 (d, J=2.4 Hz, 1H), 8.17 (dd, J=8.6, 2.7 Hz, 1H), 8.06 (t, J=5.4 Hz, 1H), 7.54-7.70 (m, 4H), 7.20-7.35 (m, 2H), 6.90 (d, J=8.8 Hz, 1H), 6.68 (d, J=8.3 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.30-4.46 (m, 2H), 3.64-3.76 (m, 1H), 3.42 (q, J=6.8 Hz, 2H), 2.48 (t, J=6.8 Hz, 2H), 2.06-1.96 (m, 1H), 0.92-1.07 (m, 6H). MS(M+1): 488.

Compound 15-4: (S)-3-(4-((2-((5-(4-(tert-butyl))pyridin-2-yl)oxy)-phenyl)pyridin-2-yl)oxy)-1-phenyethyl)amino) benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.36 (d, J=2.4 Hz, 1H), 7.78 (dd, J=8.6, 2.7 Hz, 1H), 7.40-7.49 (m, 8H), 7.22-7.36 (m, 3H), 6.80 (d, J=9.3 Hz, 2H), 6.46 (d, J=8.8 Hz, 2H), 4.73-4.86 (m, 1H), 4.51-4.63 (m, 2H), 3.61 (s, 1H), 3.60 (s, 1H), 2.59 (t, J=5.9 Hz, 2H), 1.34 (s, 9H). MS(M+1): 538.

Compound 15-5: (S)-3-(4-((2-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)-1-phenylethyl)amino) benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 12.14 (br. s., 1H), 8.74 (d, J=2.4 Hz, 1H), 8.20 (ddt, J=8.6, 4.4, 2.3 Hz, 1H), 8.03 (dd, J=7.1, 4.6 Hz, 1H), 7.48-7.66 (m, 6H), 7.23-7.40 (m, 6H), 6.93-7.05 (m, 2H), 6.57-6.64 (m, 2H), 4.93-5.01 (m, 1H), 4.49-4.61 (m, 2H), 4.00-4.05 (m, 1H), 3.25-3.49 (m, 4H), 2.42-2.53 (m, 3H), 1.98 (s, 1H), 1.1-1.32 (m, 1H). MS(M+1): 522.

Compound 15-6: (R)-3-(4-(((S)-2-((5-(4-(tert-butyl)phenyl)pyridin-2-yl)oxy)-1-phenylethyl) amino)benzamido)-2-hydroxypropanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.37 (br. s., 1H), 7.79 (d, J=7.3 Hz, 1H), 7.39-7.57 (m, 8H), 7.13-7.39 (m, 4H), 6.62-6.88 (m, 2H), 6.46 (d, J=7.8 Hz, 2H), 4.83 (br. s., 1H), 4.48-4.70 (m, 2H), 4.30 (br. s., 1H), 3.85 (d, J=13.7 Hz, 1H), 3.73 (d, J=13.7 Hz, 1H), 1.34 (s, 9H). MS(M+1): 554.

Compound 15-7: (S)-3-(4-((3-methyl-1-((5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)butan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.56 (d, J=3 Hz, 1H), 8.07-8.04 (m, 2H), 7.88 (d, J=8.8 Hz, 2H), 7.79 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 2H), 6.89 (d, J=8.8 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.40-4.32 (m, 2H), 3.86-3.67 (m, 11H), 3.41 (quartet, J=8 Hz, 2H), 2.45 (t, J=8 Hz, 2H), 2.06-1.98 (m, 1H), 1.01-0.96 (m, 6H). MS(M+1): 516.

Compound 15-8: (R)-2-hydroxy-3-(4-(((S)-3-methyl-1-((5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)butan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.54 (d, J=2.5 Hz, 1H), 8.15 (brs, 1H), 8.07-8.04 (m, 1H), 7.88 (d, J=8.8 Hz, 2H), 7.78 (d, J=8.8 Hz, 2H), 7.67 (d, J=8.8 Hz, 2H), 6.88 (d, J=8.8 Hz, 1H), 6.68 (d, J=8.8 Hz, 2H), 6.17 (d, J=8.8 Hz, 1H), 4.40-4.32 (m, 2H), 4.04 (pseudo-brs, 1H), 3.72-3.66 (m, 2H), 3.42-3.37 (m, 1H), 2.03-1.97 (m, 1H), 1.00-0.95 (m, 6H). MS(M+1): 532.

Compound 15-9: (S)-3-(4-((1-((5-(2-chloro-4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.27 (d, J=2 Hz, 1H), 8.10 (brs, 1H), 7.99 (d, J=0.9 Hz, 1H), 7.90-7.78 (m, 3H), 7.68 (d, J=8.3 Hz, 1H), 7.58 (d, J=8.8 Hz, 2H), 6.69 (d, J=8.8 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.40-4.33 (m, 2H), 3.75-3.68 (m, 1H), 3.40-3.35 (m, 2H), 3.38 (t, J=6.8 Hz, 2H), 2.05-1.95 (m, 1H), 1.01-0.96 (m, 6H). MS(M+1): 551.

Compound 15-10: (S)-3-(4-((1-((5-(2-chloro-4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.26 (d, J=2.4 Hz, 1H), 8.03-7.98 (m, 3H), 7.85 (dd, J=8.8, 2.4 Hz, 1H), 7.80 (d, J=8 Hz, 1H), 7.68 (d, J=8 Hz, 1H), 7.59 (d, J=8.8 Hz, 1H), 6.90 (d, J=8.8 Hz, 2H), 6.66 (d, J=8.8 Hz, 2H), 6.06 (d, J=8.8 Hz, 1H), 4.36-4.32 (m, 1H), 4.24-4.20 (m, 1H), 3.91-3.88 (m, 1H), 3.40-3.35 (m, 2H), 2.46 (t, J=7 Hz, 2H), 1.79-1.74 (m, 1H), 1.54-1.50 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.85 (d, J=6.8 Hz, 3H). MS(M+1): 564.

Compound 15-11: (S)-3-(4-((4-methyl-1-((5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.56 (d, J=2.5 Hz, 1H), 8.09 (dd, J=8.4, 2.5 Hz, 1H), 8.02 (t, J=5.4 Hz, 1H), 7.90 (d, J=8.4 Hz, 2H), 7.80 (d, J=8.4 Hz, 2H), 7.60 (d, J=8.8 Hz, 2H), 6.91 (d, J=8.4 Hz, 1H), 6.68 (d, J=8.8 Hz, 2H), 6.06 (d, J=8.4 Hz, 1H), 438-4.34 (m, 1H), 4.24-4.20 (m, 1H), 3.92-3.86 (m, 1H), 3.43-3.38 (m, 2H), 2.46 (t, J=7 Hz, 2H), 1.81-1.74 (m, 1H), 1.54-1.50 (m, 2H), 0.94 (d, J=6.3 Hz, 3H), 0.84 (d, J=6.3 Hz, 3H). MS(M+1): 530.

Compound 15-12: 3-(4-(((2S,3S)-3-methyl-1-((5-(4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.57 (d, J=2.5 Hz, 1H), 8.09 (dd, J=8.4, 2.5 Hz, 1H), 8.10-8.07 (m, 2H), 7.90 (d, J=7.8 Hz, 2H), 7.80 (d, J=7.8 Hz, 2H), 7.58 (d, J=8.8 Hz, 2H), 6.91 (d, J=8.8 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.05 (d, J=8.4 Hz, 1H), 4.38-4.34 (m, 1H), 4.23-4.19 (m, 1H), 3.91-3.88 (m, 1H), 3.39-3.35 (m, 2H), 2.38-2.33 (m, 2H), 1.80-1.75 (m, 1H), 1.54-1.50 (m, 1H), 0.94 (d, J=6.4 Hz, 3H), 0.84 (d, J=6.4 Hz, 3H). MS(M+1): 530.

Compound 15-13: 3-(4-(((2S,3S)-1-((5-(2-chloro-4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.26 (d, J=2.5 Hz, 1H), 8.00-7.95 (m, 2H), 7.85 (dd, J=8.4, 2.5 Hz, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.68 (d, J=8.3 Hz, 1H), 7.60 (d, J=8.3 Hz, 2H), 6.90 (d, J=8.3 Hz, 1H), 6.66 (d, J=8.3 Hz, 2H), 6.05 (d, J=8.3 Hz, 1H), 4.36-4.32 (m, 1H), 4.24-4.20 (m, 1H), 3.91-3.88 (m, 1H), 3.42-3.40 (m, 2H), 2.37 (brs, 2H), 1.80-1.74 (m, 1H), 1.54-1.50 (m, 1H), 0.94 (d, J=6.4 Hz, 3H), 0.84 (d, J=6.4 Hz, 3H). MS(M+1): 564.

Compound 15-14: 3-(4-(((2S,3S)-1-((5-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.41 (brs, 1H), 8.15-8.07 (m, 1H), 7.97-7.94 (m, 1H), 7.83-7.79 (m, 2H), 7.68-7.66 (m, 1H), 7.59-7.57 (m, 2H), 6.93 (d, J=8.3 Hz, 1H), 6.67 (d, J=8.3 Hz, 2H), 6.05 (d, J=8.3 Hz, 1H), 4.38-4.34 (m, 1H), 4.24-4.20 (m, 1H), 3.91-3.86 (m, 1H), 3.43-3.34 (m, 2H), 2.39-2.33 (m, 2H), 1.79-1.74 (m, 1H), 1.54-1.50 (m, 1H), 0.94 (d, J=6.4 Hz, 3H), 0.83 (d, J=6.4 Hz, 3H). MS(M+1): 548.

Compound 15-15: 3-(4-(((2S,3S)-1-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.72 (d, J=2.4 Hz, 1H), 8.18 (dd, J=8.8, 2.4 Hz, 1H), 8.03 (t, J=5.6 Hz, 1H), 7.50-7.71 (m, 4H), 7.19-7.35 (m, 2H), 6.90 (d, J=8.8 Hz, 1H), 6.64 (d, J=8.8 Hz, 2H), 6.15 (d, J=8.8 Hz, 1H), 4.27-4.52 (m, 2H), 3.75 (dt, J=13.0, 6.2 Hz, 1H), 3.38-3.45 (m, 2H), 2.45-2.50 (m, 2H), 1.69-1.84 (m, 1H), 1.51-1.68 (m, 1H), 1.18-1.37 (m, 1H), 0.95 (d, J=6.8 Hz, 3H), 0.90 (t, J=7.3 Hz, 2H). MS(M+1): 502.

Compound 15-16: (S)-3-(4-((1-((5-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. 1HNMR (400 MHz, DMSO-d₆): δ 8.41 (s, 1H), 8.03 (t, J=5.4 Hz, 1H), 7.85 (dt, J=8.4, 1.9 Hz, 1H), 7.94-7.79 (m, 2H), 7.68 (d, J=8.4 Hz, 1H), 7.60 (d, J=8.8 Hz, 2H), 6.93 (d, J=8.8 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.08 (d, J=8.8 Hz, 1H), 4.38-4.34 (m, 1H), 4.24-4.20 (m, 1H), 3.92-3.86 (m, 1H), 3.34-3.38 (m, 2H), 2.46 (t, J=7 Hz, 2H), 1.81-1.74 (m, 1H), 1.54-1.50 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.84 (d, J=6.8 Hz, 3H). MS(M+1): 548.

Compound 15-17: (S)-3-(4-((1-((5-(2,4-dichlorophenyl)pyridin-2-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.13 (d, J=2.0 Hz, 2H), 7.61 (dd, J=8.3, 2.4 Hz, 1H), 7.55 (d, J=8.3 Hz, 2H), 7.46 (d, J=2.0 Hz, 1H), 7.23-7.29 (m, 1H), 7.18-7.22 (m, 1H), 6.80 (t, J=5.6 Hz, 1H), 6.72 (d, J=8.8 Hz, 1H), 6.57 (d, J=8.8 Hz, 2H), 4.43-4.49 (m, 1H), 4.32-4.38 (m, 1H), 3.59-3.70 (m, 3H), 2.62 (t, J=5.6 Hz, 2H), 1.98-2.13 (m, 1H), 1.01 (t, J=6.4 Hz, 6H). MS(M+1): 516.

Compound 15-18: (S)-2-(4-((1-((5-(2-chloro-4-(fluoromethyl)phenyl)pyridin-2-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)ethane-1-sulfonic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.27 (d, J=2.5 Hz, 1H), 8.08 (t, J=4.9 Hz, 1H), 7.99 (s, 1H), 7.85 (dd, J=8.8, 2.4 Hz, 2H), 7.69 (d, J=8 Hz, 1H), 7.53 (d, J=8 Hz, 2H), 6.91 (d, J=8.8 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.36-4.33 (m, 1H), 4.25-4.21 (m, 1H), 3.92-3.85 (m, 1H), 3.50-3.45 (m, 2H), 2.64 (t, J=7 Hz, 2H), 1.81-1.74 (m, 1H), 1.55-1.50 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.85 (d, J=6.8 Hz, 3H). MS(M+1): 600.

Compound 15-19: (S)-3-(4-((4-methyl-1-((5-(6-(trifluoromethyl)pyridazin-3-yl)pyridin-2-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

White solid. H-NMR (400 MHz, DMSO-d₆): δ 9.05 (d, J=2.4 Hz, 1H), 8.58-8.54 (m, 2H), 8.34 (d, J=8.8 Hz, 1H), 8.04 (t, J=5.6 Hz, 1H), 7.60 (d, J=8.8 Hz, 2H), 7.01 (d, J=8.8, 3 Hz, 1H), 6.68 (d, J=8.8 Hz, 2H), 6.10 (d, J=8.8 Hz, 1H), 4.43-4.26 (m, 2H), 3.96-3.89 (m, 1H), 3.42-3.37 (m, 2H), 2.46 (t, J=6.8 Hz, 2H), 1.82-1.75 (m, 1H), 1.59-1.48 (m, 2H), 0.95 (d, J=6.4 Hz, 3H), 0.85 (d, J=6.4 Hz, 3H). MS(M+1): 532.

Compound 15-20: 3-(4-(((2S,3S)-1-((5-(2,4-difluorophenyl)pyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.23 (s, 1H), 7.67 (dt, J=8.8, 2.0 Hz, 1H), 7.55 (d, J=8.3 Hz, 2H), 7.31 (td, J=8.6, 6.4 Hz, 1H), 6.82-6.97 (m, 2H), 6.67-6.80 (m, 2H), 6.56 (d, J=8.8 Hz, 2H), 4.33-4.51 (m, 3H), 3.61-3.74 (m, 3H), 2.64 (t, J=5.9 Hz, 2H), 1.74-1.86 (m, 1H), 1.59-1.70 (m, 1H), 1.17-1.30 (m, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 498.

Compound 15-21: 2-(4-(((2S,3S)-1-((5-(2,4-difluorophenyl)pyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)ethane-1-sulfonic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.31 (s, 1H), 8.08 (t, J=5.1 Hz, 1H), 7.81-7.87 (m, 1H), 7.49-7.64 (m, 3H), 7.29-7.43 (m, 1H), 7.12-7.27 (m, 1H), 6.87 (d, J=9.3 Hz, 1H), 6.64 (d, J=8.8 Hz, 2H), 6.16 (d, J=8.8 Hz, 1H), 4.26-4.47 (m, 2H), 3.73 (dd, J=7.8, 5.4 Hz, 1H), 3.43-3.54 (m, 2H), 2.66 (t, J=6.8 Hz, 2H), 1.71-1.80 (m, 1H), 1.60 (ddd, J=13.3, 7.5, 4.2 Hz, 1H), 1.17-1.31 (m, 1H), 0.94 (d, J=6.8 Hz, 3H), 0.90 (t, J=7.3 Hz, 3H). MS(M+1): 534.

Compound 15-22: (S)-3-(4-((1-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.61 (d, J=2.4 Hz, 1H), 7.95 (dt, J=8.7, 2.0 Hz, 1H), 7.43-7.62 (m, 4H), 7.14-7.31 (m, 2H), 6.80-6.98 (m, 2H), 6.75 (d, J=8.8 Hz, 1H), 6.57 (d, J=8.3 Hz, 2H), 4.36-4.47 (m, 1H), 4.27 (dd, J=10.5, 4.6 Hz, 1H), 3.76 (d, J=4.9 Hz, 1H), 3.64 (d, J=5.9 Hz, 2H), 2.62 (t, J=5.1 Hz, 2H), 1.67-1.78 (m, 1H), 1.48-1.63 (m, 1H), 1.25-1.45 (m, 4H), 0.86 (t, J=6.8 Hz, 3H). MS(M+1): 502.

Compound 15-23: (S)-2-(4-((1-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)hexan-2-yl)amino)benzamido) ethane-1-sulfonic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.72 (d, J=2.4 Hz, 1H), 8.20 (dd, J=8.3, 2.4 Hz, 1H), 7.54-7.67 (m, 4H), 7.39 (s, 1H), 7.19-7.35 (m, 2H), 6.93 (d, J=8.8 Hz, 1H), 6.86 (br. s., 2H), 6.76 (d, J=6.8 Hz, 2H), 4.39 (dd, J=10.8, 5.4 Hz, 1H), 4.24 (dd, J=10.8, 5.9 Hz, 1H), 3.77-3.86 (m, 1H), 3.51 (t, J=7.1 Hz, 2H), 2.66-2.75 (m, 2H), 1.65-1.78 (m, 1H), 1.58 (td, J=8.7, 4.2 Hz, 1H), 1.19-1.45 (m, 4H), 0.84 (t, J=7.1 Hz, 3H). MS(M+1): 538.

Compound 15-24: (S)-3-(4-((1-((5-(2,4-dichlorophenyl)pyridin-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.13 (d, J=2.0 Hz, 1H), 7.62 (dd, J=8.8, 2.4 Hz, 1H), 7.56 (d, J=8.3 Hz, 2H), 7.45 (d, J=2.0 Hz, 1H), 7.23-7.29 (m, 1H), 7.18-7.22 (m, 1H), 6.90 (t, J=5.9 Hz, 1H), 6.75 (d, J=8.8 Hz, 1H), 6.57 (d, J=8.8 Hz, 2H), 4.42 (dd, J=10.8, 4.9 Hz, 1H), 4.28 (dd, J=10.3, 4.9 Hz, 1H), 3.78 (m, J=6.1 Hz, 1H), 3.63 (q, J=5.9 Hz, 2H), 2.61 (t, J=5.9 Hz, 2H), 1.69-1.80 (m, 1H), 1.52-1.62 (m, 1H), 1.28-1.44 (m, 4H), 0.86 (t, J=7.1 Hz, 3H). MS(M+1): 530.

Compound 15-25: (S)-3-(4-((1-((5-(2-chlor-4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.18 (d, J=2.0 Hz, 1H), 7.71 (d, J=1.0 Hz, 1H), 7.67 (dd, J=8.3, 2.4 Hz, 1H), 7.52-7.60 (m, 3H), 7.40 (d, J=7.8 Hz, 1H), 6.88 (t, J=5.9 Hz, 1H), 6.78 (d, J=8.3 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 4.44 (dd, J=10.8, 4.9 Hz, 1H), 4.30 (dd, J=10.8, 4.9 Hz, 1H), 3.76-3.83 (m, 1H), 3.64 (q, J=5.9 Hz, 2H), 2.62 (t, J=5.9 Hz, 2H), 1.69-1.81 (m, 1H), 1.53-1.65 (m, 1H), 1.30-1.48 (m, 4H), 0.87 (t, J=7.1 Hz, 3H). MS(M+1): 564.

Compound 15-26: (S)-3-(4-((1-((5-(2-fluoro-4-(trifluoromethyl)phenyl)pyridin-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.30 (d, J=1.5 Hz, 1H), 7.74 (dt, J=8.7, 2.0 Hz, 1H), 7.57 (d, J=8.3 Hz, 2H), 7.43-7.51 (m, 2H), 7.39 (d, J=10.3 Hz, 1H), 6.90 (t, J=5.9 Hz, 1H), 6.79 (d, J=8.3 Hz, 1H), 6.58 (d, J=8.8 Hz, 2H), 4.44 (dd, J=10.8, 4.9 Hz, 1H), 4.29 (dd, J=10.8, 5.4 Hz, 1H), 3.79 (t, J=6.4 Hz, 1H), 3.64 (q, J=5.5 Hz, 2H), 2.61 (t, J=5.6 Hz, 2H), 1.71-1.81 (m, 1H), 1.52-1.63 (m, 1H), 1.24-1.48 (m, 4H), 0.86 (t, J=7.3 Hz, 3H). MS(M+1): 548. HPLC: 97%.

Compound 15-27: (S)-3-(4-((1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)ethyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 12.13 (br. s., 1H), 8.57-8.63 (m, 1H), 8.07 (dd, J=8.8, 2.4 Hz, 1H), 8.01 (t, J=5.6 Hz, 1H), 7.84-7.93 (m, J=7.8 Hz, 2H), 7.75-7.83 (m, J=8.3 Hz, 2H), 7.68-7.75 (m, J=8.3 Hz, 2H), 7.59-7.67 (m, J=8.8 Hz, 2H), 7.48-7.58 (m, J=8.8 Hz, 2H), 6.97-7.08 (m, 2H), 6.56-6.65 (m, J=8.8 Hz, 2H), 4.99-5.11 (m, 1H), 4.53-4.66 (m, 2H), 3.35-3.43 (m, 2H), 2.44 (t, J=7.1 Hz, 2H). MS(M+1): 618.

Compound 15-28: (S)-2-(4-((2-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)ethane-1-sulfonic acid

¹H NMR ((400 MHz, DMSO-d₆): δ 8.75 (d, J=2.4 Hz, 1H), 8.22 (dd, J=8.8, 2.4 Hz, 1H), 8.08 (t, J=5.1 Hz, 1H), 7.84-7.92 (m, J=8.3 Hz, 2H), 7.76-7.83 (m, J=8.8 Hz, 2H), 7.70-7.76 (m, 2H), 7.60-7.67 (m, 4H), 7.44-7.53 (m, J=8.8 Hz, 2H), 7.41 (s, 1H), 7.21-7.36 (m, 2H), 7.05 (d, J=7.3 Hz, 1H), 7.01 (d, J=8.8 Hz, 1H), 6.58-6.68 (m, J=8.8 Hz, 2H), 5.00-5.11 (m, 1H), 4.52-4.67 (m, 2H), 3.44 (q, J=6.4 Hz, 2H), 2.60 (t, J=7.1 Hz, 2H). MS (M+1): 702. HPLC purity: 98%.

Compound 15-29: (S)-3-(4-((2-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)propanoic acid

¹H NMR ((400 MHz, DMSO-d₆): δ 12.13 (br. s., 1H), 8.75 (d, J=2.4 Hz, 1H), 8.23 (dd, J=8.8, 2.4 Hz, 1H), 8.02 (t, J=5.4 Hz, 1H), 7.84-7.92 (m, J=7.8 Hz, 2H), 7.76-7.82 (m, J=8.3 Hz, 2H), 7.69-7.76 (m, 2H), 7.59-7.67 (m, 4H), 7.51-7.58 (m, J=8.8 Hz, 2H), 7.41 (s, 1H), 7.22-7.36 (m, 2H), 6.96-7.08 (m, 2H), 6.56-6.67 (m, J=8.8 Hz, 2H), 5.06 (q, J=6.8 Hz, 1H), 4.52-4.64 (m, 2H), 3.35-3.41 (m, 2H), 2.44 (t, J=7.3 Hz, 2H). MS (M+1): 666. HPLC purity: 99%.

Compound 15-30: (S)-3-(4-((2-((5-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)oxy)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.80 (d, J=2.4 Hz, 1H), 8.23-8.14 (m, 1H), 7.63 (s, 4H), 7.57-7.48 (m, 6H), 6.85 (d, J=8.8 Hz, 1H), 6.79-6.69 (m, 1H), 6.50 (d, J=8.3 Hz, 2H), 4.94-4.84 (m, 1H), 4.73-4.58 (m, 2H), 3.65-3.54 (m, 2H), 2.63-2.53 (m, 2H), 1.46 (s, 9H). MS(M+1): 674.

Compound 15-31: Ethyl (S)-3-(4-((2-((5-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)oxy)-1-(2′-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)propanoate

¹H NMR (400 MHz, CDCl₃): δ 8.81 (d, J=2.4 Hz, 1H), 8.24-8.18 (m, 1H), 7.59-7.48 (m, 7H), 7.48-7.36 (m, 2H), 6.88 (d, J=8.8 Hz, 1H), 6.66-6.56 (m, 1H), 6.53 (d, J=8.8 Hz, 2H), 5.33-5.25 (m, 1H), 4.95-4.87 (m, 1H), 4.75-4.59 (m, 2H), 4.11 (q, J=7.1 Hz, 2H), 3.63 (q, J=5.9 Hz, 2H), 2.56 (t, J=5.9 Hz, 2H), 1.47 (s, 9H), 1.22 (t, J=7.3 Hz, 3H). MS(M+1): 720. HPLC 97.8%.

Compound 15-32: (S)-3-(4-((2-((5-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)oxy)-1-(2′-fluoro-4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.79 (d, J=2.4 Hz, 1H), 8.22-8.14 (m, 1H), 7.55-7.46 (m, 7H), 7.46-7.41 (m, 1H), 7.40-7.34 (m, 1H), 6.85 (d, J=8.8 Hz, 1H), 6.81-6.71 (m, 1H), 6.50 (d, J=8.8 Hz, 2H), 4.94-4.82 (m, 1H), 4.75-4.57 (m, 2H), 3.65-3.52 (m, 2H), 2.64-2.51 (m, 2H), 1.45 (s, 9H). MS(M+1): 692. HPLC 96.4%.

Compound 15-33: Ethyl (S)-3-(4-((2-((5-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)oxy)-1-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)propanoate

¹H NMR (400 MHz, CDCl₃): δ 8.81 (s, 1H), 8.26-8.16 (m, 1H), 7.57-7.43 (m, 5H), 7.39 (d, J=8.3 Hz, 2H), 7.32-7.20 (m, 2H), 6.88 (d, J=9.3 Hz, 1H), 6.64-6.57 (m, 1H), 6.54 (d, J=8.8 Hz, 2H), 5.26-5.19 (m, 1H), 4.96-4.86 (m, 1H), 4.78-4.61 (m, 2H), 4.12 (d, J=6.8 Hz, 2H), 3.67-3.59 (m, 2H), 2.56 (s, 2H), 1.47 (s, 9H), 1.23 (t, J=7.1 Hz, 3H). MS(M+1): 702.

Compound 15-34: (S)-3-(4-((2-((5-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)oxy)-1-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.80 (d, J=2.0 Hz, 1H), 8.26-8.12 (m, 1H), 7.54-7.45 (m, 5H), 7.38 (d, J=8.3 Hz, 2H), 7.25-7.23 (m, 2H), 6.86 (d, J=8.8 Hz, 1H), 6.64-6.59 (m, 1H), 6.52 (d, J=8.3 Hz, 2H), 4.92-4.88 (m, 1H), 4.74-4.62 (m, 2H), 3.67-3.61 (m, 2H), 2.63 (s, 2H), 1.47 (s, 9H). MS(M+1): 674.

Compound 15-35: (S)-2-(4-((2-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)-1-(4-(5-methoxypyrimidin-2-yl)phenyl)ethyl)amino)benzamido)ethane-1-sulfonic acid

¹H NMR (400 MHz, DMSO-d₆): δ 12.29 (br. s., 1H), 8.74 (d, J=2.4 Hz, 1H), 8.63 (s, 2H), 8.27 (d, J=8.3 Hz, 2H), 8.22 (dd, J=8.3, 2.4 Hz, 1H), 8.08 (t, J=5.4 Hz, 1H), 7.57-7.67 (m, 4H), 7.44-7.53 (m, J=8.8 Hz, 2H), 7.39-7.43 (m, 1H), 7.21-7.34 (m, 2H), 7.10 (d, J=7.3 Hz, 1H), 6.99 (d, J=9.3 Hz, 1H), 6.58-6.66 (m, J=8.8 Hz, 2H), 4.99-5.08 (m, 1H), 4.52-4.67 (m, 2H), 3.94 (s, 3H), 3.40-3.49 (m, 2H), 2.61-2.79 (m, 2H), MS(M+1): 666.

Compound 15-36: Ethyl (S)-3-(4-((1-((5-(benzo[d]thiazol-2-yl)pyridin-2-yl)oxy)-3-methylbutan-2-yl) amino)benzamido)propanoate

White solid. ¹H-NMR (DMSO-d₆, 400 MHz): δ 8.81 (d, J=1.6 Hz, 1H), 8.27 (dd, J=8.8, 2.9 Hz, 1H), 8.04 (d, J=8.3 Hz, 1H), 7.89 (d, J=8.3 Hz, 1H), 7.60 (d, J=8.8 Hz, 2H), 7.51-7.46 (m, 1H), 7.47-7.36 (m, 1H), 6.80 (d, J=8.8 Hz, 1H), 6.63 (d, J=8.8 Hz, 2H), 4.57 (dd, J=11.2, 5.8 Hz, 1H), 4.43 (dd, J=10.7, 5.4 Hz, 1H), 4.22 (d, J=8.8 Hz, 1H), 4.15 (q, J=8.8 Hz, 2H), 3.71-3.66 (m, 3H), 2.61 (t, J=6.8 Hz, 2H), 2.12-2.08 (m, 1H), 1.28 (t, J=6.8 Hz, 3H), 1.06 (t, J=6.8 Hz, 3H), 0.82 (t, J=6.8 Hz, 3H). MS(M+1): 533.

Compound 15-37: (S)-3-(4-((1-((5-(benzo[d]thiazol-2-yl)pyridin-2-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (DMSO-d₆, 400 MHz): δ 8.87 (d, J=1.9 Hz, 1H), 8.34 (dd, J=8.8, 5.4 Hz, 1H), 8.14 (d, J=8.8 Hz, 1H), 8.05-8.02 (m, 2H), 7.59-7.44 (m, 4H), 6.95 (d, J=8.8 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.09 (d, J=8.8 Hz, 1H), 4.46-4.37 (m, 3H), 3.75-3.69 (m, 2H), 2.46 (t, J=6.8 Hz, 2H), 2.05-2.00 (m, 1H), 1.01-0.97 (m, 6H). MS(M+1): 505.

Example 16: Synthesis of Compounds 16-1 to 16-2

Compound 16-1: (S)-3-(6-((1-((5-(2,4-dichlorophenyl)pyridin-2-yl)oxy)-3-methylbutan-2-yl)amino)nicotinamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 8.09-8.21 (m, 4H), 7.78 (t, J=4.9 Hz, 1H), 7.57-7.61 (m, 1H), 7.44 (d, J=2.0 Hz, 1H), 7.23-7.29 (m, 1H), 7.19 (d, J=8.3, 1H), 6.78 (d, J=9.3 Hz, 1H), 6.67 (d, J=8.8 Hz, 1H), 4.51-4.57 (m, 1H), 4.42 (dd, J=11.2, 7.3 Hz, 1H), 3.80 (br. s., 1H), 3.63-3.71 (m, 2H), 2.54 (dd, J=7.1, 4.2 Hz, 2H), 2.05-2.18 (m, 1H), 1.07 (t, J=6.4 Hz, 6H). MS(M+1): 517.

Compound 16-2: (S)-3-(6-((1-((5-(benzofuran-2-yl)pyridin-2-yl)oxy)-3-methylbutan-2-yl)amino)nicotinamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.71 (d, J=2.0 Hz, 1H), 8.44 (d, J=2.4 Hz, 1H), 8.18 (dd, J=8.8, 2.4 Hz, 2H), 7.72-7.80 (m, 1H), 7.59-7.67 (m, 2H), 7.38 (s, 1H), 7.23-7.34 (m, 2H), 7.04 (d, J=8.3 Hz, 1H), 6.91 (d, J=8.8 Hz, 1H), 6.55 (d, J=8.8 Hz, 1H), 4.40-4.51 (m, 1H), 4.25-4.40 (m, 2H), 3.37-3.43 (m, 2H), 2.45 (d, J=7.1 Hz, 2H), 1.99-2.07 (m, 1H), 0.97 (dd, J=6.8, 4.4 Hz, 6H). MS(M+1): 489.

Example 17: Synthesis of Compounds 17-1 to 17-12

Compound 17-1: (S)-3-(4-((1-((6-(2,4-difluorophenyl)pyridazin-3-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.06-7.89 (m, 3H), 7.62-7.58 (m, 2H), 7.43-7.38 (m, 1H), 7.28-7.23 (m, 2H), 6.68 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.54-4.40 (m, 2H), 4.03-3.96 (m, 1H), 3.42-3.39 (m, 2H), 2.48 (t, J=7 Hz, 2H), 1.82-1.75 (m, 1H), 1.59-1.53 (m, 2H), 0.94 (d, J=6.8 Hz, 3H), 0.85 (d, J=6.8 Hz, 3H). MS(M+1): 499.

Compound 17-2: (S)-3-(4-((1-((6-(2,4-dichlorophenyl)pyridazin-3-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.04 (t, J=5.4 Hz, 1H), 7.86 (d, J=8.8 Hz, 1H), 7.79 (d, J=2.0 Hz, 1H), 7.64 (d, J=8.8 Hz, 1H), 7.58 (d, J=8.8 Hz, 3H), 7.27 (d, J=8.8 Hz, 1H), 6.66 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.53-4.40 (m, 1H), 4.03-3.96 (m, 1H), 3.34-3.38 (m, 2H), 2.46 (t, J=7 Hz, 2H), 1.80-1.77 (m, 1H), 1.57-1.52 (m, 2H), 0.95 (d, J=6.8 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H). MS(M+1): 531.

Compound 17-3: 3-(4-(((2S,3S)-3-methyl-1-((6-(4-(trifluoromethyl)phenyl)pyridazin-3-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

White solid. 1HNMR (400 MHz, DMSO-d₆): δ 8.28 (d, J=8.3 Hz, 2H), 8.24 (d, J=9.3 Hz, 1H), 8.02 (t, J=5.4 Hz, 1H), 7.89 (d, J=8.3 Hz, 2H), 7.58 (d, J=8.8 Hz, 211H), 7.29 (d, J=8.8 Hz, 1H), 6.63 (d, J=8.8 Hz, 2H), 6.21 (d, J=8.8 Hz, 1H), 4.67-4.52 (m, 2H), 3.84-3.81 (m, 1H), 3.42-3.37 (m, 2H), 2.46 (t, J=7 Hz, 2H), 2.03-1.97 (m, 1H), 1.79-1.76 (m, 1H), 1.63-1.60 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.92 (t, J=6.8 Hz, 3H). MS(M+1): 531.

Compound 17-4: 3-(4-(((2S,3S)-1-((6-(2-chloro-4-(trifluoromethyl)phenyl)pyridazin-3-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. 1HNMR (400 MHz, DMSO-d₆): δ 8.05-8.01 (m, 2H), 7.94-7.82 (m, 3H), 7.58 (d, J=8.8 Hz, 2H), 7.30 (d, J=8.8 Hz, 1H), 6.64 (d, J=8.8 Hz, 1H), 6.21 (d, J=8.8 Hz, 1H), 4.66.4.53 (m, 2H), 3.85-3.82 (m, 1H), 3.42-3.37 (m, 2H), 2.45 (t, J=7 Hz, 2H), 2.03-1.97 (m, 1H), 1.79-1.65 (m, 1H), 1.65-1.60 (m, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.92 (t, J=6.8 Hz, 3H). MS(M+1): 565.

Compound 17-5: 3-(4-(((2S,3S)-1-((6-(2-fluoro-4-(trifluoromethyl)phenyl)pyridazin-3-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.12 (t, J=8.4 Hz, 1H), 8.04-7.99 (m, 2H), 7.87 (d, J=8.8 Hz, 1H), 7.80-7.75 (m, 1H), 7.56 (d, J=8.8 Hz, 2H), 7.31 (d, J=8.8 Hz, 2H), 6.20 (d, J=8.8 Hz, 1H), 4.67-4.53 (m, 2H), 3.85-3.82 (m, 1H), 3.42-3.39 (m, 2H), 2.46 (t, J=7 Hz, 2H), 1.80-1.78 (m, 1H), 1.78-1.62 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.91 (t, J=6.8 Hz, 3H). MS(M+1): 549.

Compound 17-6: 3-(4-(((2S,3S)-1-((6-(2,4-difluorophenyl)pyridazin-3-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.03 (t, J=5.4 Hz, 1H), 7.97-7.89 (m, 2H), 7.58 (d, J=8.8 Hz, 2H), 7.46-7.41 (m, 1H), 7.26 (d, J=8.8 Hz, 2H), 6.63 (d, J=8.8 Hz, 2H), 6.20 (d, J=8.8 Hz, 1H), 4.65-4.51 (m, 2H), 3.84-3.80 (m, 1H), 3.42-3.37 (m, 2H), 2.46 (t, J=7 Hz, 2H), 1.80-1.77 (m, 1H), 1.65-1.60 (m, 1H), 0.97 (d, J=6.8 Hz, 3H), 0.91 (t, J=6.8 Hz, 3H). MS(M+1): 499.

Compound 17-7: (S)-3-(4-((4-methyl-1-((6-(4-(trifluoromethyl)phenyl)pyridazin-3-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹HNMR (400 MHz, DMSO-d₆): δ 8.30-8.24 (m, 3H), 8.04 (t, J=5.4 Hz, 1H), 7.89 (d, J=8.8 Hz, 2H), 7.59 (d, J=8.8 Hz, 2H), 7.31 (d, J=8.8 Hz, 1H), 6.67 (d, J=8.8 Hz, 2H), 6.12 (d, J=8.8 Hz, 1H), 4.55-4.41 (m, 2H), 3.99-3.96 (m, 1H), 3.42-3.39 (m, 2H), 2.46 (t, J=7 Hz, 2H), 1.81-1.76 (m, 1H), 1.57-1.53 (m, 2H), 0.95 (d, J=6.8 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H). MS(M+1): 531.

Compound 17-8: (S)-3-(4-((1-((6-(benzofuran-2-yl)pyridazin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.26-7.97 (m, 9H), 6.58 (t, J=8.8 Hz, 2H), 4.48-4.82 (m, 2H), 3.67 (d, J=5.4 Hz, 4H), 2.62-2.72 (m, 2H), 0.99-1.11 (m, 6H). MS(M+1): 489.

Compound 17-9: (S)-3-(4-((1-(6-(2-fluoro-4-(trifluoromethyl)phenyl)pyridazin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.58 (dd, J=8.8, 2.0 Hz, 3H), 7.43-7.51 (m, 1H), 6.82-7.03 (m, 1H), 6.54-6.66 (m, 3H), 4.44-4.93 (m, 2H), 3.74-3.84 (m, 1H), 3.71 (q, J=6.0 Hz, 2H), 2.66-2.75 (m, 2H), 2.00-2.15 (m, 1H), 1.09 (t, J=7.2 Hz, 3H), 1.06 (t, J=7.2 Hz, 3H). MS(M+1): 535.

Compound 17-10: (S)-3-(4-((1-((6-(4-fluorophenyl)pyridazin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.85-8.01 (m, 2H), 7.67 (s, 1H), 7.55 (d, J=8.8 Hz, 2H), 7.09-7.20 (m, 2H), 6.93 (d, J=9.3 Hz, 1H), 6.60 (s, 2H), 4.57-4.79 (m, 1H), 3.61-3.96 (m, 2H), 2.64-2.73 (m, 1H), 1.24 (s, 2H), 0.94-1.14 (m, 6H). MS(M+1): 467.

Compound 17-11: (S)-3-(4-((1-((6-(2,4-difluorophenyl)pyridazin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.98-8.13 (m, 1H), 7.76 (dd, J=9.3, 2.0 Hz, 1H), 7.50-7.60 (m, 2H), 6.87-7.10 (m, 3H), 6.52-6.65 (m, 2H), 4.56-4.83 (m, 1H), 3.59-3.87 (m, 3H), 2.58-2.75 (m, 2H), 1.24 (t, J=7.10 Hz, 2H), 0.95-1.13 (m, 6H). MS(M+1): 485.

Compound 17-12: (S)-3-(4-((1-((6-(4-(tert-buty)phenyl)pyridazin-3-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.89-7.95 (m, 2H), 7.82-7.89 (m, 1H), 7.74 (d, J=9.2 Hz, 1H), 7.55-7.61 (m, 2H), 7.45-7.55 (m, 3H), 6.94 (d, J=9.2 Hz, 1H), 6.70 (t, J=6.0 Hz, 1H), 6.56-6.64 (m, 2H), 4.77 (dd, J=11.2, 6.8 Hz, 1H), 4.63 (dd, J=11.2, 4.4 Hz, 1H), 3.74-3.82 (m, 2H), 3.70 (q, J=6.0 Hz, 2H), 2.66-2.72 (m, 2H), 1.99-2.15 (m, 1H), 1.38 (s, 9H), 1.00-1.10 (m, 6H). MS(M+1): 505.

Example 18: Synthesis of Compounds 18-1 to 18-9

Compound 18-1: (S)-3-(4-((1-((5-(benzofuran-2-yl)-6-methylpyridin-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.99 (d, J=8.3 Hz, 1H), 7.53-7.62 (m, 3H), 7.48 (d, J=7.8 Hz, 1H), 7.19-7.31 (m, 2H), 6.80 (s, 1H), 6.64 (dd, J=8.3, 3.9 Hz, 3H), 4.48-4.57 (m, 1H), 4.25 (dd, J=10.8, 5.4 Hz, 1H), 3.74-3.83 (m, 1H), 3.67 (d, J=5.4 Hz, 2H), 2.69 (s, 3H), 2.66 (br. s., 2H), 1.69-1.82 (m, 1H), 1.57 (d, J=8.3 Hz, 1H), 1.30-1.46 (m, 4H), 0.81-0.92 (t, J=7.1 Hz, 3H). MS(M+1): 516. HPLC 99%.

Compound 18-2: (S)-3-(4-((1-((5-(2-chloro-4-(trifluoromethyl)phenyl)-6-methylpyridin-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, J=1.5 Hz, 1H), 7.53-7.60 (m, 3H), 7.28-7.35 (m, 2H), 6.66-6.71 (m, 1H), 6.59-6.66 (m, 3H), 4.46-4.54 (m, 1H), 4.21-4.29 (m, 1H), 3.76-3.84 (m, 1H), 3.67 (q, J=5.9 Hz, 2H), 2.65 (t, J=5.6 Hz, 2H), 2.23 (s, 3H), 1.71-1.85 (m, 1H), 1.53-1.64 (m, 1H), 1.31-1.49 (m, 4H), 0.89 (t, J=7.3 Hz, 3H). MS(M+1): 578. HPLC 99%.

Compound 18-3: 3-(4-(((2S,3S)-1-((5-(2-chloro-4-(trifluoromethyl)phenyl)-6-methylpyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.72 (d, J=1.0 Hz, 1H), 7.52-7.60 (m, 3H), 7.26-7.35 (m, 2H), 6.70 (s, 1H), 6.54-6.63 (m, 3H), 4.47 (dd, J=10.8, 5.4 Hz, 1H), 4.33-4.43 (m, 1H), 3.62-3.76 (m, 3H), 2.65 (t, J=5.6 Hz, 2H), 2.22 (s, 3H), 1.78-1.88 (m, 1H), 1.59-1.71 (m, 1H), 1.23-1.32 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.95 (t, J=7.3 Hz, 3H). MS(M+1): 578. HPLC 94%.

Compound 18-4: 3-(4-(((2S,3S)-1-((5-(benzofuran-2-yl)-6-methylpyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.97 (d, J=8.3 Hz, 1H), 7.53-7.61 (m, 3H), 7.45-7.50 (m, 1H), 7.19-7.30 (m, 2H), 6.80 (s, 1H), 6.65 (s, 1H), 6.60 (dd, J=11.0, 8.6 Hz, 3H), 4.45-4.55 (m, 1H), 4.37-4.43 (m, 1H), 3.68 (dq, J=17.7, 5.7 Hz, 3H), 2.68 (s, 3H), 2.65 (t, J=5.6 Hz, 2H), 1.77-1.88 (m, 1H), 1.60-1.72 (m, 1H), 1.23-1.32 (m, 1H), 0.99 (d, J=6.8 Hz, 3H), 0.95 (t, J=7.3 Hz, 3H). MS(M+1): 516. HPLC 99%.

Compound 18-5: 3-(4-(((2S,3S)-1-((5-(2,4-dichlorophenyl)-6-methylpyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.56 (d, J=8.3 Hz, 2H), 7.47 (d, J=2.0 Hz, 1H), 7.25-7.30 (m, 2H), 7.11 (d, J=7.8 Hz, 1H), 6.68 (t, J=5.9 Hz, 1H), 6.53-6.61 (m, 3H), 4.43-4.53 (m, 1H), 4.33-4.42 (m, 1H), 3.63-3.74 (m, 3H), 2.65 (t, J=5.9 Hz, 2H), 2.22 (s, 3H), 1.87-1.79 (m, 1H), 1.71-1.62 (m, 1H), 1.24-1.30 (m, 1H), 1.00 (d, J=6.8 Hz, 3H), 0.95 (t, J=7.3 Hz, 3H). MS(M+1): 544. HPLC 95%.

Compound 18-6: 3-(4-(((2S,3S)-1-((5-(2-fluoro-4-(trifluoromethyl)phenyl)-6-methylpyridin-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.56 (d, J=7.8 Hz, 2H), 7.45 (d, J=7.8 Hz, 1H), 7.30-7.41 (m, 3H), 6.75-6.67 (m, 1H), 6.58 (d, J=8.3 Hz, 3H), 4.44-4.51 (m, 1H), 4.36-4.42 (m, 1H), 3.63-3.74 (m, 3H), 2.69-2.60 (m, 2H), 2.31 (s, 3H), 1.78-1.87 (m, 1H), 1.66 (ddd, J=13.3, 7.5, 4.2 Hz, 1H), 1.24-1.29 (m, 1H), 0.99 (d, J=6.8 Hz, 3H), 0.94 (t, J=7.3 Hz, 3H). MS(M+1): 562. HPLC 97%.

Compound 18-7: (S)-3-(4-((1-((5-(2-chloro-4-(trifluoromethyl)phenyl)-6-methylpyridin-2-)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR ((400 MHz, DMSO-d₆): δ 8.04 (t, J=5.6 Hz, 1H), 8.01 (s, 1H), 7.80 (d, J=8.8 Hz, 1H), 7.59 (d, J=8.8 Hz, 3H), 7.51 (d, J=8.8 Hz, 1H), 6.73-6.70 (m, 3H), 6.07 (d, J=8.8 Hz, 1H), 4.40-4.36 (m, 1H), 4.13-4.08 (m, 1H), 3.90-3.89 (m, 1H), 2.46 (t, J=6.8 Hz, 2H), 2.19 (s, 3H), 1.80-1.75 (m, 1H), 1.54-1.51 (m, 2H), 0.94 (d, J=6.3 Hz, 3H), 0.83 (d, J=6.3 Hz, 3H). MS(M+1): 578.

Compound 18-8: (S)-3-(4-((1-((5-(2,4-dichlorophenyl)-6-methylpyridin-2-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR ((400 MHz, DMSO-d₆): δ 8.04 (t, J=5.6 Hz, 1H), 7.75 (s, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.52-7.44 (m, 2H), 7.39-7.36 (m, 1H), 6.72-6.68 (m, 3H), 6.07 (d, J=8.8 Hz, 1H), 4.40-4.35 (m, 1H), 4.13-4.05 (m, 1H), 3.90-3.88 (m, 1H), 2.46 (t, J=6.8 Hz, 2H), 2.18 (s, 3H), 1.81-1.75 (m, 1H), 1.53-1.50 (m, 2H), 0.94 (d, J=6.3 Hz, 3H), 0.83 (d, J=6.3 Hz, 3H). MS(M+1): 544.

Compound 18-9: (S)-3-(4-((1-((5-(benzofuran-2-yl)-6-methylpyridin-2-yl)oxy)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

White solid. ¹H-NMR (400 MHz, DMSO-d₆): δ 8.10-8.04 (m, 2H), 7.68 (d, J=7.8 Hz, 1H), 7.61 (d, J=8.8 Hz, 3H), 7.34-7.25 (m, 2H), 7.16 (s, 1H), 6.78 (d, J=7.8 Hz, 1H), 6.72 (d, J=8.8 Hz, 2H), 6.08 (d, J=8.8 Hz, 1H), 4.45-4.41 (m, 1H), 4.15-4.11 (m, 1H), 3.91-3.86 (m, 1H), 2.47 (t, J=6.8 Hz, 2H), 1.98 (s, 3H), 1.81-1.75 (m, 1H), 1.54-1.50 (m, 2H), 0.94 (d, J=6.3 Hz, 3H), 0.82 (d, J=6.3 Hz, 3H). MS(M+1): 516.

Reaction Scheme IV illustrates the general procedures that can be used to synthesize the following compounds of the formula (I) of the present disclosure.

tert-butyl (R)-(3-(4-iodophenyl)-1-morpholino-1-oxopropan-2-yl)carbamate

Step I: Amide Formation

To a solution of the (R)-2-((tert-butoxycarbonyl)amino)-3-(4-iodophenyl)propanoic acid (20 g, 51.1 mmol) in DCM (200 mL) was combined with morpholine (8.9 ml, 102.2 mmol), EDC.HCl (11.8 g, 102.2 mmol), HOBt (8.30 g, 61.3 mmol), and triethylamine (14.2 mL, 102.2 mmol). The resulting solution was stirred overnight at room temperature. The reaction was then quenched by the addition of water (100 mL). The resulting mixture was washed with 1M HCl (2×100 mL) and saturated NaHCO₃ (1×100 mL), then dried over anhydrous MgSO₄ and concentrated in vacuo and purified by flash column chromatography on silica gel to yield tert-butyl (R)-(3-(4-iodophenyl)-1-morpholino-1-oxopropan-2-yl)carbamate (20.5 g, 87%) as a white solid.

tert-butyl (R)-(1-morpholino-1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)carbamate

Step II: Suzuki Coupling

To a degassing solution of tert-butyl (R)-(3-(4-iodophenyl)-1-morpholino-1-oxopropan-2-yl)carbamate (18.3 g, 42.2 mmol), (4-(trifluoromethyl)phenyl)boronic acid (9.60 g, 50.6 mmol), Pd(dppf)Cl₂ (3.1 g, 4.2 mmol), and 2M K₂CO₃ (65 mL, 126.7 mmol) in 1,4-dioxane (200 mL) was heated at 90° C. for 18 h. The reaction mixture was cooled, poured into water, and extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. Purification of the residue by silica gel chromatography to afford tert-butyl (R)-(1-morpholino-1-oxo-3-(4′-(trifluormethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)carbamate (18 g, 90%).

tert-butyl (R)-(3-oxo-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)carbamate

Step III: Formation of Tertibutyl

To a stirred solution of amide (R)-(1-oxo-1-(piperidin-1-yl)-3-(4′-(trifluoromethyl) [1,1′-biphenyl]-4-yl)propan-2-yl)carbamate (5 g, 10.4 mmol) in THF (60 mL), was added dropwise a solution of n-Propylmagnesium chloride (26 mL, 52.2 mmol, 2 M in THF) at 0° C. The mixture was stirred for 1 h. at 0° C. and 1 h at rt. Then an aqueous solution of HCl (1 M, 100 mL) was carefully added at 0° C. The aqueous layer was extracted with EA (3×100 mL). The organic phases were combined, washed with water (100 mL), brine (100 mL), dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by flash column chromatography on silica gel to give tert-butyl (R)-(3-oxo-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)carbamate (3.3 g, 73%).

tert-butyl ((2R)-3-hydroxy-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)carbamate

Step IV: Reduction

To a stirred solution of tert-butyl (R)-(3-oxo-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)carbamate (2.0 g, 4.45 mmol) in THF (20 mL), was added LAH (0.17 g, 4.45 mmol) at 0° C. The mixture was stirred for 2 h at 0° C. The cooled reaction mixture was slowly quenched with saturated sodium sulfate solution (0.3 mL) and 1M-NaOH (0.3 mL). The precipitated solids were filtered off and washed with DCM (50 mL). The filtrate was concentrated under vacuum. The residue was purified by flash column chromatography on silica gel to give tert-butyl ((2R)-3-hydroxy-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)carbamate (1.33 g, 68%).

(2R)-2-((tert-butoxycarbonyl)amino)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-3-yl methanesulfonate

Step V: Mesylation

Tert-butyl ((2R)-3-hydroxy-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl) hexan-2-yl)carbamate(0.68 g, 1.7 mmol) was dissolved in anhydrous DCM (5 mL) and Et₃N (0.47 mL, 3.3 mmol) was added to the solution. A solution of methanesulfonyl chloride (0.14 mL, 1.8 mmol) was added drop wised to the mixture. The reaction mixture was stirred for 3 h. The mixture was poured to the cold water and white solid was precipitated to give crude product (2R)-2-((tert-butoxycarbonyl)amino)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-3-yl methanesulfonate (0.85 g, in qualitatively yield), which was of suitable purity to use directly in next reaction.

tert-butyl (S)-(1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)carbamate

Step VI: Reductive Elimination

(2R)-2-((tert-butoxycarbonyl)amino)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-3-yl methanesulfonate (0.8 g, 1.64 mmol) was dissolved in anhydrous THF (10 mL), was added Red-A1 (1.4 mL, 4.92 mmol, 3.5 M in THF) at 0° C. The mixture was stirred for 3 h at 0° C. The cooled reaction mixture was slowly quenched with saturated sodium sulfate solution (0.3 mL) and IM-NaOH (0.3 mL). The precipitated solids were filtered off and washed with DCM (50 mL). The filtrate was concentrated under vacuum. The residue was purified by flash column chromatography on silica gel to give tert-butyl (S)-(1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl) carbamate (0.22 g, 33%).

(S)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-amine

Step VII: Deprotection

Tert-butyl (S)-(1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl) carbamate (235 mg, 0.56 mmol) was suspended in trifluoroacetic acid (1.3 mL, 16.86 mmol) in anhydrous dichloromethane (5 mL) at room temperature for 2 h. After reaction, excess trifluoroacetic acid was neutralized by dropwise addition of Na₂CO_3(aq) until pH=10. Then it was extracted with CH₂Cl₂. The combined organic layer was dried with anhydrous MgSO₄ and concentrated in vacuo to give crude product. It was further purified by silica gel flash column chromatography using dichloromethane and methanol as eluant to give (S)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl) hexan-2-amine (220 mg, in qualitatively yield).

ethyl (S)-3-(4-((1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)amino)benzamido)propanoate

Step VIII: Ullmann Reaction

A seal tube was charged with CuI (13 mg, 0.068 mmol), K₂CO₃ (207 mg, 1.5 mmol), (S)-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl) hexan-2-amine (220 mg, 0.68 mmol), ethyl 3-(4-iodobenzamido)propanoate (260 mg, 0.75 mmol) and DMF (6 mL). The seal tube was fitted with a septum and purged with nitrogen. Next, the test tube was capped and stirred in an oil bath at 90° C. for 24 h. Cool the mixture to ambient temperature, dilute with EtOAc, filter through a pad of silica gel or through Celite washing with EtOAc, and evaporate the solvent to obtain the crude mixture. Alternatively, partition the reaction mixture between brine or saturated aqueous NaHCO₃ and EtOAc, dry the organic layer over Na₂SO₄, and concentrate to obtain the crude mixture. The residue was purified by silica gel chromatography to afford ethyl (S)-3-(4-((1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)amino)benzamido)propanoate (39 mg, 11%).

(S)-5-oxo-5-(4-((1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)amino)phenyl)pentanoic acid

Step IX. Hydrolysis

Ester Compound IV-i (50 mg, 0.09 mmol) was dissolved in MeOH (2 mL)/THF (2 mL) followed by addition of LiOH (2.0 M, 0.5 mL). The reaction mixture was stirred at room temperature for overnight. The reaction was monitored by TLC. With completion of the reaction, the solvent was removed by rotary evaporation and HCl (2.0 M, 5 mL) was added to the mixture. The aqueous layer was extracted with EA (3×100 mL). The organic phases were combined, dried over Na₂SO₄, filtered and concentrated under vacuum to give the corresponding acid IV-j, (S)-3-(4-(1-(4′-(trifluoromethyl)biphenyl-4-yl)hexan-2-ylamino)benzamido)propanoic acid (42 mg, 88%). Exact Mass: 512.2; m/z: 512.23 (100.0%), 513.23 (32.6%), 514.24 (4.9%).

Compound 19-1: (R)-3-(4-((1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.01 (t, J=5.6 Hz, 1H), 7.84-7.88 (m, J=8.3 Hz, 2H), 7.76-7.80 (m, J=8.3 Hz, 2H), 7.64 (d, J=8.3 Hz, 2H), 7.56-7.60 (m, J=8.8 Hz, 2H), 7.33-7.39 (m, J=8.3 Hz, 2H), 6.58 (d, J=8.8 Hz, 2H), 6.04 (d, J=8.8 Hz, 1H), 3.61-3.72 (m, 1H), 3.36-3.43 (m, 2H), 2.75-2.86 (m, 2H), 2.46 (t, J=7.3 Hz, 2H), 1.47-1.56 (m, 1H), 1.36-1.47 (m, 2H), 1.21-1.31 (m, 3H), 0.82 (t, J=7.1 Hz, 3H). MS(M+1): 513.

Compound 19-2: (S)-3-(4-((1-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (d, J=2.4 Hz, 1H), 7.57-7.63 (m, 2H), 7.48 (dd, J=8.3, 2.0 Hz, 1H), 7.41 (d, J=8.3 Hz, 1H), 7.35 (s, 2H), 7.15-7.31 (m, 2H), 6.59 (t, J=9.3 Hz, 2H), 3.66-3.83 (m, 1H), 3.40 (d, J=6.4 Hz, 2H), 2.82-2.95 (m, 1H), 2.57-2.73 (m, 1H), 2.44-2.49 (m, 2H), 1.04-1.15 (m, 3H). MS(M+1): 471.

Compound 19-3: (S)-3-(4-((1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.86-7.89 (m, J=8.3 Hz, 2H), 7.77-7.81 (m, J=8.3 Hz, 2H), 7.66 (d, J=8.3 Hz, 2H), 7.59-7.63 (m, J=8.8 Hz, 2H), 7.38 (d, J=8.3 Hz, 2H), 6.57-6.64 (m, J=8.8 Hz, 2H), 3.74-3.83 (m, 1H), 3.43 (br. s., 2H), 2.91 (dd, J=13.2, 5.9 Hz, 1H), 2.71 (dd, J=13.7, 6.8 Hz, 1H), 2.44-2.49 (m, 2H), 1.12 (d, J=6.4 Hz, 3H). MS(M+1): 471.

Compound 19-4: (S)-3-(4-((1-(4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.60 (d, J=8.8 Hz, 2H), 7.55 (dd, J=8.3, 2.4 Hz, 4H), 7.45 (d, J=8.3 Hz, 2H), 7.31 (d, J=8.3 Hz, 2H), 6.60 (d, J=8.3 Hz, 2H), 3.65-3.35 (m, 1H), 3.40 (d, J=5.9 Hz, 2H), 2.75-2.65 (m, 1H), 2.69 (d, J=6.8 Hz, 1H), 2.45-2.48 (m, 2H), 1.31 (s, 9H), 1.11 (d, J=6.4 Hz, 3H). MS(M+1): 459.

Compound 19-5: (R)-3-(4-((1-(4-(benzofuran-2-yl)phenyl)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (s, 1H), 7.82 (d, J=8.3 Hz, 2H), 7.64 (dd, J=7.8, 1.5 Hz, 1H), 7.58 (d, J=8.8 Hz, 2H), 7.25-7.37 (m, 5H), 6.60 (d, J=8.8 Hz, 2H), 3.75-3.65 (m, 1H), 3.39 (d, J=5.4 Hz, 2H), 2.78 (s, 2H), 2.46 (t, J=7.1 Hz, 2H), 1.22-1.31 (m, 3H), 0.88 (d, J=6.4 Hz, 3H), 0.78 (d, J=6.4 Hz, 3H). MS(M+1): 485.

Compound 19-6: (R)-3-(4-((1-(4-(benzofuran-2-yl)phenyl)heptan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (s, 1H), 7.81 (d, J=7.8 Hz, 2H), 7.56-7.65 (m, 5H), 7.34-7.36 (m, 3H), 7.23-7.32 (m, 3H), 6.58 (d, J=8.8 Hz, 2H), 3.67 (br. s., 1H), 3.38-3.41 (m, 2H), 2.79 (t, J=5.6 Hz, 2H), 2.46 (t, J=7.1 Hz, 2H), 1.47 (br. s., 1H), 1.38-1.44 (m, 2H), 1.17-1.26 (m, 6H), 0.78-0.85 (m, 4H). MS(M+1): 499.

Compound 19-7: (R)-3-(4-((1-(4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.52-7.59 (m, 6H), 7.43-7.46 (m, 2H), 7.29 (d, J=8.3 Hz, 2H), 6.58 (d, J=8.8 Hz, 2H), 3.68-3.60 (m, 1H), 3.42-3.36 (m, 2H), 1.82-1.72 (m, 2H), 2.46 (s, 2H), 1.30-1.31 (m, 9H), 1.52-1.36 (m, 3H), 1.22-1.26 (m, 3H), 0.80-0.85 (m, 3H). MS(M+1): 501.

Compound 19-8: (R)-3-(4-((1-(4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)-4-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.52-7.60 (m, 7H), 7.45 (d, J=8.8 Hz, 2H), 7.27 (d, J=8.3 Hz, 2H), 6.60 (d, J=8.8 Hz, 2H), 3.40 (d, J=5.4 Hz, 2H), 2.76 (s, 2H), 2.46 (t, J=7.1 Hz, 2H), 1.74-1.83 (m, 1H), 1.45-1.35 (m, 1H), 1.31 (s, 9H), 0.88 (d, J=6.8 Hz, 3H), 0.78 (d, J=6.4 Hz, 3H). MS(M+1): 501.

Compound 19-9: (S)-3-(4-((1-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)heptan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.74 (d, J=8.8 Hz, 2H), 7.58 (dd, J=8.3, 5.9 Hz, 4H), 7.41 (d, J=8.3 Hz, 2H), 7.32 (d, J=7.8 Hz, 2H), 6.59 (d, J=8.8 Hz, 2H), 6.03 (d, J=8.3 Hz, 1H), 3.60-3.69 (m, 1H), 3.41 (br. s., 2H), 2.72-2.85 (m, 2H), 2.43-2.48 (m, 2H), 1.36-1.52 (m, 3H), 1.21-1.34 (m, 5H), 0.81 (t, J=6.6 Hz, 3H). MS(M+1): 543.

Compound 19-10: (S)-3-(4-((5-methyl-1-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.81-7.88 (m, 4H), 7.78 (t, J=7.6 Hz, 2H), 7.55-7.67 (m, 6H), 3.41-3.47 (m, 5H), 2.79 (br. s., 1H), 2.44-2.47 (m, 1H), 1.38-1.57 (m, 3H), 1.22 (br. s., 2H), 0.81 (d, J=6.8 Hz, 6H). MS(M+1): 527.

Compound 19-11: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenyl)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 7.99-8.06 (m, 3H), 7.76-7.94 (m, 2H), 7.54-7.68 (m, 3H), 7.20-7.44 (m, 4H), 6.58 (d, J=8.3 Hz, 1H), 3.35-3.42 (m, 5H), 2.79 (br. s., 1H), 2.41-2.48 (m, 1H), 1.61-1.79 (m, 1H), 1.32-1.61 (m, 3H), 1.19-1.32 (m, 4H), 0.77-0.89 (m, 3H); MS(M+1): 485.

Compound 19-12: (S)-3-(4-((1-(4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)-3-propoxypropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.68 (d, J=8.0 Hz, 2H), 7.52-7.61 (m, 4H), 7.48 (d, J=8.0 Hz, 2H), 7.36 (d, J=8.0 Hz, 2H), 6.71 (d, J=8.0 Hz, 2H), 3.85-4.01 (m, 1H), 3.55-3.63 (m, 2H), 3.47 (dd, J=4.9, 2.4 Hz, 2H), 3.36-3.43 (m, 2H), 3.02 (d, J=6.4 Hz, 1H), 2.93 (d, J=6.8 Hz, 1H), 2.60 (t, J=6.8 Hz, 2H), 1.53-1.64 (m, 2H), 1.34 (s, 9H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 517.

Compound 19-13: (S)-3-(4-((1-propoxy-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.86 (d, J=8.0 Hz, 2H), 7.77 (d, J=8.0 Hz, 2H), 7.68 (d, J=8.0 Hz, 2H), 7.65 (d, J=8.0 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H), 6.71 (d, J=8.0 Hz, 2H), 3.89-4.01 (m, 1H), 3.59 (t, J=8.0 Hz, 2H), 3.44-3.51 (m, 2H), 3.37-3.43 (t, J=8.0 Hz, 2H), 3.04-3.11 (m, 1H), 2.91-2.98 (m, 1H), 2.61 (t, J=6.6 Hz, 2H), 1.52-1.65 (m, 2H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 528.

Compound 19-14: (S)-3-(4-((1-propoxy-3-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.75 (d, J=8.0 Hz, 2H), 7.68 (d, J=8.0 Hz, 2H), 7.59 (d, J=8.0 Hz, 2H), 7.36-7.44 (m, 4H), 6.70 (d, J=8.0 Hz, 2H), 3.88-4.00 (m, 1H), 3.59 (t, J=6.8 Hz, 2H), 3.43-3.51 (m, 2H), 3.37-3.43 (m, 2H), 3.02-3.10 (m, 1H), 2.89-2.97 (m, 1H), 2.61 (t, J=6.8 Hz, 2H), 1.52-1.63 (m, 2H), 0.93 (t, J=7.6 Hz, 3H). MS(M+1): 545.

Compound 19-15: (S)-3-(4-((1-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)-3-propoxypropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.87 (d, J=8.0 Hz, 2H), 7.56 (d, J=4.0 Hz, 1H), 7.33-7.45 (m, 6H), 6.69 (d, J=8.0 Hz, 2H), 3.95 (m, 1H), 3.59 (t, J=6.8 Hz, 2H), 3.44-3.52 (m, 2H), 3.38-3.44 (m, 2H), 3.03-3.11 (m, 1H), 2.90-2.97 (m, 1H), 2.61 (t, J=6.8 Hz, 2H), 1.53-1.64 (m, 2H), 0.92 (t, J=8.0 Hz, 3H). MS(M+1): 529.

Compound 19-16: (S)-3-(4-((1-propoxy-3-(2′,4′,6′-trimethyl-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.65 (d, J=8.8 Hz, 2H), 7.43 (br. s., 1H), 7.36 (d, J=7.8 Hz, 2H), 7.01 (d, J=7.8 Hz, 2H), 6.89 (s, 21H), 6.67 (d, J=8.8 Hz, 2H), 3.94 (br. s., 1H), 3.55-3.64 (m, 21H), 3.45-3.53 (m, 2H), 3.41 (t, J=6.4 Hz, 2H), 3.05 (m, 1H), 2.92 (m, 1H), 2.61 (t, J=6.8 Hz, 2H), 2.27 (s, 3H), 1.92 (s, 6H), 1.58 (q, J=6.8 Hz, 2H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 503.

Compound 19-17: (R)-3-(4-((1-(4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)-3-isobutoxypropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.68 (d, J=8.8 Hz, 2H), 7.54-7.59 (m, 4H), 7.48 (d, J=8.8 Hz, 2H), 7.36 (d, J=8.8 Hz, 2H), 6.71 (d, J=8.8 Hz, 2H), 3.90-3.98 (m, 1H), 3.58 (t, J=6.8 Hz, 3H), 3.44-3.49 (m, 2H), 3.22 (d, J=6.8 Hz, 2H), 3.03 (m, 1H), 2.82 (m, 1H), 2.61 (t, J=6.8 Hz, 3H), 1.86 (m, 1H), 1.34 (s, 9H), 0.92 (dd, J=6.8, 2.4 Hz, 6H). MS(M+1): 531.

Compound 19-18: (R)-3-(4-(1-isobutoxy-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.86 (d, J=7.8 Hz, 2H), 7.77 (d, J=7.8 Hz, 2H), 7.64-7.69 (m, 4H), 7.43 (d, J=7.8 Hz, 2H), 6.71 (d, J=8.3 Hz, 2H), 3.96 (m, J=4.9 Hz, 1H), 3.59 (t, J=6.4 Hz, 2H), 3.42-3.52 (m, 2H), 3.22 (d, J=6.4 Hz, 2H), 3.09 (m, 1H), 2.91 (m, 1H), 2.61 (t, J=6.6 Hz, 2H), 1.86 (m, 1H), 0.92 (dd, J=6.4, 2.4 Hz, 6H); MS(M+1): 543.

Compound 19-19: (R)-3-(4-((1-isobutoxy-3-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.73-7.79 (m, 2H), 7.65-7.71 (m, 2H), 7.57-7.63 (m, 2H), 7.45 (br. s., 1H), 7.37-7.43 (m, 4H), 6.70 (d, J=8.8 Hz, 2H), 5.23-5.41 (m, 1H), 3.95 (br. s., 1H), 3.55-3.64 (m, 2H), 3.47 (dd, J=4.9, 1.5 Hz, 2H), 3.22 (d, J=6.8 Hz, 2H), 3.07 (dd, J=13.7, 6.8 Hz, 2H), 2.94 (dd, J=13.7, 6.8 Hz, 2H), 2.60 (t, J=6.8 Hz, 2H), 1.86 (dt, J=13.2, 6.6 Hz, 1H), 0.89-0.95 (m, 6H); MS(M+1): 559.

Compound 19-20: (R)-3-(4-((1-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)-3-isobutoxypropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.68 (d, J=8.0 Hz, 2H), 7.57 (d, J=2.0 Hz, 2H), 7.41-7.45 (m, 1H), 7.32-7.41 (m, 5H), 6.70 (d, J=8.0 Hz, 2H), 3.89-4.03 (m, 1H), 3.60 (t, J=6.8 Hz, 2H), 3.44-3.53 (m, 2H), 3.18-3.26 (m, 2H), 3.05-3.11 (m, 1H), 2.94 (m, 1H), 2.62 (t, J=6.8 Hz, 2H), 1.86 (m, 1H), 0.91 (dd, J=6.6, 2.2 Hz, 6H); MS(M+1): 543.

Compound 19-21: (R)-3-(4-((1-(4-(benzofuran-2-yl)phenyl)-3-isobutoxypropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.83-7.87 (m, 2H), 7.66-7.70 (m, 2H), 7.61-7.64 (m, 1H), 7.52-7.57 (m, 1H), 7.44-7.50 (m, 1H), 7.42 (d, J=8.3 Hz, 2H), 7.27-7.33 (m, 1H), 7.21-7.26 (m, 2H), 6.68-6.74 (m, 2H), 5.09-5.55 (m, 1H), 3.97 (br. s., 1H), 3.56-3.62 (m, 2H), 3.47 (d, J=4.4 Hz, 2H), 3.22 (d, J=6.8 Hz, 2H), 3.04-3.12 (m, 1H), 2.91-2.98 (m, 1H), 2.61 (t, J=6.6 Hz, 2H), 1.81-1.93 (m, 1H), 0.90-0.95 (m, 6H). MS(M+1): 515.

Compound 19-22: (S)-3-(4-((1-propoxy-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.84-7.88 (m, 2H), 7.75-7.80 (m, 5H), 7.63-7.71 (m, 10H), 7.45-7.51 (m, 1H), 7.43 (d, J=8.3 Hz, 2H), 6.67-6.73 (m, 2H), 5.35 (br. s., 1H), 3.96 (br. s., 1H), 3.55-3.63 (m, 2H), 3.43-3.52 (m, 2H), 3.36-3.43 (m, 2H), 3.03-3.13 (m, 1H), 2.94 (dd, J=13.7, 6.8 Hz, 1H), 2.61 (t, J=6.6 Hz, 2H), 1.58 (sxt, J=7.0 Hz, 2H), 0.93 (t, J=7.6 Hz, 3H). MS(M+1): 529.

Compound 19-23: (S)-3-(4-((1-propoxy-3-(3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.89-7.97 (m, 2H), 7.62-7.72 (m, 14H), 7.45-7.50 (m, 1H), 7.43 (d, J=8.3 Hz, 2H), 6.67-6.74 (m, 5H), 5.35 (d, J=4.9 Hz, 2H), 3.95 (br. s., 1H), 3.55-3.62 (m, 2H), 3.44-3.51 (m, 2H), 3.37-3.43 (m, 2H), 3.07 (dd, J=13.7, 6.8 Hz, 1H), 2.90-2.98 (m, 1H), 2.61 (t, J=6.6 Hz, 2H), 1.53-1.64 (m, 2H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 529.

Compound 19-24: (S)-3-(4-((1-propoxy-3-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.73-7.79 (m, 2H), 7.64-7.71 (m, 2H), 7.57-7.62 (m, 2H), 7.43-7.50 (m, 1H), 7.35-7.43 (m, 4H), 6.67-6.73 (m, 2H), 5.24-5.42 (m, 1H), 3.90-4.00 (m, 1H), 3.55-3.62 (m, 2H), 3.47 (dd, J=4.9, 2.9 Hz, 2H), 3.41 (td, J=6.6, 1.0 Hz, 2H), 3.03-3.08 (m, 2H), 2.93 (dd, J=13.7, 6.8 Hz, 2H), 2.60 (t, J=6.8 Hz, 2H), 1.54-1.63 (m, 2H), 0.93 (t, J=7.3 Hz, 3H); MS(M+1): 545.

Compound 19-25: (S)-3-(4-((1-propoxy-3-(3′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.65-7.70 (m, 3H), 7.60-7.64 (m, 2H), 7.55-7.60 (m, 2H), 7.46 (br. s., 1H), 7.42 (d, J=8.3 Hz, 2H), 7.27-7.33 (m, 1H), 6.70 (d, J=8.8 Hz, 2H), 5.24-5.42 (m, 1H), 3.95 (d, J=5.9 Hz, 1H), 3.56-3.62 (m, 2H), 3.44-3.50 (m, 2H), 3.38-3.43 (m, 2H), 3.07 (dd, J=13.7, 6.4 Hz, 1H), 2.94 (dd, J=13.7, 6.8 Hz, 1H), 2.60 (t, J=6.8 Hz, 2H), 1.53-1.64 (m, 2H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 545.

Compound 19-26: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenyl)-3-propoxypropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.83-7.87 (m, 2H), 7.66-7.70 (m, 4H), 7.61-7.65 (m, 1H), 7.52-7.58 (m, 1H), 7.42 (d, J=8.3 Hz, 3H), 7.28-7.33 (m, 1H), 7.21-7.26 (m, 2H), 6.68-6.73 (m, 2H), 5.14-5.51 (m, 1H), 3.87-4.05 (m, 1H), 3.55-3.62 (m, 2H), 3.47 (dd, J=4.9, 2.0 Hz, 2H), 3.38-3.44 (m, 2H), 3.04-3.10 (m, 1H), 2.94 (dd, J=13.7, 6.8 Hz, 1H), 2.61 (t, J=6.8 Hz, 2H), 1.53-1.64 (m, 2H), 0.91-0.97 (m, 3H). MS(M+1): 501.

Compound 19-27: (S)-3-(4-((1-(4-(1H-indol-2-yl)phenyl)-3-propoxypropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): 10.59 (br. s., 1H), 7.75-7.78 (m, 2H), 7.66-7.70 (m, 2H), 7.54 (d, J=7.8 Hz, 1H), 7.41-7.49 (m, 1H), 7.34-7.40 (m, 3H), 6.98-7.11 (m, 2H), 6.83-6.87 (m, 1H), 6.68-6.73 (m, 2H), 5.11-5.54 (m, 1H), 3.94 (d, J=3.9 Hz, 1H), 3.56-3.62 (m, 2H), 3.44-3.50 (m, 2H), 3.41 (t, J=6.4 Hz, 2H), 3.04 (dd, J=13.7, 6.4 Hz, 1H), 2.88-2.94 (m, 1H), 2.61 (t, J=6.8 Hz, 2H), 1.54-1.63 (m, 2H), 0.93 (t, J=7.3 Hz, 3H). MS(M+1): 501.

Compound 19-28: (S)-3-(4-((1-isobutoxy-3-(3′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.90-7.97 (m, 2H), 7.63-7.72 (m, 6H), 7.40-7.52 (m, 3H), 6.68-6.73 (m, 2H), 5.19-5.49 (m, 1H), 3.97 (d, J=4.9 Hz, 1H), 3.56-3.62 (m, 2H), 3.43-3.51 (m, 2H), 3.19-3.26 (m, 2H), 3.09 (dd, J=13.7, 6.4 Hz, 1H), 2.95 (dd, J=13.4, 6.6 Hz, 1H), 2.60 (t, J=6.8 Hz, 2H), 1.87 (dt, J=13.3, 6.8 Hz, 1H), 0.92 (dd, J=6.6, 2.7 Hz, 6H). MS(M+1): 543.

Compound 19-29: (S)-3-(4-((1-isobutoxy-3-(2′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.80 (d, J=7.8 Hz, 1H), 7.65-7.70 (m, 6H), 7.56-7.60 (m, 2H), 7.47 (br. s., 2H), 7.37 (d, J=7.8 Hz, 5H), 7.25 (d, J=7.8 Hz, 4H), 6.68-6.74 (m, 2H), 5.34 (br. s., 1H), 3.96 (br. s., 1H), 3.57-3.62 (m, 2H), 3.48 (d, J=4.4 Hz, 2H), 3.22 (d, J=6.4 Hz, 2H), 3.08 (dd, J=13.7, 6.4 Hz, 1H), 2.92-2.99 (m, 1H), 2.61 (t, J=6.6 Hz, 2H), 1.86 (dt, J=13.3, 6.8 Hz, 1H), 0.92 (dd, J=6.8, 2.9 Hz, 6H). MS(M+1): 543.

Compound 19-30: (S)-3-(4-((1-isobutoxy-3-(3′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.65-7.71 (m, 3H), 7.60-7.64 (m, 2H), 7.54-7.60 (m, 2H), 7.47 (t, J=5.4 Hz, 1H), 7.42 (d, J=8.3 Hz, 2H), 7.30 (ddd, J=9.3, 2.4, 1.0 Hz, 1H), 6.66-6.73 (m, 2H), 5.34 (d, J=8.3 Hz, 1H), 3.96 (br. s., 1H), 3.59 (q, J=6.4 Hz, 2H), 3.43-3.50 (m, 2H), 3.23 (d, J=1.0 Hz, 2H), 3.08 (dd, J=13.7, 6.4 Hz, 5H), 2.94 (dd, J=13.4, 6.6 Hz, 3H), 2.60 (t, J=6.8 Hz, 2H), 1.86 (dt, J=13.3, 6.8 Hz, 1H), 0.92 (dd, J=6.8, 2.4 Hz, 6H); MS(M+1): 559.

Compound 19-31: (S)-3-(4-((1-isobutoxy-3-(3′,4′,5′-trifluoro-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.65-7.70 (m, 2H), 7.57-7.64 (m, 2H), 7.43-7.52 (m, 3H), 7.39-7.43 (m, 2H), 6.66-6.72 (m, 2H), 5.34 (br. s., 1H), 3.96 (br. s., 1H), 3.55-3.63 (m, 2H), 3.42-3.51 (m, 2H), 3.17-3.26 (m, 2H), 3.08 (dd, J=13.7, 6.4 Hz, 1H), 2.93 (dd, J=13.7, 6.8 Hz, 1H), 2.60 (t, J=6.8 Hz, 2H), 1.86 (dt, J=13.4, 6.5 Hz, 1H), 0.88-0.94 (m, 6H). MS(M+1): 529.

Compound 19-32: (S)-3-(4-((1-(4-(benzofuran-2-yl)phenyl)-3-isobutoxypropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.81-7.88 (m, 2H), 7.65-7.70 (m, 2H), 7.60-7.65 (m, 1H), 7.51-7.58 (m, 1H), 7.43 (d, J=8.3 Hz, 3H), 7.29 (dd, J=7.8, 1.5 Hz, 1H), 7.20-7.27 (m, 2H), 6.65-6.77 (m, 2H), 5.24-5.41 (m, 1H), 3.89-4.05 (m, 1H), 3.55-3.62 (m, 2H), 3.43-3.51 (m, 2H), 3.23 (d, J=5.9 Hz, 2H), 3.06 (d, J=6.4 Hz, 1H), 2.97 (d, J=6.4 Hz, 1H), 2.61 (t, J=6.8 Hz, 2H), 1.80-1.94 (m, 1H), 0.92 (dd, J=6.4, 2.4 Hz, 6H). MS(M+1): 515.

Compound 19-33: (S)-3-(4-((1-isobutoxy-3-(4′-(trifluoromethoxy)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.73-7.78 (m, 2H), 7.64-7.70 (m, 2H), 7.56-7.62 (m, 2H), 7.37-7.44 (m, 4H), 6.66-6.74 (m, 2H), 3.95 (s, 1H), 3.58 (t, J=6.8 Hz, 2H), 3.43-3.51 (m, 2H), 3.22 (d, J=5.9 Hz, 2H), 3.04-3.12 (m, 1H), 2.94 (dd, J=13.7, 6.8 Hz, 1H), 2.61 (t, J=6.8 Hz, 2H), 1.80-1.92 (m, 1H), 0.92 (dd, J=6.8, 2.4 Hz, 6H). MS(M+1): 559.

Compound 19-34: (S)-3-(4-((1-isobutoxy-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 7.83-7.90 (m, 2H), 7.73-7.81 (m, 2H), 7.63-7.70 (m, 4H), 7.44 (d, J=8.3 Hz, 3H), 6.68-6.74 (m, 2H), 5.33 (br. s., 1H), 3.97 (br. s., 1H), 3.55-3.63 (m, 2H), 3.43-3.52 (m, 2H), 3.19-3.26 (m, 2H), 3.09 (dd, J=13.7, 6.4 Hz, 1H), 2.95 (dd, J=13.7, 6.8 Hz, 1H), 2.61 (t, J=6.8 Hz, 2H), 1.87 (dt, J=13.3, 6.8 Hz, 1H), 0.92 (dd, J=6.4, 2.4 Hz, 6H). MS(M+1): 543.

Reaction Scheme V illustrates the general procedures that can be used to synthesize the following compounds of the formula (I) of the present disclosure.

Step I: Preparation of (S)-tert-butyl-(3-(4-iodophenyl)-1-(2-(3-methylbenzofuran-2-carbonyl)hydrazinyl)-1-oxopropan-2-yl)carbamate

To a Solution of 3-methylbenzofuran-2-carbohydrazide, (S)-2-(tert-butoxycarbonylamino)-3-(4-iodophenyl)propanoic acid, EDCI and HOBt in DMF. The reaction was stirred at room temperature for overnight then concentrated in vacuo. Water was added to the residue and the aqueous layer was extracted with ethyl acetate. It was further concentrated in vacuo to give a residue. Purification of the crude oil residue by column chromatography (hexane/EtOAc 100:20) afforded pale white solid product(S)-tert-butyl 3-(4-iodophenyl)-1-(2-(3-methylbenzofuran-2-carbonyl)hydrazinyl)-1-oxopropan-2-ylcarbamate.

Step II: Preparation of (S)-tert-butyl 2-(4-iodophenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethylcarbamate

(S)-tert-butyl 3-(4-iodophenyl)-1-(2-(3-methylbenzofuran-2-cabonyl)hydrazinyl)-1-oxopropan-2-yl)carbamate (16.90 g, 30 mmol), TsCl (1.5 equiv), and TEA (3 equiv) were mixed in ACN (50 ml) was stirred at room temperature for 10 mins. To this reaction solution, concentrated to remove methanol and extracted with EtOAc. The organic layer was washed with water and dried over anhydrous magnesium sulfate. It was filtered, the solvent evaporated under reduced pressure. The crude product of (S)-tert-butyl 2-(4-iodophenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethylcarbamate obtained (9.93 g, 61% yield) as brown oil, and was used without any further purification in the successive step.

Step III. Preparation of (S)-tert-butyl-(2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethyl)carbamate

A solution of (S)-tert-butyl 2-(4-iodophenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethylcarbamate (8.5 g, 15.5 mmol), 2-benzofuranylboronic acid (3.02 g, 18.6 mmol), palladium acetate(II) (0.36 g, 1.6 mmol), triphenylphosphine (0.81 g, 3.2 mmol) in EtOH/PhMe (20 mL/40 mL) were purged with nitrogen for 30 min. K₂CO₃ (7.50 g, 54.25 mmol) in 20 mL H₂O was added and purged with nitrogen for another 10 min. The mixture was heated at 90° C. for 12 h. The reaction mixture was cooled and extracted with EtOAc. The organic layer was dried over MgSO₄ and concentrated in vacuo. The residue was purified by silica gel chromatography to afford (S)-tert-butyl 2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethylcarbamate (3.09 g, 37%) as a white solid.

Step IV. Preparation of (S)-2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethan-1-amine

The compound (S)-tert-butyl 2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethylcarbamate (3.09 g, 5.7 mmol) was suspended in trifluoroacetic acid (6.6 mL, 86.25 mmol) in anhydrous dichloromethane (30 mL) at room temperature for 2 h. After reaction, excess trifluoroacetic acid was neutralized by dropwised addition of NaHCO_3(aq) until pH=10. Then it was extracted with CH₂Cl₂. The combined organic layer was dried with anhydrous MgSO₄ and concentrated in vacuo to give crude product (S)-2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethanamine.

Step V: Preparation of ethyl (S)-4-((2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethyl)amino)benzoate

To a degassing solution of (S)-2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethan-1-amine (1.74 g, 4 mmol), BINAP (1 g, 1.6 mmol), cesium carbonate (1.95 g, 6 mmol) and ethyl 3-(4-(((trifluoromethyl)sulfonyl)oxy)benzamido)propanoate (1.78 g, 4.8 mmol) in 40 mL PhMe were purged with nitrogen for 30 min then added Pd(OAc)₂ (0.18 g, 0.8 mmol). The mixture was stirred in an oil bath at 100° C. for 18 h. Cool the mixture to ambient temperature, dilute with EtOAc, filter through Celite washing with EtOAc. The mixture was washed with water and brine, dried the organic layer over Na₂SO₄, and concentrate to obtain the crude mixture. The residue was purified by silica gel chromatography to afford (S)-4-((2-(4-(benzofuran-2-yl) phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethyl)amino) benzoate.

Step VI: Preparation of(S)-4-((2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethyl)amino)benzoic acid

Ethyl (S)-4-((2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethyl)amino)benzoate (1.00 g, 1.67 mmol) was dissolved in dioxane (20 mL) followed by addition of 2M/LiOH_(aq) 20 mL. The reaction mixture was heat to reflux for overnight. The reaction was monitored by TLC. With completion of the reaction, the solvent was removed by rotary evaporation and was added HCl_(aq) to pH4-5. The mixture cpd. was extracted with EtOAc. The combined organic layer was dried with anhydrous Na₂SO₄ and concentrated in vacuo to give brown oil product (S)-4-((2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethyl)amino)benzoic acid (0.74 g, 77%).

Step VII: Preparation of ethyl (S)-3-(4-((2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethyl)amino)benzamido)propanoate

A solution of (S)-4-((2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethyl)amino)benzoic acid, f-alanine ethyl ester:HCl, EDCI, Et₃N and HOBt in dry THF. The reaction was stirred at room temperature for overnight then concentrated in vacuo. Water was added to the residue and the aqueous layer was extracted with ethyl acetate. It was further concentrated in vacuo to give a residue. Purification of the crude oil residue by column chromatography (hexane/EtOAc 100:40) afforded colorness oil product, Compound V-h (0.65 g, 48%).

Step VII: Preparation of (S)-3-(4-(2-(4-(benzofuran-2-yl)phenyl)-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)ethylamino)benzamido)propanoic acid

Compound V-h (0.66 g, 1.00 mmol) was dissolved in THF (20 mL) followed by addition of 2M/LiOH(aq) 20 mL. The reaction mixture stirred at room temperature for overnight. The reaction was monitored by TLC. With completion of the reaction, the solvent was removed by rotary evaporation and was added HCl(aq) to pH4-5. The mixture cpd. was extracted with EtOAc. The combined organic layer was dried with anhydrous Na₂SO₄ and concentrated in vacuo to give brown oil product, Compound V-i.

Compound 20-1: (S)-3-(4-((2-(4-(benzofuran-2-yl)phenyl)-1-(5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-yl)ethyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.10 (s, 1H), 7.84 (d, J=8.4 Hz, 2H), 7.81 (d, J=8.4 Hz, 2H), 7.55-7.66 (m, 6H), 7.47 (d, J=8.4 Hz, 2H), 7.37 (s, 1H), 7.22-7.32 (m, 2H), 6.98 (d, J=8.4 Hz, 1H), 6.75 (d, J=8.8 Hz, 2H), 5.30-5.32 (m, 1H), 3.35-3.43 (m, 4H), 2.43 (t, J=4.0 Hz, 2H), 1.28 (s, 9H). MS(M+1): 629.

Compound 20-2: 3-(4-(((1S)-2-methyl-1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)butyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.10 (t, J=5.4 Hz, 1H), 7.77 (d, J=7.8 Hz, 1H), 7.58-7.69 (m, 3H), 7.45-7.50 (m, 1H), 7.33-7.39 (m, 1H), 6.69-6.80 (m, 2H), 4.77-4.91 (m, 1H), 3.54 (t, J=7.2 Hz, 2H), 2.54 (d, J=3.2 Hz, 2H), 2.45 (t, J=7.2 Hz, 2H), 2.09-2.30 (m, 1H), 1.41-1.49 (m, 1H), 1.09 (d, J=6.4 Hz, 2H), 0.83-0.97 (m, 6H). MS(M+1): 477.

Compound 20-3: 3-(4-(((1S)-1-(5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-yl)-2-methylbutyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.89 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.8 Hz, 2H), 7.39-7.50 (m, 2H), 6.97 (s, 1H), 6.65 (d, J=8.8 Hz, 2H), 4.67-4.81 (m, 1H), 3.63 (d, J=6.0 Hz, 2H), 2.60 (t, J=6.0 Hz, 2H), 2.02-2.16 (m, 1H), 1.15-1.39 (m, 10H), 1.08 (d, J=6.8 Hz, 2H), 0.76-1.01 (m, 6H). MS(M+1): 479.

Compound 20-4: (S)-3-(4-((1-(5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-yl)-2-methylpropyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.87-7.92 (m, 2H), 7.58 (d, J=8.8 Hz, 2H), 7.41-7.51 (m, 2H), 7.24 (s, 1H), 6.68 (d, J=8.8 Hz, 2H), 4.67 (d, J=6.8 Hz, 1H), 3.66 (d, J=5.4 Hz, 2H), 2.63 (t, J=5.6 Hz, 2H), 1.31 (s, 9H), 1.12 (d, J=6.8 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H). MS(M+1): 465.

Compound 20-5: (S)-3-(4-((1-(5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-yl)-2-(2′,4′,6′-trimethyl-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 10.42 (s, 1H), 10.35 (s, 1H), 8.08 (s, 1H), 7.84 (d, J=8.3 Hz, 2H), 7.47-7.60 (m, 4H), 7.32-7.47 (m, J=7.8 Hz, 2H), 6.95-7.04 (m, J=7.8 Hz, 2H), 6.88 (s, 2H), 6.63 (d, J=8.8 Hz, 2H), 6.53 (d, J=8.8 Hz, 1H), 3.18 (br. s., 3H), 2.39-2.54 (m, 4H), 2.24 (s, 3H), 1.88 (s, 6H), 1.30 (s, 9H). S(M+1): 631.

Compound 20-6: (S)-3-(4-((1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)-2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 10.41 (s, 1H), 8.10 (t, J=5.6 Hz, 1H), 7.88 (d, J=6.0 Hz, 2H), 7.72-7.80 (m, 3H), 7.48-7.69 (m, 8H), 7.36 (t, J=8.0 Hz, 1H), 6.65 (d, J=8.8 Hz, 2H), 6.55 (d, J=8.8 Hz, 1H), 4.36 (td, J=9.2, 4.0 Hz, 1H), 3.30-3.46 (m, 2H), 3.23 (dd, J=12.0, 8.0 Hz, 1H), 3.05 (m, 1H), 2.55 (s, 3H), 2.45-2.49 (m, 2H). MS(M+1): 655.

Compound 20-7: (S)-2-(4-((1-(5-(3-methylbenzofuran-2-yl)-1,3,4-oxadiazol-2-yl)-2-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)ethyl)amino)benzamido)ethane-1-sulfonic acid

¹H NMR (400 MHz, DMSO-d₆): δ 10.43 (s, 1H), 8.15 (d, J=8.8 Hz, 1H), 7.98 (dd, J=8.6, 2.7 Hz, 2H), 7.84-7.91 (m, 3H), 7.65-7.81 (m, 8H), 7.48-7.63 (m, 1H), 6.76-6.91 (d, J=8.8 Hz, 2H), 6.65-6.74 (m, 1H), 4.54 (br. s., 1H), 4.39 (br. s., 2H), 3.19-3.43 (m, 2H), 2.98-3.19 (m, 2H), 2.55 (s, 3H). MS(M+1): 661.

Example 21: Synthesis of Compounds 21-1 to 21-3

Compound 21-1: (S)-3-(4-((1-(5-(4-(tert-butyl)phenyl)-1,2,4-oxadiazol-3-yl)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ8.00 (d, J=8.0 Hz, 2H), 7.56 (d, J=8.0 Hz, 2H), 7.51 (d, J=8.8 Hz, 2H), 6.81 (s, 1H), 6.58 (d, J=8.0 Hz, 2H), 3.92 (m, 1H), 3.65 (m, 2H), 2.99 (t, J=6.0 Hz, 2H), 2.63 (t, J=6.0 Hz, 2H), 1.56 (m, 2H), 1.19-1.42 (m, 13H), 0.78-1.01 (m, 4H). MS(M+1): 493.

Compound 21-2: 3-(4-(((2R)-1-(5-(4-(tert-butyl)phenyl)-1,2,4-oxadiazol-3-yl)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.95-7.99 (m, 2H), 7.39-7.56 (m, 4H), 7.24 (s, 1H), 6.55 (d, J=8.8 Hz, 3H), 3.82-3.99 (m, 1H), 3.64 (s, 2H), 2.89-3.03 (m, 2H), 2.64 (t, J=5.9 Hz, 2H), 1.32 (s, 9H), 1.24 (s, 2H), 0.80-1.04 (m, 6H). MS(M+1): 493

Compound 21-3: (R)-3-(4-((1-(5-(4-(tert-butyl)phenyl)-1,2,4-oxadiazol-3-yl)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.97 (d, J=8.4 Hz, 3H), 7.37-7.60 (m, 4H), 6.55 (d, J=8.4 Hz, 2H), 3.74-3.90 (m, 1H), 3.57-3.73 (m, 2H), 2.89-3.04 (m, 2H), 2.62 (m, 2H), 1.83-1.99 (m, 1H), 1.15-1.38 (m, 13H), 0.98 (m, 6H). MS(M+1): 479.

Reaction Scheme VI illustrates the general procedures that can be used to synthesize the following compounds of the formula (I) of the present disclosure.

Step I: OH Protection

L-Norleucinol (10.40 g, 88 mmol) was dissolved in anhydrous DCM (150 mL), TBDPSCl (48.78 g, 117 mmol) and Et₃N (26 mL, 195 mmol) was added to the solution. The reaction mixture was stirred overnight. The aqueous phase extracted with CH₂Cl₂. Drying by MgSO₄ and concentration to give a crude product. Purification of the crude oil residue by column chromatography (EA:Hex=15:100) afforded colorless oil product, Compound VI-a.

Step II: Pd-Coupling

To a solution of Pd(OAc)₂ (0.22 g, 1 mmol), BINAP (1.24 g, 2 mmol), Cesium carbonate (6.51 g, 20 mmol), ethyl 4-(trifluoromethylsulfonyloxy)benzoate (3.57 g, 12 mmol), and L-Norleucinol-TBDPS, Compound VI-a (3.55 g, 10 mmol) in 100 mL toluene were purged with nitrogen for 30 min. The mixture was stirred in an oil bath at 90° C. overnight. Cool the mixture to ambient temperature, dilute with EtOAc, filter through Celite washing with EtOAc. The mixture was washed with water and brine, dried the organic layer over MgSO₄, and concentrate to obtain the crude mixture. The residue was purified by silica gel chromatography to give brown oil product, Compound VI-b.

Step III: Deprotection

To a solution of SM, Compound VI-b (9.2 g, 17.1 mmol) in THF (20 mL) was added TBAF (52 mL, 52 mmol, 1M in THF) at room temperature. The mixture was stirred overnight, diluted with water, and extracted with ethyl acetate. The combined organic layers were washed with brine and dried over MgSO₄. Solvent was carefully removed under vacuum. The residue was purified by flash column chromatography on silica gel (EA:Hex=15:100) to give 4.24 g (93%) of a light yellow liquid, Compound VI-c.

¹H NMR (400 MHz, CDCl₃): δ 7.80-7.84 (m, 2H), 6.54-6.58 (m, 2H), 4.08-4.12 (m, 1H), 3.70-3.74 (m, 1H), 3.56-3.61 (m, 1H), 1.45-1.65 (m, 2H), 1.27-1.37 (m, 6H), 0.84-0.91 (m, 3H).

Step IV

To a clean oven-dried 250 mL flask with a magnetic stirring bar was charged with 1,1-carbonyldiimidazole (3.40 g, 21 mmol) and 20 mL THF under nitrogen. The flask was cooled in a ice-water bath. A solution of alcohol, Compound VI-c (2.79 g, 10.5 mmol) in 20 mL THF was added slowly and stirred for 0.5 h. Most solvent was removed in vacuo by a rotavaporator and the crude product 4.6 g (122%) of a yellow liquid (Compound VI-c′), no further purification to use directly in next reaction.

Step V: Synthesis of (S)-2-(4-(ethoxycarbonyl)phenylamino)hexyl hydrazinecarboxylate

To a solution of hydrazine hydrate (1.05 g, 21 mmol) was added dropwise to a solution of Compound VI-c′ (4.6 g. 10.5 mmol) in THF (100 mL). The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated and extracted with EA to obtain white solid crude product, Compound VI-d (3.7 g, 109%). No further purification to use directly in next reaction.

Step VI. Synthesis of (S)-2-(4-(ethoxycarbonyl)phenylamino)hexyl 2-(4-tert-butylbenzoyl)hydrazinecarboxylate

To a Solution of Compound VI-d (1.90 g, 5.88 mmol), tert-butylbenzoic acid (1.15 g, 6.47 mmol), EDCI (1.69 g, 8.81 mmol) and HOBt (1.35 g, 8.81 mmol) in 20 mL DMF. The reaction was stirred at room temperature for overnight then concentrated in vacuo. Water was added to the residue and the aqueous layer was extracted with ethyl acetate. It was further concentrated in vacuo to give a residue. Purification of the crude oil residue by column chromatography (EA:Hex=25:100) afforded colorless oil product, Compound VI-d′ (2.2 g, 75%).

Step VII. Annulations

Compounds VI-d′ (2.20 g, 4.42 mmol), TsCl (1.34, 13.26 mmol), and TEA (2 mL, 13.26 mmol) were mixed in ACN (20 mL) was stirred at room temperature for 1 hr. To this reaction solution, concentrated to remove methanol and extracted with EtOAc. The organic layer was washed with water and dried over anhydrous magnesium sulfate. It was filtered, the solvent evaporated under reduced pressure. Purification of the crude oil residue by column chromatography (EA:Hex=20:100) afforded colorless oil product, Compound VI-e.

Step VIII: Hydrolysis

Compound VI-e (2.05 g, 4.42 mmol) was dissolved in dioxane (20 mL) followed by addition of 2M/LiOH(aq) 20 mL. The reaction mixture was heat to 60° C. for 1 hr. The reaction was monitored by TLC. With completion of the reaction, the solvent was removed by rotary evaporation and was added HCl(a) to pH4-5. The mixture cpd. was extracted with EtOAc. The combined organic layer was dried with anhydrous MgSO₄ and concentrated in vacuo to give white solid crude, Compound VI-f (1.50 g, 78%, two steps yield).

Step IX: Amidation

A solution of Compound VI-f, f-alanine ethyl ester hydrochloride, EDCI, Et₃N and HOBt in dry THF. The reaction was stirred at room temperature for overnight then concentrated in vacuo. Water was added to the residue and the aqueous layer was extracted with ethyl acetate. It was further concentrated in vacuo to give a residue. Purification of the crude oil residue by column chromatography (EA:Hex=60:100) afforded colorless oil product, Compound VI-g.

Step X. Hydrolysis

Compound VI-g (1.84 g, 3.43 mmol) was dissolved in THF (20 mL) followed by addition of 2M/LiOH(aq) 20 mL. The reaction mixture stirred at room temperature for overnight. The reaction was monitored by TLC. With completion of the reaction, the solvent was removed by rotary evaporation and was added HCl_(aq) to pH4-5. The mixture cpd. was extracted with EtOAc. The combined organic layer was dried with anhydrous MgSO₄ and concentrated in vacuo to give brown oil product, Compound VI-h.

Example 22: Synthesis of Compounds 22-1 to 22-20

Compound 22-1:3-(4-(((2S,3S)-1-((5-(2-fluoro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.37 (d, J=2.0 Hz, 1H), 8.47 (m, 1H), 7.82-7.95 (m, 4H), 7.70-7.82 (m, 2H), 7.59-7.70 (m, 1H), 4.85 (dt, J=7.6, 4.0 Hz, 1H), 4.41-4.57 (m, 2H), 3.41-3.55 (m, 2H), 2.51-2.55 (m, 2H), 1.78-1.92 (m, 1H), 1.28-1.46 (m, 1H), 1.07-1.28 (m, 1H), 0.81-0.96 (m, 3H), 0.75 (d, J=6.8 Hz, 3H). MS(M+1): 539.

Compound 22-2: (S)-3-(4-((1-((5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.40 (s, 1H), 8.40-8.56 (m, 1H), 7.92 (d, J=8.8 Hz, 2H), 7.85 (s, 4H), 7.43 (d, J=7.6 Hz, 2H), 4.63-4.86 (m, 1H), 4.48-4.61 (m, 1H), 4.24-4.44 (m, 1H), 2.52 (m, 2H), 1.46-1.75 (m, 2H), 1.07-1.39 (m, 4H), 0.82 (t, J=6.8 Hz, 3H). MS(M+1): 537.

Compound 22-3: (S)-3-(4-((1-((5-(2-fluoro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 10.41 (d, J=2.0 Hz, 1H), 8.47 (t, J=5.6 Hz, 1H), 7.74-7.89 (m, 6H), 7.62-7.69 (m, 1H), 4.68-4.79 (m, 1H), 4.52-4.67 (m, 1H), 4.34-4.43 (m, 1H), 3.43-3.52 (m, 2H), 2.51-2.57 (m, 2H), 1.46-1.71 (m, 2H), 1.11-1.36 (m, 4H), 0.78-0.90 (m, 3H). MS(M+1): 539.

Compound 22-4: (S)-3-(4-((1-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.28 (s, 1H), 8.47 (t, J=5.6 Hz, 1H), 7.82-7.91 (m, 6H), 7.76 (d, J=7.8 Hz, 2H), 7.67 (d, J=8.3 Hz, 2H), 7.54 (s, 1H), 7.45 (ddd, J=8.4, 7.2, 1.5 Hz, 1H), 7.28-7.37 (m, 2H), 4.79 (br. s., 1H), 4.60 (t, J=8.1 Hz, 1H), 4.42 (dd, J=8.6, 3.2 Hz, 1H), 3.44-3.50 (m, 3H), 1.49-1.75 (m, 3H), 1.26 (td, J=14.3, 6.6 Hz, 6H), 0.83 (t, J=6.8 Hz, 3H). MS(M+1): 493.

Compound 22-5: (S)-3-(4-((1-((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.51 (s, 1H), 8.50 (t, J=5.4 Hz, 2H), 8.00 (d, J=7.8 Hz, 4H), 7.79-7.90 (m, 12H), 4.72-4.83 (m, 2H), 4.57 (t, J=7.8 Hz, 2H), 4.37 (dd, J=8.6, 3.2 Hz, 2H), 3.43-3.48 (m, 6H), 1.51-1.74 (m, 4H), 1.13-1.40 (m, 111H), 0.77-0.89 (m, 8H). MS(M+1): 521.

Compound 22-6: (S)-3-(4-((1-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.37 (s, 1H), 8.47 (t, J=5.4 Hz, 1H), 7.79-7.91 (m, 4H), 7.42-7.48 (m, 2H), 4.57 (t, J=8.1 Hz, 1H), 3.42-3.49 (m, 4H), 1.13-1.40 (m, 7H), 0.73-0.91 (m, 5H). MS(M+1): 522.

Compound 22-7: 3-(4-(((2S,3 S)-1-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 9.42 (s, 1H), 7.94-7.99 (m, 2H), 7.88-7.94 (m, 2H), 7.83 (br. s., 1H), 7.76 (d, J=7.8 Hz, 1H), 7.60 (dd, J=8.3, 1.0 Hz, 1H), 7.42-7.51 (m, 2H), 7.29-7.37 (m, 1H), 4.89-4.97 (m, 1H), 4.58-4.72 (m, 2H), 3.61-3.69 (m, 2H), 2.62-2.69 (m, 2H), 1.43-1.56 (m, 1H), 1.23-1.36 (m, 1H), 0.98 (t, J=7.3 Hz, 3H), 0.86 (d, J=6.8 Hz, 3H). MS(M+1): 493.

Compound 22-8: 3-(4-(((2S)-3-methyl-1-((5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.35 (s, 1H), 8.46 (t, J=4.0 Hz, 1H), 7.93 (d, J=8.0 Hz, 2H), 7.87 (s, 4H), 7.43 (d, J=8.0 Hz, 2H), 4.85 (m, 1H), 4.39-4.54 (m, 2H), 3.47 (m, 2H), 2.45-2.58 (m, 2H), 1.77-1.90 (m, 1H), 1.30-1.44 (m, 1H), 1.12-1.22 (m, 1H), 0.84-0.96 (d, J=8.0 Hz, 3H), 0.76 (d, J=8.0 Hz, 3H). MS(M+1): 537.

Compound 22-9: 3-(4-(((2S)-1-((5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.07 (s, 1H), 8.46 (s, 1H), 7.87 (s, 4H), 7.74 (d, J=8.0 Hz, 2H), 7.45 (d, J=8.0 Hz, 2H), 4.83-4.85 (m, 1H), 4.44-4.47 (m, 2H), 3.46-3.49 (m, 2H), 2.50-2.55 (m, 2H), 1.77-1.94 (m, 1H), 1.32-1.46 (m, 1H), 1.30 (s, 9H), 1.07-1.25 (m, 1H), 0.90 (t, J=8.0 Hz, 3H), 0.76 (d, J=8.0 Hz, 3H). MS(M+1): 509.

Compound 22-10: 3-(4-(((2S,3S)-3-methyl-1-((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.48 (s, 1H), 8.48 (s, 1H), 8.00 (d, J=7.8 Hz, 2H), 7.87 (s, 4H), 7.82 (d, J=8.3 Hz, 4H), 4.81-4.90 (m, 1H), 4.42-4.54 (m, 2H), 3.46 (d, J=5.9 Hz, 3H), 1.78-1.90 (m, 1H), 1.38 (s, 1H), 1.12-1.23 (m, 1H), 0.90 (t, J=7.3 Hz, 3H), 0.76 (d, J=6.8 Hz, 3H). MS(M+1): 521

Compound 22-11: 3-(4-(((2S,3S)-1-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)oxy)-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.33 (s, 1H), 8.47 (t, J=5.4 Hz, 2H), 7.80-7.91 (m, 7H), 7.45 (s, 3H), 4.84 (dt, J=7.6, 3.5 Hz, 1H), 4.43-4.55 (m, 3H), 1.08-1.46 (m, 3H), 0.88-0.92 (m, 3H), 0.74 (d, J=6.8 Hz, 3H). MS(M+1): 522.

Compound 22-12: (S)-3-(4-((1-((5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.26 (s, 1H), 8.48 (t, J=5.4 Hz, 2H), 7.83-7.93 (m, 8H), 7.76 (d, J=7.3 Hz, 2H), 7.67 (d, J=8.3 Hz, 2H), 7.53 (d, J=1.0 Hz, 2H), 7.45 (td, J=7.7, 1.2 Hz, 2H), 7.29-7.37 (m, 2H), 4.76-4.85 (m, 1H), 4.49-4.58 (m, 2H), 3.44-3.50 (m, 2H), 2.11 (d, J=3.4 Hz, 1H), 0.92 (d, J=6.8 Hz, 3H), 0.78 (d, J=6.8 Hz, 3H). MS(M+1): 479.

Compound 22-13: (S)-3-(4-((3-methyl-1-((5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)butan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.49 (s, 1H), 8.52 (t, J=5.4 Hz, 2H), 8.00 (d, J=8.3 Hz, 5H), 7.84-7.92 (m, 9H), 7.82 (d, J=8.3 Hz, 5H), 4.74-4.83 (m, 2H), 4.48 (d, J=5.9 Hz, 5H), 3.42-3.48 (m, 6H), 2.46 (t, J=7.1 Hz, 5H), 2.11 (td, J=6.8, 3.4 Hz, 2H), 0.91 (d, J=7.3 Hz, 6H), 0.78 (d, J=6.8 Hz, 3H). MS(M+1): 507.

Compound 22-14: (S)-3-(4-((1-((5-(2,4-dichlorophenyl)-1,3,4-oxadiazol-2-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ8.05 (t, J=5.4 Hz, 1H), 7.85-7.92 (m, 2H), 7.83 (d, J=8.3 Hz, 3H), 7.62-7.65 (m, 2H), 7.61 (d, J=8.3 Hz, 2H), 7.57 (d, J=8.8 Hz, 3H), 7.22-7.43 (m, 9H), 7.10 (d, J=8.8 Hz, 1H), 4.12 (d, J=8.3 Hz, 1H), 3.79 (dd, J=13.9, 6.6 Hz, 2H), 2.98 (d, J=7.8 Hz, 3H), 2.46 (t, J=7.3 Hz, 3H), 1.00 (d, J=6.4 Hz, 4H), 0.90 (d, J=6.4 Hz, 3H). MS(M+1): 508.

Compound 22-15: (S)-3-(4-((3-methyl-1-((5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)oxy)butan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ12.19 (br. s., 1H), 10.35 (s, 1H), 8.46 (m, 1H), 7.82-7.95 (m, 6H), 7.43 (d, J=8.0 Hz, 2H), 4.70-4.81 (m, 1H), 4.47 (m, 2H), 3.40-3.62 (m, 2H), 2.51-2.55 (m, 2H), 2.06-2.19 (m, 1H), 0.91 (d, J=6.8 Hz, 3H), 0.78 (d, J=6.8 Hz, 3H). MS(M+1): 523.

Compound 22-16: (S)-3-(4-((1-((5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)-3-methylbutan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.08 (s, 1H), 8.46 (s, 1H), 7.87-7.92 (m, 4H), 7.74 (d, J=8.4 Hz, 2H), 7.42-7.56 (m, 2H), 4.76-4.77 (m, 1H), 4.46-4.47 (m, 2H), 3.46-3.48 (m, 2H), 2.50-2.57 (m, 2H), 1.30 (s, 9H), 0.91 (d, J=6.8 Hz, 3H), 0.78 (d, J=6.8 Hz, 3H). MS(M+1): 495.

Compound 22-17: (S)-3-(4-((1-((5-(2-fluor-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)-3-methylbutan-2-yl)amino)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.38 (s, 1H), 8.47 (t, J=5.6 Hz, 1H), 7.74-7.91 (m, 6H), 7.62-7.69 (m, 1H), 4.67-4.81 (m, 1H), 4.42-4.62 (m, 2H), 3.37-3.59 (m, 2H), 2.46-2.55 (m, 2H), 1.98-2.16 (m, 1H), 0.89-0.96 (d, J=6.4 Hz, 3H), 0.76 (d, J=6.4 Hz, 3H). MS(M+1): 525.

Compound 22-18: (S)-3-(4-((1-((5-(4-(tert-butyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy)hexan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ12.21 (br. s., 1H), 10.12 (s, 1H), 8.47 (t, J=5.6 Hz, 1H), 7.87 (s, 4H), 7.76 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz, 2H), 4.74 (m, 1H), 4.54 (m, 1H), 4.35 (m, 1H), 3.40-3.59 (m, 2H), 3.35 (m, 1H), 2.44-2.61 (m, 2H), 1.58-1.66 (m, 1H), 1.16-1.29 (m, 13H), 0.83 (t, J=6.8 Hz, 3H). MS(M+1): 509.

Compound 22-19: 3-(4-(((2S,3S)-1-((5-(2-chloro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)oxy-3-methylpentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, CDCl₃): δ 7.72-7.85 (m, 3H), 7.60-7.70 (m, 3H), 7.50-7.59 (m, 2H), 4.60 (dt, J=7.8, 3.9 Hz, 1H), 4.49 (t, J=8.0 Hz, 1H), 4.32-4.37 (m, 1H), 3.65 (t, J=6.0 Hz, 2H), 2.64 (t, J=6.0 Hz, 2H), 1.84-1.97 (m, 1H), 1.09-1.34 (m, 2H), 0.83-0.96 (t, J=8.0 Hz, 3H), 0.78 (d, J=6.8 Hz, 3H). MS(M+1): 555.

Compound 22-20: Methyl 3-(4-(((2S,3S)-1-((5-(2-fluoro-4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl) oxy)-3-methylpentan-2-yl)amino)benzamido)propanoate

¹H NMR (400 MHz, CDCl₃): δ 8.24 (t, J=7.6 Hz, 1H), 7.75 (d, J=8.8 Hz, 2H), 7.65 (d, J=8.0 Hz, 2H), 7.49 (dd, J=8.0, 1.2 Hz, 1H), 7.36 (d, J=8.0 Hz, 1H), 7.29 (dd, J=8.0 Hz, 8.0 Hz, 1H), 4.56-4.59 (m, 1H), 4.50 (t, J=8.4 Hz, 1H), 4.37 (dd, J=8.0, 4.0 Hz, 1H), 3.66 (s, 3H), 3.63 (t, J=6.4 Hz, 2H), 2.62 (t, J=6.4 Hz, 2H), 1.85-1.99 (m, 1H), 1.23-1.36 (m, 1H), 1.09-1.23 (m, 1H), 0.91 (t, J=8.0 Hz, 3H), 0.78 (d, J=6.8 Hz, 3H). MS(M+1): 553.

Reaction Scheme VII illustrates the general procedures that can be used to synthesize the following compounds of the formula (I) of the present disclosure.

Herein, Reaction Scheme VII′ as one example of Reaction Scheme VII illustrates the general procedures that can be used to synthesize the following compounds of the formula (I) of the present disclosure.

Step I: Synthesis of (R)-tert-butyl 3-(4-iodophenyl)-1-oxo-1-(4-(trifluoromethoxy)phenylamino) propan-2-ylcarbamate

To a mixture of (R)-2-((tert-butoxycarbonyl)amino)-3-(4-iodophenyl)propanoic acid (3.91 g, 10 mmol), EDCI (2.30 g, 12 mmol) and HOBt (1.51 g, II mmol) in anhydrous THF (50 ml) was added and stirred at 0° C. for 30 min. 4-(trifluoromethoxy)benzenamine (2.13 g, 12 mmol) and N-Ethyldiisopropylamine (3.48 ml, 20 mmol) were added to the mixture and the reaction was stirred at room temperature for 16 hours. The reaction mixture was washed with IN HCl and then saturated NaHCO₃. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (silica gel, ethyl acetate:hexane 1:4) to give the desired product, Compound VII-a. Colorless liquid, yield 4.4 g, 80%.

Step II. Synthesis of tert-butyl (R)-(1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)carbamate

A solution of tert-butyl (R)-(3-(4-iodophenyl)-1-oxo-1-((4-(trifluoromethyl) phenyl)amino)propan-2-yl)carbamate (1.50 g, 2.81 mmol), 4-trifluoromethylphenyl boronic acid (640 mg, 3.37 mmol), palladium acetate(II) (65 mg, 0.28 mmol), triphenylphosphate (150 mg, 0.56 mmol) and 2M K₂CO₃ (5 mL, 9.83 mmol) in EtOH/PhMe (1 mL/6 mL) was heated at 90° C. for 18 h. The reaction mixture was cooled, poured into half-saturated NaHCO_3(aq), and extracted with EtOAc. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was purified by silica gel chromatography to afford the tert-butyl (R)-(1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)carbamate (871 mg, 56.2%).

Step III: Synthesis of(R)-2-amino-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-N-(4-(trifluoromethyl)phenyl)propanamide

The compound tert-butyl (R)-(1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)carbamate (871 mg, 1.58 mmol) was suspended in trifluoroacetic acid (1.8 mL, 23.65 mmol) in anhydrous dichloromethane (20 mL) at room temperature for overnight. After reaction, excess trifluoroacetic acid was neutralized by dropwise addition of Na₂CO_3(aq) until pH=10. Then it was extracted with CH₂Cl₂. The combined organic layer was dried with anhydrous MgSO₄ and concentrated in vacuo to give crude product. It was further purified by silica gel flash column chromatography using dichloromethane and methanol as eluent to give compound (R)-2-amino-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-N-(4-(trifluoromethyl)phenyl)propanamide(695.2 m, 97.5%).

Step IV: Synthesis of ethyl (R)-3-(4-((1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoate

A seal tube was charged with CuI (21 mg, 0.11 mmol, 10 mol %), K₂CO₃ (465 mg, 3.36 mmol), ethyl 3-(4-iodobenzamido)propanoate (430 mg, 1.23 mmol), and (R)-2-amino-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-N-(4-(trifluoromethyl)phenyl)propanamide (506 mg, 1.12 mmol). The seal tube was fitted with a septum and purged with nitrogen before added DMF (1.5 mL). Next, the test tube was capped and stirred in an oil bath at 100° C. for 2 d. The reaction mixture was cooled to room temperature and filtered, washing well with ethyl acetate. The filtrate (25 mL) was washed with NH₄Cl and the acid extracts were washed with EtOAc. The organic layers were dried over MgSO₄, filtered, and concentrated. It was further purified by silica gel flash column chromatography using dichloromethane and methanol as eluent to give compound ethyl (R)-3-(4-((1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoate (385 mg, 51.3%).

Step V: Synthesis of (R)-3-(4-((1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]4-yl)-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoic acid

Ethyl (R)-3-(4-((1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoate (100 mg, 0.15 mmol) was dissolved in MeOH (2 mL)/THF (2 mL) followed by addition of LiOH (2.0 M, 1.0 mL). The reaction mixture was stirred at room temperature for overnight. The reaction was monitored by TLC. With completion of the reaction, the solvent was removed by rotary evaporation and HCl (2.0 M, 5 mL) was added to the mixture. The white solid was collected by suction filtration and air-dried to give the corresponding acid to yield title compound (R)-3-(4-((1-oxo-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoic acid (51.9 mg, 58%).

Example 23: Synthesis of Compounds 23-1 to 23-35

Compound 23-1: (S)-3-(4-((1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-2: (S)-3-(4-((1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-3: (S)-3-(4-((1-oxo-3-phenyl-1-((2′,4′,6′-trimethyl-[1,1′-biphenyl]-4-yl)amino)propan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-4: (S)-3-(4-((4-methyl-1-oxo-1-((4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)amino)pentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ11.78-12.46 (m, 1H), 10.03-10.42 (m, 1H), 8.00-8.09 (m, 1H), 7.85 (s, 2H), 7.79 (s, 2H), 7.72 (d, J=5.9 Hz, 4H), 7.59 (s, 2H), 6.67 (d, J=8.8 Hz, 2H), 6.35-6.43 (m, 1H), 4.05-4.18 (m, 1H), 3.36-3.42 (m, 2H), 2.45 (s, 2H), 1.56-1.85 (m, 3H), 0.98 (d, J=6.4 Hz, 3H), 0.92 (d, J=6.4 Hz, 3H). MS(M+1): 542.

Compound 23-5: (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-6: Ethyl (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-7: Ethyl (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-8: (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.32 (s, 1H), 8.05 (t, J=5.6 Hz, 1H), 7.82-7.88 (m, 4H), 7.69 (d, J=8.8 Hz, 2H), 7.55-7.65 (m, 4H), 7.34-7.39 (m, 2H), 7.16-7.32 (m, 6H), 6.66 (d, J=8.8 Hz, 3H), 6.58 (d, J=8.8 Hz, 2H), 4.37 (d, J=5.9 Hz, 1H), 3.00-3.17 (m, 2H), 2.44 (t, J=7.1 Hz, 2H). MS(M+1): 548.

Compound 23-9: Ethyl (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-(4-fluorophenyl)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-10: (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-(4-fluorophenyl)-1-oxopropan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-11: Ethyl (S)-3-(4-((1-((4-(benzo[b]thiophen-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-12: (S)-3-(4-((1-((4-(benzo[b]thiophen-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.25 (s, 1H), 8.05 (s, 1H), 7.94 (d, J=7.8 Hz, 1H), 7.81 (d, J=7.3 Hz, 1H), 7.69-7.78 (m, 5H), 7.60 (d, J=8.8 Hz, 3H), 7.36 (dd, J=7.6, 1.2 Hz, 1H), 7.34 (dd, J=7.6, 1.2 Hz, 1H), 6.67 (d, J=8.8 Hz, 3H), 6.39 (d, J=8.3 Hz, 1H), 4.05-4.17 (m, 1H), 3.37-3.41 (m, 3H), 2.45 (t, J=7.1 Hz, 3H), 1.55-1.86 (m, 4H), 0.98 (d, J=6.4 Hz, 3H), 0.92 (d, J=6.4 Hz, 3H). MS(M+1): 530.

Compound 23-13: Ethyl (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-14: (S)-3-(4-((1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-15: Ethyl (S)-3-(4-((1-((2′,4′-dichloro-[1,1′-biphenyl]-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-16: (R)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino) benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.83 (s, 1H), 8.29 (t, J=5.6 Hz, 2H), 7.74-7.86 (m, 7H), 7.56-7.64 (m, 4H), 7.21-7.30 (m, 9H), 7.12-7.17 (m, 3H), 3.41-3.48 (m, 4H), 3.00-3.17 (m, 2H), 2.44 (t, J=6.8 Hz, 2H). MS(M+1): 598.

Compound 23-17: Ethyl (S)-3-(4-((1-((4-(tert-butyl)phenyl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-18: (S)-3-(4-((1-((4-(tert-butyl)phenyl)amino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-19: Ethyl (S)-3-(4-((1-((4-(tert-butyl)phenyl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-20: (S)-3-(4-((1-((4-(tert-butyl)phenyl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.40-10.71 (m, 1H), 8.24-8.51 (m, 1H), 7.69-7.93 (m, 6H), 7.50-7.55 (m, 4H), 7.40-7.49 (m, 6H), 725 (d, J=8.8 Hz, 3H), 7.03-7.14 (m, 1H), 6.68 (d, J=8.8 Hz, 3H), 4.34-4.46 (m, 1H), 2.13 (s, 3H), 1.22 (s, 9H). MS(M+1): 538.

Compound 23-21: Ethyl (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-22: (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-23: (S)-3-(4-((1-oxo-3-phenyl-1-((2′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)amino)propen-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-24: (S)-2-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)amino) benzamido)ethane-1-sulfonic acid

¹H NMR (400 MHz, DMSO-d₆): δ 10.29 (s, 1H), 7.92-8.28 (m, 1H), 7.80-7.90 (m, 2H), 7.65-7.73 (m, 2H), 7.57-7.65 (m, 2H), 7.52 (d, J=8.8 Hz, 2H), 7.33-7.38 (m, 2H), 7.16-7.32 (m, 6H), 6.67 (d, J=8.8 Hz, 2H), 4.37 (dd, J=8.1, 6.1 Hz, 1H), 3.42-3.49 (m, 2H), 2.97-3.20 (m, 2H), 2.63 (t, J=7.1 Hz, 2H). MS(M+1): 584.

Compound 23-25: (S)-3-(4-((1-((tert-butyl)phenyl)amino)-1-oxo-3-(2′,4′,6′-trimethyl-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-26: (S)-2-(4-((1-((4-(tert-butyl)phenyl)amino)-1-oxo-3-(2′,4′,6′-trimethyl-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)ethane-1-sulfonic acid

¹H NMR (400 MHz, DMSO-d₆): δ 9.93 (s, 1H), 7.87-8.30 (m, 1H), 7.51 (d, J=8.8 Hz, 3H), 7.34-7.44 (m, 5H), 7.22-7.30 (m, 3H), 6.98 (d, J=7.8 Hz, 3H), 6.87 (s, 3H), 6.69 (d, J=8.8 Hz, 3H), 4.39 (s, 2H), 3.46 (t, J=7.1 Hz, 3H), 3.10 (d, J=7.3 Hz, 3H), 2.61-2.66 (m, 3H), 2.23 (s, 4H), 1.82 (s, 8H), 1.23 (s, 13H). MS(M+1): 642.

Compound 23-27: Ethyl (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-28: Methyl (S)-3-(4-((1-((4-(1H-indol-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-29: (S)-3-(4-((1-((4-(1H-indol-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-30: 3-(4-(((2S,3S)-1-((6-methoxynaphthalen-2-yl)amino)-3-methyl-1-oxopentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.29 (s, 1H), 8.07 (t, 1H), 7.83-7.89 (m, 2H), 7.71-7.76 (m, 2H), 7.55-7.65 (m, 4H), 7.21-7.32 (m, 3H), 6.71 (d, 2H), 6.35 (d, 1H), 4.04 (q, 2H), 3.89 (t, 1H), 3.41 (t, 2H), 1.85-1.95 (m, 1H), 1.63-1.72 (m, 1H), 1.25-1.36 (m, 1H), 1.15 (t, 3H), 0.98 (d, 3H), 0.88 (t, 3H). MS(M+1): 542.

Compound 23-31: 3-(4-(((2S,3S)-1-((4-(benzofuran-2-yl)phenyl)amino)-3-methyl-1-oxopentan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-32: Ethyl (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-methyl-1-oxobutan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 23.

Compound 23-33: (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-methyl-1-oxobutan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-34: (S)-2-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-3-methyl-1-oxobutan-2-yl)amino)benzamido)ethane-1-sulfonic acid

The mass data of this compound is listed in the following Table 23.

Compound 23-35: (S)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-1-oxohexan-2-yl)amino)benzamido) propanoic acid

¹H NMR (400 MHz, Acetone-d₆): δ 9.52 (s, 1H), 7.86 (d, J=8.0 Hz, 2H), 7.79 (d, J=8.0 Hz, 2H), 7.70 (d, J=8.0 Hz, 2H), 7.61 (d, J=8.0 Hz, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.29 (t, J=8.0 Hz, 1H), 7.23 (t, J=8.0 Hz, 1H), 7.19 (s, 1H), 6.74 (d, J=8.0 Hz, 2H), 5.73 (s, 1H), 3.98-4.12 (m, 1H), 3.53-3.63 (m, 2H), 2.60 (d, J=8.0 Hz, 2H), 1.84-1.95 (m, 2H), 1.46-1.59 (m, 2H), 1.34-1.43 (m, 2H), 0.91 (t, J=7.3 Hz, 3H). MS(M+1): 514.

Example 24: Synthesis of Compounds 24-1 to 24-28

Compound 24-1: Ethyl (R)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propenoate

The mass data of this compound is listed in the following Table 24.

Compound 24-2: (R)-3-(4-((1-((4-(benzofuran-2-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.26 (s, 1H), 7.96-8.14 (m, 1H), 7.86 (d, J=8.8 Hz, 2H), 7.74 (d, J=8.8 Hz, 2H), 7.63 (dd, J=7.8, 1.5 Hz, 1H), 7.57-7.61 (m, 3H), 7.20-7.34 (m, 3H), 6.67 (d, J=8.8 Hz, 2H), 6.34-6.45 (m, 1H), 4.05-4.19 (m, 1H), 3.38 (d, J=5.9 Hz, 3H), 2.45 (t, J=7.3 Hz, 2H), 1.56-1.86 (m, 3H), 0.98 (d, J=6.4 Hz, 3H), 0.92 (d, J=6.8 Hz, 3H). MS(M+1): 514.

Compound 24-3: Ethyl (R)-3-(4-((1-oxo-3-phenyl-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-4: (S)-3-(4-((1-oxo-3-phenyl-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.44 (s, 1H), 8.04 (s, 2H), 7.70-7.79 (m, 4H), 7.63-7.69 (m, 4H), 7.57 (d, J=8.8 Hz, 4H), 7.31-7.38 (m, 4H), 7.27 (t, J=7.6 Hz, 4H), 7.19 (d, J=7.3 Hz, 2H), 6.64 (d, J=8.8 Hz, 4H), 6.59 (d, J=8.8 Hz, 2H), 4.28-4.44 (m, 1H), 3.37 (d, J=5.9 Hz, 2H), 2.99-3.16 (m, 2H), 2.44 (t, J=7.1 Hz, 2H). MS(M+1): 500.

Compound 24-5: Ethyl (S)-3-(4-((1-oxo-3-phenyl-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-6: (S)-3-(4-((1-oxo-3-phenyl-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ11.91-12.33 (m, 1H), 10.21-10.61 (m, 1H), 7.92-8.11 (m, 1H), 7.71-7.79 (m, 2H), 7.62-7.69 (m, 2H), 7.53-7.61 (m, 2H), 7.23-7.37 (m, 4H), 7.15-7.22 (m, 1H), 6.61-6.69 (m, 2H), 6.53-6.61 (m, 1H), 4.30-4.43 (m, 1H), 3.34-3.41 (m, 2H), 3.07-3.17 (m, 1H), 2.97-3.07 (m, 1H), 2.62-2.74 (m, 1H), 2.40-2.47 (m, 2H). MS(M+1): 500.

Compound 24-7: Ethyl 3-(4-(((2S,3S)-1-((6-methoxynaphthalen-2-yl)amino)-3-methyl-1-oxopentan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-8:3-(4-(((2S,3S)-1-((6-methoxynaphthalen-2-yl)amino)-3-methyl-1-oxopentan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ12.12 (s, 1H), 10.16 (s, 2H), 8.15 (d, J=1.5 Hz, 2H), 8.03 (t, J=5.6 Hz, 2H), 7.74 (dd, J=12.7, 8.8 Hz, 4H), 7.52-7.64 (m, 7H), 7.25 (d, J=2.4 Hz, 2H), 7.12 (dd, J=8.8, 2.4 Hz, 2H), 6.72 (d, J=8.8 Hz, 4H), 6.32 (d, J=8.8 Hz, 2H), 3.90 (t, J=8.6 Hz, 1H), 3.34-3.43 (m, 2H), 2.45 (t, J=7.1 Hz, 2H), 1.84-1.99 (m, 1H), 1.60-1.75 (m, 1H), 1.22-1.39 (m, 1H), 0.98 (d, J=6.8 Hz, 3H), 0.90 (t, J=7.6 Hz, 3H). MS(M+1): 478.

Compound 24-9: Ethyl (R)-3-(4-((4-methyl-1-oxo-1-((4-(trifluoromethyl)phenyl)amino)pentan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-10: (R)-3-(4-((4-methyl-1-oxo-1-((4-(trifluoromethyl)phenyl)amino)pentan-2-yl)amino) benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ10.45 (s, 1H), 8.05 (s, 2H), 7.81 (d, J=8.8 Hz, 4H), 7.66 (d, J=8.8 Hz, 4H), 7.59 (d, J=8.8 Hz, 4H), 6.65 (d, J=8.8 Hz, 4H), 6.42 (d, J=8.3 Hz, 2H), 4.11 (s, 2H), 3.35-3.41 (m, 5H), 2.44 (t, J=7.3 Hz, 4H), 1.56-1.84 (m, 6H), 0.97 (d, J=6.4 Hz, 6H), 0.90 (d, J=6.4 Hz, 3H). MS(M+1): 466.

Compound 24-11: Ethyl (S)-3-(4-((1-(isopropylamino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-12: (S)-3-(4-((1-(isopropylamino)-3-(naphthalen-1-yl)-1-oxopropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ11.85-12.36 (m, 1H), 8.15 (d, J=8.3 Hz, 2H), 8.05 (t, J=5.6 Hz, 2H), 7.91 (d, J=6.8 Hz, 2H), 7.79 (d, J=7.8 Hz, 4H), 7.49-7.60 (m, 7H), 7.38-7.46 (m, 4H), 6.58 (d, J=8.8 Hz, 4H), 4.19 (br. s., 2H), 3.75 (dd, J=14.2, 6.8 Hz, 2H), 3.42-3.52 (m, 2H), 3.35-3.40 (m, 5H), 2.45 (t, J=7.1 Hz, 4H), 0.96 (d, J=6.8 Hz, 5H), 0.78 (d, J=6.4 Hz, 3H). MS(M+1): 448.

Compound 24-13: Ethyl (S)-3-(4-((1-(isopropylamino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-14: (S)-3-(4-((1-(isopropylamino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)amino)benzamido)propanoic acid

¹H NMR (400 MHz, DMSO-d₆): δ 8.04 (s, 1H), 7.72-7.89 (m, 9H), 7.56 (d, J=8.8 Hz, 2H), 7.41-7.51 (m, 3H), 6.60 (d, J=8.8 Hz, 2H), 6.31-6.44 (m, 1H), 4.12-4.26 (m, 1H), 3.69-3.84 (m, 1H), 3.38 (d, J=5.4 Hz, 2H), 3.10 (d, J=2.0 Hz, 2H), 2.45 (t, J=7.1 Hz, 2H), 0.98 (d, J=6.8 Hz, 3H), 0.81 (d, J=6.8 Hz, 3H). MS(M+1): 448.

Compound 24-15: Ethyl (R)-3-(4-((3-(4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)-1-oxo-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-16: (R)-3-(4-((3-(4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)-1-oxo-1-((4-(trifluormethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 24.

Compound 24-17: Ethyl (R)-3-(4-((3-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)-1-oxo-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-18: (R)-3-(4-((3-(2′,4′-dichloro-[1,1′-biphenyl]-4-yl)-1-oxo-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 24.

Compound 24-19: Ethyl (R)-3-(4-((3-(4-(benzofuran-2-yl)phenyl)-1-oxo-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-20: (R)-3-(4-((3-(4-(benzofuran-2-yl)phenyl)-1-oxo-1-((4-(trifluoromethyl)phenyl)amino)propan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 24.

Compound 24-21: Ethyl (R)-3-(4-((3-(4-(benzofuran-2-yl)phenyl)-1-(isopropylamino)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-22: (R)-3-(4-((3-(4-(benzofuran-2-yl)phenyl)-1-(isopropylamino)-1-oxopropan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 24.

Compound 24-23: Ethyl (R)-3-(4-((3-(4-(benzofuran-2-yl)phenyl)-1-((3,5-difluorophenyl)amino)-1-oxopropan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-24: (R)-3-(4-((3-(4-(benzofuran-2-yl)phenyl)-1-((3,5-difluorophenyl)amino)-1-oxopropan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 24.

Compound 24-25: Ethyl (R)-3-(4-((3-(4′-(tert-butyl)-[1,1′-biphenyl]-4-yl)-1-oxo-1-((4-(trifluoromethoxy)phenyl)amino)propan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-26: (R)-3-(4-((3-(4′-(tat-butyl)-[1,1′-biphenyl]-4-yl)-1-oxo-1-((4-(trifluoromethoxy)phenyl)amino)propan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 24.

Compound 24-27: Ethyl (R)-3-(4-((1-oxo-1-((4-(trifluoromethoxy)phenyl)amino)-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoate

The mass data of this compound is listed in the following Table 24.

Compound 24-28: (R)-3-(4-((1-oxo-1-((4-(trifluoromethoxy)phenyl)amino)-3-(4′-(trifluoromethyl)-[1,1′-biphenyl]-4-yl)propan-2-yl)amino)benzamido)propanoic acid

The mass data of this compound is listed in the following Table 24.

In EXAMPLES 1-24, the detail synthesized procedures of some compounds are not repeated again if the synthesized procedures thereof are similar to those of the forgoing compounds.

Example 25: Evaluation of Compounds of Formula (I) in In Vitro Assays

Glucagon cAMP Inhibition Assay

Downstream secondary messenger cAMP induced by glucagon was detected by Cisbio cAMP Dynamic 2 kit. Testing compounds were each prepared as a dimethyl sulfoxide (DMSO) solution at the concentration of 10 mM. To evaluate the potency of compounds in inhibiting the cAMP production, glucagon receptor (GCGR) overexpressed CHO-K1 cells or human primary hepatocytes were treated with compounds with a serial dilution. The cells were re-suspended in Hank's Balanced Salt solution (HBSS) contained 0.1% (w/v) bovine serum albumin and 800 nM 3-isobutyl-1-methylxanthine (IBMX) and seeded into low volume, 384 wells white plate. The diluted compounds were then added into the plate for 30 minutes pre-incubation where the final DMSO concentration was 1%. The cells were stimulated with glucagon at the concentration equaled to EC50 (an indicium of the concentration of a drug that gives half-maximal response) for 30 minutes at room temperature. After incubation, lysis buffer contain cAMP antibody and fluorescence acceptor were added into each well for additional 60 minutes incubation. Results were recorded by Molecular Devices SpectraMax Paradigm with the HTRF Detection Cartridges and the IC₅₀ value of each compound in inhibiting the cAMP production was calculated with non-linear regression based on the amount of cAMP production.

I¹²⁵-Glucagon binding assay

The binding affinity of each compound was evaluated by a competition assay with I¹²⁵-glucagon. GCGR membrane fractions were obtained from GCGR overexpressed CHO-K1 cells as a stock of 1 mg/ml concentration. To evaluate the IC₅₀ of compounds binding to GCGR, GCGR membrane fractions were treated with compounds with a serial dilution. The membrane fractions were diluted to 7.5 microgram per well in 70 microliter assay buffer contained 50 mM Tris pH 7.4 and 0.5% (w/v) bovine serum albumin and added into 96 wells plate. The membrane fractions were then mixed with 10 microliter diluted compounds. After 5 minutes pre-incubation, 20 microliter I¹²⁵ labeled glucagon (Perkin Elmer) was added into each well at the final concentration of 0.0625 nM. The assay mixtures were incubated at 25° C. for 30 minutes and then transferred onto the Millipore MultiScreen GF/B Plate coated with 0.5% (w/v) Polyethyleneimine. The filter plate was washed with wash buffer contained 50 mM Tris pH 7.4 for 2 times, 300 microliter each time. The residual isotope was detected by Hidex CHAMELEON V micro-beta counter and the IC₅₀ value of each compound binding to GCGR was calculated with non-linear regression.

The compounds prepared in EXAMPLES 1-24 were tested in two in vitro assays described below. The results are shown in Tables 1-24 shown below.

TABLE 1
					IC50binding	IC50cAMP
Compound	R1	R9	R5	Chirality	(nM)a	(nM)
1-1	isopropyl	Benzofuranyl	Ethyl	S	802.5	1177
			propionate
1-2	isopropyl	Benzofuranyl	Propanoic acid	S	207	195.6
1-3	2-butyl	4-tert-butyl	Propanoic acid	S	319	884.4
		phenyl
1-4	2-butyl	Benzofuranyl	Propionic acid	S	184	528
1-5	2-butyl	4-(trifluoro-	Propionic acid	S	213	839
		methyl)phenyl
1-6	2-butyl	4-Trifluoro-	Propionic acid	S	228	1078
		methoxy phenyl
1-7	2-butyl	2,4-dichloro	Propionic acid	S	139	494.8
		phenyl
1-8	2-butyl	Benzofuranyl	5-methyl-1H-	S	98	3305
			tertazole
1-9	2-butyl	Benzofuranyl	(R)-2-hydroxy-	S	260	3600
			propanoic acid
1-10	n-butyl	Benzofuranyl	Propionic acid	S	122	629.8
1-11	n-butyl	Trimethyl	Propionic acid	S	150	320.3
		benzene
1-12	isopropyl	N,N-	Propanoic	S	224	414.3
		dimethylaniline	acid
1-13	2-butyl	2,4-dichloro	5-methyl-1H-	S	141	1730
		phenyl	tertazole
1-14	2-butyl	2,4-dichloro	(R)-2-hydroxy-	S	112	3553
		phenyl	propanoic acid
1-15	n-butyl	4-(trifluoro-	Propanoic acid	S	211	338.8
		methyl)phenyl
1-16	n-butyl	4-(trifluoro-	5-methyl-1H-	S	52	948.8
		methyl)phenyl	tertazole
1-17	n-butyl	2,4-dichloro	Propanoic acid	S	34	864.4
		phenyl
1-18	n-butyl	2,4-dichloro	5-methyl-1H-	S	31	1564
		phenyl	tertazole
1-19	n-butyl	2-chloro-4-	Propanoic acid	S	11	93
		(trifluoromethyl)
		phenyl
1-20	n-butyl	2-chloro-4-	5-methyl-1H-	S	96	524
		(trifluoromethyl)	tertazole
		phenyl
1-21	isopropyl	N,N-	(R)-2-hydroxy-	S	>30000	>30000
		dimethylaniline	propanoic acid
1-22	isopropyl	2-chloro-4-	Propanoic acid	S	70	14.2
		(trifluoromethyl)
		phenyl
1-23	Phenyl	Benzofuranyl	Propionic acid	—	148	39.8
1-24	isopropyl	4-(trifluoro-	Propanoic acid	S	134	187.5
		methyl)pyridine
1-25	isopropyl	2-fluoro-4-	Propanoic acid	S	44	90.4
		(trifluoromethyl)
		phenyl
1-26	2-butyl	2,4-	Propanoic acid	S	N/A	213
		difluorophenyl
1-27	n-butyl	2-fluoro-4-	Propanoic acid	S	108	96.5
		(trifluoromethyl)
		phenyl
1-28	Phenyl	4-(trifluoro-	Propanoic acid	—	150	287.7
		methyl)phenyl
1-29	isopropyl	6-	Propanoic acid	S	2791	>30000
		(trifluoromethyl)
		pyridazine
1-30	isopropyl	Benzo[d]thiazol-	Ethyl	S	7626	1214
		2-yl	propionate
1-31	isopropyl	benzo[d]thiazole	Methyl	S	5771	83
			propanoate
1-32	isopropyl	Benzo[d]thiazol-	Propanoic	S	57	152
		2-yl	acid
1-33	isopropyl	2-fluoro-4-	Ethanesulfonic	S	1900	3767
		(trifluoromethyl)	acid
		phenyl
1-34	isopropyl	Benzofuranyl	Propanoic acid	R	113	238.7
1-35	isopropyl	2-chloro-4-	Propanoic acid	R	145	209.3
		(trifluoromethyl)
		phenyl
1-36	t-butyl	2,4-	Propanoic acid	S	141	243
		dichlorophenyl
1-37	isopropyl	2-chloro-N,N-	Propanoic acid	S	372	376
		dimethylaniline
1-38	2-butyl	2-chloro-4-	Propanoic acid	S	172	203
		methoxyphenyl
1-39	isopropyl	Imidazo[1,2-a]	Propanoic acid	S	3812	17895
		pyridin-2-yl
1-40	t-butyl	Benzofuranyl	Propanoic acid	S	195	235.3
1-41	isopropyl	furo[3,2-b]	Propanoic acid	S	227	1403
		pyridin-2-yl
1-42	t-butyl	2-chloro-4-	Propanoic acid	S	234	298
		(trifluoromethyl)
		phenyl
1-43	isopropyl	5-(trifluoro-	Propanoic acid	S	583	>30000
		methyl)-1,3,4-
		oxadiazol-2-yl
1-44	2-butyl	5-(trifluoro-	Propanoic acid	S	388	10000
		methyl)-1,3,4-
		oxadiazol-2-yl
1-45	2-butyl	5-(tert-butyl)-	Propanoic acid	5	1522	11981
		1,3,4-
		oxadiazol-2-yl
1-46	2-butyl	5-phenyl-1,3,4-	Propanoic acid	S	601	5441
		oxadiazol-2-yl
1-47	isopropyl	benzo[d]oxazole	Ethyl	S	>30000	170
			propanoate		(56%)
1-48	isopropyl	benzo[d]oxazole	Propanoic acid	S	138	546
1-49	n-butyl	2-(tert-butyl)-	Propanoic acid	S	7200	7065
		1,3,4-
		oxadiazole
1-50	n-butyl	5-phenyl-1,3,4-	Propanoic acid	S	715	1622
		oxadiazole
1-51	isopropyl	Benzo[d]thiazol-	Ethyl	R	>30 uM	197
		2-yl	propanoate
1-52	isopropyl	Benzo[d]thiazol-	Propanoic acid	R	89	377
		2-yl
1-53	isopropyl	benzo[d]oxazole	Ethyl	R	24480	90
			propanoate
1-54	isopropyl	benzo[d]oxazole	Propanoic acid	R	95	213
athe number in pathenthesis represents the percentage of inhibition when a compound was administered at the concentration of 30 μM.

TABLE 2
					IC50binding	IC50cAMP
Compound	R1	R9	R5	Chirality	(nM)	(nM)
2-1	Benzyl	4-	Propanoic	R	266	322.9
		(trifluoromethyl)	acid
		phenyl
2-2	Benzyl	4-Trifluoromethoxy	Propanoic	R	377.5	474.8
		phenyl	acid
2-3	isobutyl	4-Trifluoromethoxy	Propionic	S	465	493
		phenyl	acid
2-4	isopropyl	4-	Propionic	S	91	245.8
		(trifluoromethyl)	acid
		phenyl
2-5	isopropyl	4-tert-butyl phenyl	Propanoic	S	347	352
			acid
2-6	2-butyl	4-tert-butyl phenyl	Propanoic	S	67	448
			acid
2-7	2-butyl	Benzofuranyl	Propanoic	S	158	468
			acid
2-8	2-butyl	4-	Propanoic	S	627	602
		(trifluoromethoxy)	acid
		phenyl
2-9	2-butyl	2,4-dichloro phenyl	Propanoic	S	60	447.6
			acid
2-10	2-butyl	4-	Propanoic	S	90	241.4
		(trifluoromethyl)	acid
		phenyl
2-11	isopropyl	2-chloro-4-	Propanoic	S	872	277.2
		(trifluoromethyl)	acid
		phenyl
2-12	n-butyl	Benzofuranyl	Propanoic	S	108	62.8
			acid
2-13	n-butyl	Benzofuranyl	5-methyl-	S	167	148.5
			1H-tertazole

TABLE 3
					IC50binding	IC50cAMP
Compound	R1	R9	R5	R7	(nM)	(nM)
3-1	2-butyl	Benzofuranyl	5-methyl-1H-	H	217	1822
			tertazole
3-2	isopropyl	2-chloro-4-	(R)-2-	H	135	>10000
		(trifluoromethyl)	hydroxybutanoic
		phenyl	acid
3-3	isopropyl	2-chloro-4-	5-methyl-1H-	H	86	1250
		(trifluoromethyl)	tertazole
		phenyl
3-4	isopropyl	2-chloro-4-	Propanoic acid	H	17	313.6
		(trifluoromethyl)
		phenyl
3-5	isopropyl	Benzofuranyl	5-methyl-1H	H	117	1863
			tertazole
3-6	isopropyl	Benzofuranyl	(R)-2-	H	184	9291
			hydroxybutanoic
			acid
3-7	isopropyl	Benzofuranyl	Propanoic acid	H	103	363.5
3-8	n-butyl	2-chloro-4-	Propanoic acid	H	26	35
		(trifluoromethyl)
		phenyl
3-9	n-butyl	2-chloro-4-	5-methyl-1H	H	37	528.1
		(trifluoromethyl)	tertazole
		phenyl
3-10	n-butyl	Benzofuranyl	Propanoic acid	H	20	88.7
3-11	n-butyl	Benzofuranyl	5-methyl-1H-	H	149	672.8
			tertazole
3-12	n-butyl	2,4-dichloro phenyl	Propanoic acid	H	30	28.1
3-13	n-butyl	2,4-dichloro phenyl	5-methyl-1H-	H	92	279.9
			tertazole
3-14	isopropyl	Benzofuranyl	Propanoic acid	Cl	58	115.4
3-15	Phenyl	2-chloro-4-	Propanoic acid	H	97	330.4
		(trifluoromethyl)
		phenyl
3-16	n-butyl	4-	Propanoic acid	H	51	367.7
		(trifluoromethyl)
		phenyl
3-17	n-butyl	4-	5-methyl-1H	H	111	105
		(trifluoromethyl)	tertazole
		phenyl
3-18	isopropyl	Benzofuranyl	Ethanesulfonic	H	836	>30000
			acid
3-19	2-butyl	Benzofuranyl	Propanoic acid	Cl	64	130
3-20	2-butyl	2-chloro-4-	Propanoic acid	Cl	73	44
		(trifluoromethyl)
		phenyl
3-21	2-butyl	2-fluoro-4-	Propanoic acid	Cl	295	653
		(trifluoromethyl)
		phenyl
3-22	n-butyl	2-fluoro-4-	Propanoic acid	H	83	54
		(trifluoromethyl)
		phenyl
3-23	t-butyl	Benzofuranyl	Proparioic acid	H	156	293
3-24	t-butyl	2-fluoro-4-	Propanoic acid	H	53	80
		(trifluoromethyl)
		phenyl

TABLE 4
						IC50binding	IC50cAMP
Compound	R1	R2	R5	A1	A3	(nM)	(nM)
4-1	isopropyl	4-(trifluoromethyl)-	Propanoic	N	C	369	626.9
		1,1′-biphenyl	acid
4-2	isopropyl	2-phenylbenzofuran	Propanoic	N	C	90	121.3
			acid
4-3	2-butyl	2,4-dichloro-	Propanoic	N	C	610	414
		biphenyl	acid
4-4	2-butyl	2-(tert-butyl)-5-	Propanoic	N	C	2395	>30000
		phenyl-1,3,4-	acid
		oxadiazole
4-5	2-butyl	2,5-diphenyl-1,3,4-	Propanoic	N	C	708	11200
		oxadiazole	acid

TABLE 5
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
5-1	isopropyl	Benzofuranyl	Propanoic acid	2041	14405
5-2	2-butyl	4-(trifluoromethyl)phenyl	Propanoic acid	1193	2465
5-3	2-butyl	Benzofuranyl	Propanoic acid	400	946.9

TABLE 6
					IC50binding	IC50cAMP
Compound	R1	R9	R3	R5	(nM)	(nM)
6-1	isopropyl	Benzofuranyl	Methyl	Propanoic acid	391	204.2
6-2	isopropyl	Benzofuranyl	n-ethyl	Propanoic acid	645	164.3
6-3	Ethoxymethyl	Benzofuranyl	H	Propanoic acid	479	3859

TABLE 7
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
7-1	isopropyl	Benzofuranyl	Propanoic	93	495
			acid
7-2	isopropyl	2-chloro-4-	Propanoic	177	201
		(trifluoro-	acid
		methyl)phenyl
7-3	isopropyl	4-(trifluoro-	Propanoic	107	140
		methyl)phenyl	acid
7-4	isopropyl	2-fluoro-4-	Propanoic	182	165
		(trifluoro-	acid
		methyl)phenyl
7-5	isobutyl	2-chloro-4-	Propanoic	75	811
		(trifluoro-	acid
		methyl)phenyl
7-6	isobutyl	4-(trifluoro-	Propanoic	144	371
		methyl)phenyl	acid
7-7	isobutyl	2-fluoro-4-	Propanoic	307	689
		(trifluoro-	acid
		methyl)phenyl
7-8	isobutyl	2,4-dichloro-	Propanoic	49	329
		phenyl	acid
7-9	isobutyl	3,5-dichloro-	Propanoic	262	816
		phenyl	acid
7-10	isobutyl	Benzofuranyl	Propanoic	145	730.9
			acid
7-11	isopropyl	2,4-dichloro-	Propanoic	74	209
		phenyl	acid

TABLE 8
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
8-1	isopropyl	2-fluoro-4-	Propanoic acid	112	61.9
		(trifluoromethyl)phenyl
8-2	isopropyl	2-fluoro-4-	Ethanesulfonic	1713	12144
		(trifluoromethyl)phenyl	acid
8-3	isopropyl	Benzofuranyl	Propanoic acid	83	84.4
8-4	isopropyl	Benzofuranyl	Ethanesulfonic	1720	10292
			acid
8-5	isopropyl	2-chloro-4-	Propanoic acid	75	85
		(trifluoromethyl)phenyl
8-6	isobutyl	2-fluoro-4-	Propanoic acid	172	428
		(trifluoromethyl)phenyl
8-7	2-butyl	Benzofuranyl	Propanoic acid	186	129
8-8	2-butyl	2-chloro-4-	Propanoic acid	277	500
		(trifluoromethyl)phenyl
8-9	isopropyl	2,4-dichlorophenyl	Propanoic acid	145	365
8-10	2-butyl	2-fluoro-4-	Propanoic acid	186	353.2
		(trifluoromethyl)phenyl
8-11	2-butyl	2,4-dichlorophenyl	Propanoic acid	51	269.1
8-12	isopropyl	3,5-dichlorophenyl	Propanoic acid	227	1243
8-13	n-butyl	Benzofuranyl	Propanoic acid	44	84
8-14	2-butyl	4-(trifluoromethyl)phenyl	Propanoic acid	251	250
8-15	n-butyl	2-chloro-4-	Propanoic acid	59	129
		(trifluoromethyl)phenyl
8-16	n-butyl	2,4-dichlorophenyl	Propanoic acid	89	135
8-17	n-butyl	2-fluoro-4-	Propanoic acid	308	227.6
		(trifluoromethyl)phenyl
8-18	n-butyl	4-(trifluoromethyl)phenyl	Propanoic acid	158	153.5
8-19	isobutyl	2,4-dichlorophenyl	Propanoic acid	101	182
8-20	isobutyl	Benzofuranyl	Propanoic acid	83	234
8-21	t-butyl	Benzofuranyl	Propanoic acid	111	181
8-22	t-butyl	2,4-dichlorophenyl	Propanolc acid	68	166.9
8-23	t-butyl	2-fluoro-4-	Propanoic acid	81	89.46
		(trifluoromethyl)phenyl
8-24	n-butyl	5-(trifluoromethyl)-1,3,4-	Propanoic acid	366	2701
		oxadiazol-2-yl
8-25	isopropyl	Benzo[d]thiazol-2-yl	Propanoic acid	95	653

TABLE 9
					IC50binding	IC50cAMP
Compound	R1	R2	A1	A3	(nM)	(nM)
9-1	isopropyl	2-phenylbenzofuran	N	N	125	386.1
9-2	2-butyl	2,4-dichloro-1,1′-biphenyl	N	N	363	427
9-3	isopropyl	4-(trifluoromethyl)-1,1′-biphenyl	C	N	120	487
9-4	2-butyl	2,6-difluoro-4′-(trifluorometlyl)-	N	C	1668	2300
		1,1′-biphenyl
9-5	isopropyl	2-(2-fluorophenyl)benzo[d]thiazole	N	C	606	2408
9-6	isopropyl	4-((1-((1-(2,4-difluorophenyl)-1H-	C	C	3650	5577
		pyrazol-4-yl)oxy

TABLE 10
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
10-1	isopropyl	4-(trifluoromethyl)phenyl	Propanoic acid	531	1959
10-2	isopropyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	255	1805
		phenyl
10-3	isopropyl	2-fluoro-4-	Propanoic acid	511	1206
		(trifluoromethyl)phenyl
10-4	isopropyl	2,4-dichlorophenyl	Propanoic acid	445	4036
10-5	isopropyl	3,5-dichlorophenyl	Propanoic acid	441	3690
10-6	isopropyl	Benzofuranyl	Propanoic acid	252	2650
10-7	n-butyl	2,4-dichlorophenyl	Propanoic acid	319	732
10-8	n-butyl	2-fluoro-4-	Propanoic acid	180	344
		(trifluoromethyl)phenyl
10-9	n-butyl	4-(trifluoromethyl)phenyl	Propanoic acid	127	465
10-10	n-butyl	3,5-dichlorophenyl	Propanoic acid	314	493
10-11	n-butyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	270	537.4
		phenyl
10-12	n-butyl	Benzofuranyl	Propanoic acid	181	791.6
10-13	2-butyl	Benzofuranyl	Propanoic acid	224	863.9
10-14	2-butyl	2-fluoro-4-	Propanoic acid	306	497.1
		(trifluoromethyl)phenyl
10-15	2-butyl	2,4-dichlorophenyl	Propanoic acid	179	301
10-16	2-butyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	141	272
		phenyl
10-17	isobutyl	4-(trifluoromethyl)phenyl	Propanoic acid	542	847
10-18	isobutyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	234	880
		phenyl
10-19	isobutyl	2,4-dichlorophenyl	Propanoic acid	301	1064

TABLE 11
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
11-1	isopropyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	1736	8711
		phenyl
11-2	isopropyl	Benzofuranyl	Propanoic acid	926	14398

TABLE 12
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
12-1	isobutyl	3-methyl-4-(trifluoromethyl)-	Propanoic acid	674	14170
		1H-pyrazol-1-yl
12-2	isopropyl	Benzofuranyl	Propanoic acid	266	6849
12-3	isobutyl	Benzofuranyl	Propanoic acid	608	>30000
12-4	isopropyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	539	9828
		phenyl
12-5	n-butyl	2-chloro-4-(trifluromethyl)	Propanoic acid	451	2357
		phenyl
12-6	isopropyl	2,4-dichlorophenyl	Propanoic acid	1667	>30000
12-7	n-butyl	2,4-dichlorophenyl	Propanoic acid	888	3868
12-8	2-butyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	331	2719
		phenyl
12-9	isobutyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	501	19185
		phenyl
12-10	2-butyl	2,4-dichlorophenyl	Propanoic acid	337	890
12-11	isobutyl	2,4-dichlorophenyl	Propanoic acid	233	3585

TABLE 13
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
13-1	2-butyl	Benzofuranyl	Propanoic acid	46	157
13-2	2-butyl	2,4-dichlorophenyl	Propanoic acid	92	254
13-3	2-butyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	57	71
		phenyl
13-4	2-butyl	2-fluoro-4-(trifluoromethyl)	Propanoic acid	68	131
		phenyl
13-5	isopropyl	Benzofuranyl	Propanoic acid	111	112
13-6	isopropyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	89	97
		phenyl
13-7	isopropyl	2,4-dichlorophenyl	Propanoic acid	95	139
13-8	isopropyl	2-fluoro-4-(trifluoromethyl)	Propanoic acid	79	77.8
		phenyl
13-9	n-butyl	2,4-dichlorophenyl	Propanoic acid	54	219
13-10	isoproopyl	4-(trifluoromethyl)phenyl	Propanoic acid	92	246
13-11	n-butyl	4-(trifluoromethyl)phenyl	Propanoic acid	47	118
13-12	2-butyl	5-phenyl-1,3,4-oxadiazol-2-yl	Propanoic acid	608	23347
13-13	2-butyl	5-(tert-butyl)-1,3,4-	Propanoic acid	883	300000
		oxadiazol-2-yl
13-14	n-butyl	2-fluoro-4-(trifluoromethyl)	Propanoic acid	15	66
		phenyl

TABLE 14
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
14-1	isopropyl	Benzofuranyl	Propanoic acid	750	1232
14-2	n-butyl	2-fluoro-4-(trifluoromethyl)	Propanoic acid	74	508
		phenyl

TABLE 15
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
15-1	Phenyl	Benzofuranyl	5-methyl-1H-	388	7356
			tertazole
15-2	Isopropyl	4-	5-methyl-1H-	390	1543
		(trifluoromethyl)phen-	tertazole
		yl
15-3	Isopropyl	Benzofuranyl	Propanoic acid	51	111
15-4	Phenyl	4-t-butylphenyl	Propanoic acid	626	3241
15-5	Phenyl	Benzofuranyl	Propanoic acid	706	2067
15-6	Phenyl	4-t-butylphenyl	(R)-2-	172	>30000
			hydroxypropan-
			oic acid
15-7	Isopropyl	4-	Propanoic acid	753	258.8
		(trifluoromethyl)phen-
		yl
15-8	Isopropyl	4-	(R)-2-	3302	>30000
		(trifluoromethyl)phen-	hydroxy-
		yl	propanoic acid
15-9	Isopropyl	2-chloro-4-	Propanoic acid	330	81.5
		(trifluoromethyl)
		phenyl
15-10	Isobutyl	2-chloro-4-	Propanoic acid	80	198.4
		(trifluoromethyl)
		phenyl
15-11	Isobutyl	4-	Propanoic acid	210	284.7
		(trifluoromethyl)phen-
		yl
15-12	2-butyl	4-	Propanoic acid	376	294
		(trifluoromethyl)phen-
		yl
15-13	2-butyl	2-chloro-4-	Propanoic acid	98	123
		(trifluoromethyl)
		phenyl
15-14	2-butyl	2-fluoro-4-	Propanoic acid	379	280.6
		(trifluoromethyl)phen-
		yl
15-15	2-butyl	Benzofuranyl	Propanoic acid	207	32.73
15-16	Isobutyl	2-fluoro-4-	Propanoic acid	669	999
		(trifluoromethyl)
		phenyl
15-17	Isopropyl	2,4-dichlorophenyl	Propanoic acid	216	196
15-18	Isobutyl	2-chloro-4-	Ethanesulfonic	1306	>30000
		(trifluoromethyl)	acid
		phenyl
15-19	Isobutyl	6-	Propanoic acid	2990	>30000
		(trifluoromethyl)
		pyridazin-3-yl
15-20	2-butyl	2,4-difluorophenyl	Propanoic acid	382	1255
15-21	2-butyl	2,4-difluorophenyl	Ethanesulfonic	5280	>30000
			acid
15-22	n-butyl	Benzofuranyl	Propanoic acid	89	168
15-23	n-butyl	Benzofuranyl	Ethanesulfonic	453	>30000
			acid
15-24	n-butyl	2,4-	Propanoic acid	301	293.9
		dichlorophenyl
15-25	n-butyl	2-chloro-4-	Propanoic acid	218	245
		(trifluoromethyl)
		phenyl
15-26	n-butyl	2-fluoro-4-	Propanoic acid	228	206.6
		(trifluoromethyl)phen-
		yl
15-27	4′-	trifluoromethyl	Propanoic acid	101	316
	(trifluoromethyl)-
	[1,1′-
	biphenyl]-4-yl
15-28	4′-	Benzofuranyl	Ethanesulfonic	100	11647
	(trifluoromethyl)-		acid
	[1,1′-
	biphenyl]-4-yl
15-29	4′-	Benzofuranyl	Propanoic acid	20	107
	(trifluoromethyl)-
	[1,1′-
	biphenyl]-4-yl
15-30	4′-	2-(tert-butyl)-1,3,4-	Propanoic acid	1997	18257
	(trifluoromethyl)-	oxadiazole
	1,1′-biphenyl
15-31	2-fluoro-4-	2-(tert-butyl)--1,3,4-	Ethyl	>30000	>30000
	(trifluoromethyl)-	oxadiazole	propionate
	1,1′-biphenyl
15-32	2-fluoro-4-	2-(tert-butyl)--1,3,4-	Propanoic acid	151	809
	(trifluoromethyl)-	oxadiazole
	1,1′-biphenyl
15-33	2,4-dichloro-	2-(tert-butyl)--1,3,4-	Ethyl	>30000	>30000
	1,1′-biphenyl	oxadiazole	propionate
15-34	2,4-dichloro-	2-(tert-butyl)--1,3,4-	Propanoic acid	2999	4558
	1,1′-biphenyl	oxadiazole
15-35	5-methoxy-2-	Benzofuranyl	Ethanesulfonic	584	>30000
	phenylpyrimidine		acid
15-36	Isopropyl	Benzo[d]thiazol-2-yl	Ethyl	>30 uM	1973
			propionate
15-37	Isopropyl	Benzo[d]thiazol-2-yl	Propanoic acid	468	1609

TABLE 16
Com-				IC50binding	IC50cAMP
pound	R1	R9	R5	(nM)	(nM)
16-1	iso-	2,4-dichlorophenyl	Propanoic acid	215	357.2
	propyl
16-2	iso-	Benzofuranyl	Propanoic acid	528	239.3
	propyl

TABLE 17
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
17-1	isobutyl	2,4-difluorophenyl	Propanoic acid	2259	4239
17-2	isobutyl	2,4-dichlorophenyl	Propanoic acid	139	716
17-3	2-butyl	4-(trifluoromethyl)phenyl	Propanoic acid	989	1307
17-4	2-butyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	609	1266
		phenyl
17-5	2-butyl	2-fluoro-4-	Propanoic acid	769	3332
		(trifluoromethyl)phenyl
17-6	2-butyl	2,4-difluorophenyl	Propanoic acid	445	10157
17-7	isobutyl	4-(trifluoromethyl)phenyl	Propanoic acid	1318	7647
17-8	isopropyl	Benzofuranyl	Propanoic acid	2045	10741
17-9	isopropyl	2-fluoro-4-	Propanoic acid	2600	11597
		(trifluoromethyl)phenyl
17-10	isopropyl	4-fluorophenyl	Propanoic acid	2295	>30000
17-11	isopropyl	2,4-difluorophenyl	Propanoic acid	1013	>30000
17-12	isopropyl	4-t-butylphenyl	Propanoic acid	20000	6494

TABLE 18
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
18-1	n-butyl	Benzofuranyl	Propanoic acid	386	250
18-2	n-butyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	42	49
		phenyl
18-3	2-butyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	62	75
		phenyl
18-4	2-butyl	Benzofuranyl	Propanoic acid	203	151
18-5	2-butyl	2,4-dichlorophenyl	Propanoic acid	165	151
18-6	2-butyl	2-fluoro-4-	Propanoic acid	179	204
		(trifluoromethyl)phenyl
18-7	isobutyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	74	80
		phenyl
18-8	isobutyl	2,4-dichlorophenyl	Propanoic acid	49	122.5
18-9	isobutyl	Benzofuranyl	Propanoic acid	207	429.9

TABLE 19
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
19-1	n-butyl	4-(trifluoromethyl)	Propanoic acid	109	393.8
		phenyl
19-2	Methyl	2,4-dichlorophenyl	Propanoic acid	6316	5186
19-3	Methyl	4-(trifluoromethyl)	Propanoic acid	2728	2719
		phenyl
19-4	Methyl	4-t-butylphenyl	Propanoic acid	1633	3488
19-5	Isobutyl	Benzofuranyl	Propanoic acid	163	1082
19-6	n-pentyl	Benzofuranyl	Propanoic acid	158	632
19-7	n-butyl	4-t-butylphenyl	Propanoic acid	299	731
19-8	Isobutyl	4-t-butylphenyl	Propanoic acid	152	877
19-9	n-pentyl	4-(trifluoromethoxy)	Propanoic acid	151	76.8
		phenyl
19-10	Isopentyl	4-(trifluoromethyl)	Propanoic acid	194.9	373
		phenyl
19-11	n-butyl	Benzofuranyl	Propanoic acid	283	259.9
19-12	1-methoxypropyl	4-t-butylphenyl	Propanoic acid	763	1788
19-13	1-methoxypropyl	4-(trifluoromethyl)	Propanoic acid	621	740
		phenyl
19-14	1-methoxypropyl	4-(trifluoromethoxy)	Propanoic acid	444	787
		phenyl
19-15	1-methoxypropyl	2,4-dichlorophenyl	Propanoic acid	2671	2029
19-16	1-methoxypropyl	2,4,6-trimethyl	Propanoic acid	3698	1729
19-17	3-	4-t-butylphenyl	Propanoic acid	1044	1225
	isobutoxypropan-
	2-yl
19-18	1-isobutoxy	4-(trifluoromethyl)	Propanoic acid	688	916.8
		phenyl
19-19	1-methoxy-2-	4-(trifluoromethoxy)	Propanoic acid	317	582.5
	methylpropyl	phenyl
19-20	1-methoxy-2-	2,4-dichlorophenyl	Propanoic acid	1151	822.4
	methylpropyl
19-21	1-methoxy-2-	Benzofuranyl	Propanoic acid	269	437.3
	methylpropyl
19-22	1-methoxypropyl	4-(trifluoromethyl)	Propanoic acid	745	986.5
		phenyl
19-23	1-methoxypropyl	3-(trifluoromethyl)	Propanoic acid	1310	1126
		phenyl
19-24	1-methoxypropyl	4-(trifluoromethoxy)	Propanoic acid	512	630.4
		phenyl
19-25	1-methoxypropyl	3-	Propanoic acid	1282	1513
		(trifluoromethyl)phen-
		yl
19-26	1-methoxypropyl	Benzofuranyl	Propanoic acid	592	902.8
19-27	1-methoxypropyl	2H-indole	Propanoic acid	455	4952
19-28	1-methoxy-2-	3-	Propanoic acid	872	726
	methylpropyl	(trifluoromethyl)phen-
		yl
19-29	1-methoxy-2-	2-	Propanoic acid	2117	871
	methylpropyl	(trifluoromethyl)phen-
		yl
19-30	1-methoxy-2-	4-(trifluoromethoxy)	Propanoic acid	548	1104
	methylpropyl	phenyl
19-31	1-methoxy-2-	3,4,5-	Propanoic acid	500	1341
	methylpropyl	trifluorobenzene
19-32	1-methoxy-2-	Benzofuranyl	Propanoic acid	483	1017
	methylpropyl
19-33	1-methoxy-2-	4-(trifluoromethoxy)	Propanoic acid	284	472
	methylpropyl	phenyl
19-34	1-methoxy-2-	4-	Propanoic acid	380	487
	methylpropyl	(trifluoromethyl)phen-
		yl

TABLE 20
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
20-1	2-(4-	4-t-butylphenyl	Propanoic acid	201	1403
	methylphenyl)benzo-
	furanyl
20-2	2-butyl	3-	Propanoic acid	974	22191
		methylbenzofuran-
		yl
20-3	2-butyl	Benzofuranyl	Propanoic acid	801	9163
20-4	Isopropyl	4-t-butylphenyl	Propanoic acid	1041	4853
20-5	4′-methyl-2,4,6-	4-t-butylphenyl	Propanoic acid	4855	>30000
	trimethyl-1,1′-
	biphenyl
20-6	4-methyl-4′-	3-	Propanoic acid	2678	>30000
	(trifluoromethyl)-	methylbenzofuran-
	1,1′-bipehnyl	yl
20-7	4-methyl-4′-	3-	Ethanesulfonic	>30000	>30000
	(triflouromethyl)-	methylbenzofuran-	acid
	1,1′-biphenyl	yl

TABLE 21
Com-				IC50binding	IC50cAMP
pound	R1	R9	R5	(nM)	(nM)
21-1	n-butyl	4-t-butylphenyl	Propanoic acid	803	170.4
21-2	2-butyl	4-t-butylphenyl	Propanoic acid	637	1242
21-3	isopropyl	4-t-butylphenyl	Propanoic acid	1128	5436

TABLE 22
				IC50binding	IC50cAMP
Compound	R1	R9	R5	(nM)	(nM)
22-1	2-butyl	2-fluoro-4-	Propanoic acid	62	>30000
		(trifluoromethyl)phenyl
22-2	n-butyl	4-(trifluoromethoxy)phenyl	Propanoic acid	1432	>30000
22-3	n-butyl	2-fluoro-4-	Propanoic acid	13581	>30000
		(trifluoromethyl)phenyl
22-4	n-butyl	Benzofuranyl	Propanoic acid	>30000	>30000
22-5	n-butyl	4-(trifluoromethoxy)phenyl	Propanoic acid	>30000	>30000
22-6	n-butyl	2,4-dichlorophenyl	Propanoic acid	>30000	>30000
22-7	2-butyl	Benzofuranyl	Propanoic acid	>30000	>30000
22-8	2-butyl	4-(trifluoromethxoy)phenyl	Propanoic acid	>30000	N/A
22-9	2-butyl	4-t-butylphenyl	Propanoic acid	>30000	N/A
22-10	2-butyl	4-(trifluoromethyl)phenyl	Propanoic acid	>30000	>30000
22-11	2-butyl	2,4-dichlorophenyl	Propanoic acid	>30000	>30000
22-12	isopropyl	Benzofuranyl	Propanoic acid	>30000	>30000
22-13	isopropyl	4-(trifluoromethyl)phenyl	Propanoic acid	>30000	>30000
22-14	isopropyl	2,4-dichlorophenyl	Propanoic acid	>30000	>30000
22-15	isopropyl	4-(trifluoromethoxy)phenyl	Propanoic acid	>30000	>30000
22-16	isopropyl	4-t-butylphenyl	Propanoic acid	>30000	>30000
22-17	isopropyl	2-fluoro-4-	Propanoic acid	>30000	>30000
		(trifluoromethyl)phenyl
22-18	n-butyl	4-t-butylphenyl	Propanoic acid	>30000	>30000
22-19	2-butyl	2-chloro-4-(trifluoromethyl)	Propanoic acid	>30000	>30000
		phenyl
22-20	2-butyl	2-fluoro-4-	Methyl	>30000	>30000
		(trifluoromethyl)phenyl	propionate

TABLE 23
				IC50binding	IC50cAMP	LC-MS
Compound	R1	R9	R11	(nM)	(nM)	Data
23-1	Isobutyl		CO2H	87	3600	542
23-2	Benzyl		CO2H	462	5200	576
23-3	Benzyl		CO2H	388	5800	550
23-4	Isopropyl		CO2H	269	3200	542
23-5	Isobutyl		CO2H	80	3500	514
23-6	Isobutyl		CO2Et	2507	181	542
23-7	Benzyl		CO2Et	4274	64.3	576
23-8	Benzyl		CO2H	>10 uM	2000	548
23-9			CO2Et	1939	2600	594
23-10			CO2H	61	1900	566
23-11	Isobutyl		CO2Et	>10 uM	6800	558
23-12	Isobutyl		CO2H	375	4100	530
23-13			CO2Et	>10 uM	>10 uM	626
23-14	Benzyl		CO2H	>10 uM	>10 uM	576
23-15	Benzyl		CO2Et	>10 uM	6300	604
23-16			CO2H	3011	1193	598
23-17		tBu	CO2Et	>10 uM	7400	566
23-18		tBu	CO2H	1870	4700	538
23-19		tBu	CO2Et	>10 uM	5400	566
23-20		tBu	CO2H	724	4700	538
23-21			CO2Et	>10 uM	>10 uM	626
23-22			CO2H	>10 uM	32100	598
23-23	Benzyl		CO2H	4147	5800	576
23-24	Benzyl		SO3H	>10 uM	>10 uM	584
23-25		tBu	CO2H	458	3100	606
23-26		tBu	SO3H	NA	39300	642
23-27			CO2Et	NA	34600	615
23-28	Isobutyl		CO2Me	6941	179	527
23-29	Isobutyl		CO2H	141	>10 uM	513
23-30	sec-Butyl		CO2Et	1477	25.2	542
23-31	sec-Butyl		CO2H	294	4145	514
23-32	Isopropyl		CO2Me	5184	92.8	514
23-33	Isopropyl		CO2H	1007	1633	500
23-34	Isopropyl		SO3H	2566	75611	536
23-35	n-butyl		CO2H	186	15397	514

TABLE 24
							LC-
							MS
Com-					IC50binding	IC50cAMP	Da-
pound	R1	R2	R11	R/S	(nM)	(nM)	ta
24-1	isobutyl		CO2Et	R	>10 uM	1500	542
24-2	isobutyl		CO2H	R	311	598.6	514
24-3	benzyl		CO2Et	R	>10 uM	208	528
24-4	benzyl		CO2H	R	6020	>10 uM	500
24-5	benzyl		CO2Et	S	>10 uM	5800	528
24-6	benzyl		CO2H	S	7397	>10 uM	500
24-7	sec-Butyl		CO2Et	S	11369	217	506
24-8	sec-Butyl		CO2H	S	1026	>10 uM	478
24-9	isobutyl		CO2H	R	>10 uM	1059	494
24-10	isobutyl		CO2Et	R	5821	30780	466
24-11		isopropyl	CO2Et	S	—	>10 uM	476
24-12		isopropyl	CO2H	S	—	>10 uM	448
24-13		isopropyl	CO2Et	S	—	>10 uM	476
24-14		isopropyl	CO2H	S	—	>10 uM	448
24-15			CO2Et	R	578	7988	660
25-16			CO2H	R	126	252.4	632
24-17			CO2Et	S	>30 uM	167.1	672
24-18			CO2H	S	239.5	1510	644
24-19			CO2Et	R	1366	538.4	644
24-20			CO2H	R	192.7	1947	616
24-21		isopropyl	CO2Et	R	4097	>10 uM	542
24-22		isopropyl	CO2H	R	17625	9522	514
24-23			CO2Et	R	168.5	9529	612
24-24			CO2H	R	1215	214	584
24-25			CO2Et	R	225.6	>10 uM	676
24-26			CO2H	R	45.7	831.3	648
24-27			CO2Et	R	1281	318.5	688
24-28			CO2H	R	46.5	1540	660

Shown in Tables 1-24 are the structures and in vitro activities of 390 exemplary compounds of formula (I). All 390 compounds were found to bind to glucagon receptor and inhibit the level of glucagon downstream cAMP to various degrees as indicated by their IC₅₀ values (IC₅₀ being the concentration of an inhibitor where the response or binding is reduced by half) included in the above tables.

OTHER EMBODIMENTS

All of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

Further, from the above description, one skilled in the art can easily ascertain the essential characteristics of the present disclosure, and without departing from the spirit and scope thereof can make various changes and modifications of the disclosure to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

Claims

1. A compound of formula (I):

2. The compound or salt of claim 1, wherein R3 is H, and R4 is H.

3. The compound or salt of claim 1, wherein

4. The compound or salt of claim 1, wherein X is —O— or —S—, Y is —CH2—, R2 is

5. The compound or salt of claim 4, wherein R2 is

6. The compound or salt of claim 5, wherein R7 and R8 are the same, and R7 and R8 are H, methyl, ethyl, propyl, isopropyl, butyl t-butyl, F or Cl.

7. The compound or salt of claim 5, wherein R7 is F, Cl, methoxy, ethoxy, propoxy or isobutoxy, and R8 is H.

8. The compound or salt of claim 4, wherein R2 is

9. The compound or salt of claim 1, wherein R2 is

10. The compound or salt of claim 9, wherein R7 is methyl or ethyl.

11. The compound or salt of claim 1, wherein X is —CH2—, Y is a direct bond, R2 is

12. The compound or salt of claim 11, wherein R7 and R8 are H.

13. The compound or salt of claim 1, wherein X is —CH2—, Y is a direct bond, R2 is

14. The compound or salt of claim 1, wherein X and Y are direct bonds, R2 is

15. The compound or salt of claim 1, wherein X is —O—, Y is —CH2—, R2 is

16. The compound or salt of claim 1, wherein X is —NH—, Y is —(C═O)—, R2 is

17. The compound or salt of claim 1, wherein R1 is methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, n-pentyl, isopentyl, methoxy, ethoxymethyl, 1-methoxypropyl, 1-methoxy-2methylpropyl, ethoxy, n-propoxy, i-propoxy, 3-isobutoxypropan-2-yl, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, phenyl, benzyl, biphenyl, naphthyl, benzofuranyl or indolyl; each of the methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, n-pentyl and isopentyl, is optionally substituted with one to three moieties selected from the group consisting of F, Cl, methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, phenyl, biphenyl and naphthyl; each of the methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy and t-butoxy is optionally substituted with one to three F or Cl; each of the phenyl, biphenyl, naphthyl and indolyl is optionally substituted with one to three moieties selected from the group consisting of F, Cl, methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, trifluoromethyl, benzofuranyl and methoxy substituted pyrimidyl.

18. The compound or salt of claim 1, wherein R5 is tetrazolyl, —CH2-tetrazolyl, —CH2CH2CO2H, —CH2CH2CO2Et, —CH2CH2CO2Me, —CH2CH(OH)CO2H, or —(CH2)2SO3H.

19. The compound or salt of claim 1, wherein R9 is methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, phenyl, benzyl, biphenyl, naphthyl, pyridinyl, pyridazinyl, benzofuranyl, benzothiazolyl, imidazopyridinyl, oxadiazol, benzooxazol, pyrazol or indolyl; each of the methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl and t-butyl is optionally substituted with one to three moieties selected from the group consisting of F, Cl, methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, phenyl, biphenyl and naphthyl; each of the methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy and t-butoxy is optionally substituted with one to three F, Cl or amino; each of the phenyl, benzyl, biphenyl, naphthyl, pyridinyl, pyridazinyl, benzofuranyl, benzothiazolyl, imidazopyridinyl, oxadiazol, benzooxazol, pyrazol and indolyl is optionally substituted with one to three moieties selected from the group consisting of F, Cl, methyl, ethyl, n-propyl, i-propyl, 2-butyl, n-butyl, i-butyl, t-butyl, methoxy, ethoxy, n-propoxy, i-propoxy, 2-butoxy, n-butoxy, i-butoxy, t-butoxy, —CF3, —OCF3 and phenyl.

20. The compound or salt of claim 1, which is represented by the following formula (II):

21. The compound or salt of claim 1, which is any one selected from the group consisting of Compounds 1-1 to 1-54, Compounds 2-1 to 2-13, Compounds 3-1 to 3-24, Compounds 4-1 to 4-5, Compounds 5-1 to 5-3, Compounds 6-1 to 6-3, Compounds 7-1 to 7-11, Compounds 8-1 to 8-25, Compounds 9-1 to 9-6, Compounds 10-1 to 10-19, Compounds 11-1 to 11-2, Compounds 12-1 to 12-11, Compounds 13-1 to 13-14, Compounds 14-1 and 14-2, Compounds 15-1 to 15-37, Compounds 16-1 and 16-2, Compounds 17-1 to 17-12, Compounds 18-1 to 18-9, Compounds 19-1 to 19-34, Compounds 20-1 to 20-7, Compounds 21-1 to 21-3, Compounds 22-1 to 22-20, Compounds 23-1 to 23-35 and Compounds 24-1 to 24-28.

22. The compound or salt of claim 21, which is any one selected from the group consisting of Compound 1-2, Compound 1-8, Compound 1-9, Compound 1-12, Compound 1-16, Compound 1-17, Compound 1-18, Compound 1-19, Compound 1-20, Compound 1-22, Compound 1-25, Compound 1-30, Compound 1-32, Compound 1-48, Compound 1-52, Compound 1-54, Compound 2-4, Compound 2-6, Compound 2-9, Compound 2-10, Compound 3-2, Compound 3-3, Compound 3-4, Compound 3-5, Compound 3-8, Compound 3-9, Compound 3-10, Compound 3-12, Compound 3-13, Compound 3-14, Compound 3-15, Compound 3-19, Compound 3-20, Compound 3-22, Compound 3-24, Compound 4-2, Compound 7-1, Compound 7-5, Compound 7-8, Compound 7-11, Compound 8-3, Compound 8-5, Compound 8-8, Compound 8-11, Compound 8-13, Compound 8-15, Compound 8-16, Compound 8-20, Compound 8-22, Compound 8-23, Compound 8-25, Compound 9-1, Compound 11-1, Compound 11-2, Compound 13-1, Compound 13-2, Compound 13-3, Compound 13-4, Compound 13-6, Compound 13-7, Compound 13-8, Compound 13-9, Compound 13-10, Compound 13-11, Compound 13-14, Compound 14-2, Compound 15-3, Compound 15-7, Compound 15-9, Compound 15-10, Compound 15-13, Compound 15-22, Compound 15-28, Compound 15-29, Compound 18-2, Compound 18-3, Compound 18-7, Compound 18-8, Compound 19-5, Compound 22-1, Compound 22-18, Compound 23-1, Compound 23-5 and Compound 23-10.

23. A pharmaceutical composition comprising a compound or salt of claim 1 and a pharmaceutically acceptable carrier.

24. A method for reducing the glycemic level in a subject, the method comprising administering to the subject in need thereof an effective amount of a compound or salt of claim 1.

25. A method of treating disorders associated with glucagon, the method comprising administering to a subject in need thereof an effective amount of a compound or salt of claim 1.